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Abstract
Background
Melanoma has one of the fastest rising incidence rates of any cancer. It accounts for a small percentage of skin cancer
cases but is responsible for the majority of skin cancer deaths. Early detection and treatment is key to improving survival;
however, anxiety around missing early cases needs to be balanced against appropriate levels of referral and excision of
benign lesions. Used in conjunction with clinical or dermoscopic suspicion of malignancy, or both, reflectance confocal
microscopy (RCM) may reduce unnecessary excisions without missing melanoma cases.
Objectives
To determine the diagnostic accuracy of reflectance confocal microscopy for the detection of cutaneous invasive melanoma
and atypical intraepidermal melanocytic variants in adults with a) any lesion suspicious for melanoma and b) lesions that are
difficult to diagnose, and to compare its accuracy with that of dermoscopy.
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Search methods
We undertook a comprehensive search of the following databases from inception up to 28 August 2016: Cochrane Central
Register of Controlled Trials; MEDLINE; Embase; CINAHL; CPCI; Zetoc; Science Citation Index; US National Institutes of
Health Ongoing Trials Register; NIHR Clinical Research Network Portfolio Database; and the World Health Organization
International Clinical Trials Registry Platform. We studied reference lists and published systematic review articles.
Selection criteria
Studies of any design that evaluated RCM alone, or RCM in comparison to dermoscopy, in adults with lesions suspicious for
melanoma or atypical intraepidermal melanocytic variants, compared with a reference standard of either histological
confirmation or clinical follow-up.
Data collection and analysis
Two review authors independently extracted all data using a standardised data extraction and quality assessment form
(based on QUADAS-2). We contacted authors of included studies where information related to the target condition or
diagnostic threshold were missing. We estimated summary sensitivities and specificities per algorithm and threshold using
the bivariate hierarchical model. To compare RCM with dermoscopy, we grouped studies by population (defined by difficulty
of lesion diagnosis) and combined data using hierarchical summary ROC methods. Analysis of studies allowing direct
comparison between tests was undertaken. To facilitate interpretation of results, we computed values of specificity at the
point on the SROC curve with 90% sensitivity as this value lies within the estimates for the majority of analyses. We
investigated the impact of using a purposely developed RCM algorithm and in-person test interpretation.
Main results
Eighteen publications reporting on a total of 19 study cohorts with 2838 lesions (including 658 with melanoma) were
included, providing 67 datasets for RCM and 7 for dermoscopy. Studies were generally at high or unclear risk of bias across
almost all domains and of high or unclear concern regarding applicability of the evidence. Selective participant recruitment,
lack of blinding of the reference test to the RCM result, and differential verification were particularly problematic. Studies may
not be representative of populations eligible for RCM, and test interpretation was often undertaken remotely from the patient
and blinded to clinical information.
Meta-analysis found RCM to be more accurate than dermoscopy in studies of participants with any lesion suspicious for
melanoma and in those with lesions that are more difficult to diagnose (equivocal lesion populations). Assuming a fixed
sensitivity of 90% for both tests, specificities were 82% for RCM and 42% for dermoscopy for any lesion suspicious for
melanoma (9 RCM datasets; 1452 lesions and 370 melanomas). For a hypothetical population of 1000 lesions at the median
observed melanoma prevalence of 30%, this equates to a reduction in unnecessary excisions with RCM of 280 compared to
dermoscopy, with 30 melanomas missed by both tests. For studies in equivocal lesions, specificities of 86% and 49% would
be observed for RCM and for dermoscopy (7 RCM datasets; 1177 lesions and 180 melanomas). At the median observed
melanoma prevalence of 20%, this reduces unnecessary excisions by 296 with RCM compared with dermoscopy, with 20
melanomas missed by both tests. Across all populations, algorithms and thresholds assessed, the sensitivity and specificity
of the Pellacani RCM score at a threshold of ≥3 were estimated at 92% (95% confidence interval (CI) 87 to 95) and 72%
(95% CI 62 to 81), respectively.
Authors' conclusions
RCM may have a potential role in clinical practice, particularly for the assessment of lesions that are difficult to diagnose
using visual inspection and dermoscopy alone, where the evidence suggests that RCM may be both more sensitive and
specific in comparison to dermoscopy. Given the paucity of data to allow comparison with dermoscopy, the results presented
require further confirmation in prospective studies comparing RCM with dermoscopy in a real world setting in a
representative population.
Plain language summary
What is the diagnostic accuracy of the imaging test reflectance confocal microscopy (RCM) for the detection of
melanoma in adults?
What is the aim of the review?
The aim of this Cochrane Review was to find out how accurate reflectance confocal microscopy (RCM) is on its own and
used in addition to dermoscopy compared to dermoscopy alone for diagnosing melanoma. Researchers in Cochrane
included 18 publications to answer this question.
Why is improving the diagnosis of melanoma important?
Melanoma is one of the most dangerous forms of skin cancer. Not recognising a melanoma when it is present (a false
negative test result) delays surgery to remove it, risking cancer spreading to other organs in the body and possibly death.
Diagnosing a skin lesion as a melanoma when it is not present (a false positive result) may result in unnecessary surgery,
further investigations and patient anxiety.
What was studied in the review?
Microscopic techniques are used by skin cancer specialists to allow a more detailed, magnified examination of suspicious
skin lesions than can be achieved using the naked eye alone. Currently, dermoscopy (a handheld device using natural light)
can be used as part of the clinical examination of suspicious skin lesions. RCM is a new microscopic technique (a handheld
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device or static unit using infrared light) that can visualise deeper layers of the skin compared to dermoscopy. Both
techniques are painless procedures, but RCM is more expensive, time consuming, and requires additional training.
Dermoscopy can be used by general practitioners whereas RCM is likely to only be used by secondary care specialists in
people who have been referred with a lesion suspicious for skin cancer. Researchers sought to find out whether RCM should
be used instead of, or in addition to dermoscopy, to diagnose melanoma in any suspicious skin lesion or only in particularly
difficult to diagnose skin lesions.
What are the main results of the review?
The review included 18 publications reporting data for 19 groups of participants with lesions suspected of melanoma. The
main results are based on 16 of the 19 datasets.
The review included 9 datasets with 1452 lesions in participants with any suspicious skin lesion, 3/9 comparing RCM to
dermoscopy. The results suggest that in a cohort of 1000 lesions, of which 300 (30%) actually are melanoma:
- An estimated 396 will have an RCM result indicating melanoma is present, and of these, 126 (32%) will not be melanoma
(false positive results).
- In the same group of 1000 lesions, dermoscopy would produce 406 false positive results, meaning RCM would avoid
unnecessary surgery in 280 lesions compared to dermoscopy.
- Of the 604 lesions with an RCM result indicating that melanoma is not present (and 324 lesions with a dermoscopy result
indicating that melanoma is not present), 30 will actually be melanoma (false negative results). This equates to a false
negative rate of 5% for RCM and 9% for dermoscopy.
The review also included 7 datasets with 1177 lesions in participants with particularly difficult to diagnose skin lesions, three
comparing RCM to dermoscopy. The results suggest that if RCM was to be used by skin specialists in a group of 1000
lesions, of which 200 (20%) actually are melanoma:
- An estimated 292 will have an RCM result indicating melanoma is present, and of these, 112 (38%) will not be melanoma
(false positive results).
- In the same group of 1000 lesions, dermoscopy would produce 408 false positive results, meaning RCM would avoid
unnecessary surgery in 296 lesions compared to dermoscopy.
- Of the 708 lesions with an RCM result indicating that melanoma is not present (and 412 lesions with a dermoscopy result
indicating that melanoma is not present), 20 will actually have melanoma (false negative results). This equates to a false
negative rate of 3% for RCM and 5% for dermoscopy.
How reliable are the results of the studies of this review?
In all included studies, the diagnosis of melanoma was made by lesion biopsy (RCM/dermoscopy positive) (a biopsy involves
taking a sample of body cells and examining them under a microscope), and the absence of melanoma was confirmed by
biopsy or by follow up over time to make sure the skin lesion remained negative for melanoma (RCM/dermoscopy negative)*.
This is likely to have been a reliable method for deciding whether patients really had melanoma. Only a small number of
studies compared the accuracy of dermoscopy and RCM. Most were conducted by specialist research teams with high levels
of experience with RCM. RCM may therefore appear more accurate than it actually is. Participants in the 9 studies of any
suspicious lesion may have had very obvious disease compared to that seen in practice leading to a lower number of false
positive results than would actually occur. It is not possible to recommend a definition of a positive RCM test that will reliably
produce the results presented here due to differences between studies.
Who do the results of this review apply to?
Eleven studies were undertaken in Europe (61%), with the remainder undertaken in Oceania, North America or more than
one continent. Mean age ranged from 39 to 54.7 years. The percentage of individuals with melanoma ranged between 1.9%
and 41.5% (a median of 19% for difficult to diagnose skin lesions and 32% for any suspicious lesion). The majority of studies
only included people with certain types of skin lesion. In many studies it was not clear what tests participants had received
before RCM.
What are the implications of this review?
RCM appears to be an accurate test for identifying melanoma, and it may reduce the number of individuals receiving
unnecessary surgery by up to three quarters compared to dermoscopy. There is considerable variation and uncertainty in
results and in study conduct, reducing the reliability of findings. Use of RCM may be of most benefit in those with particularly
difficult to diagnose lesions rather than those with any lesion suspicious for melanoma. Further research comparing RCM
and dermoscopy in well described groups of people with difficult to diagnose skin lesions is needed.
How up-to-date is this review?
The review authors searched for and used studies published up to August 2016.
*In these studies biopsy or clinical follow up were the reference standards.
Background 
Target condition being diagnosed
Melanoma arises from uncontrolled proliferation of melanocytes - the epidermal cells that produce pigment or
melanin. Melanoma can occur in any organ that contains melanocytes, including mucosal surfaces, the back of the
eye, and lining around the spinal cord and brain, but most commonly arises in the skin. The incidence of melanoma
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rose to over 200,000 newly diagnosed cases worldwide in 2012 (Erdmann 2013; Ferlay 2015), with an estimated
55,000 deaths (Ferlay 2015). In the UK, melanoma has one of the fastest rising incidence rates of any cancer, and has
had the biggest projected increase in incidence between 2007 and 2030 (Mistry 2011). In the decade leading up to
2013, age standardised incidence increased by 46%, with 14,500 new cases in 2013 and 2,459 deaths in 2014 (Cancer
Research UK 2017b). Rates are higher in women than in men; however, the rate of incidence in men is increasing
faster than in women (Arnold 2014).
Definitions: Cutaneous melanoma refers to any skin lesion with malignant melanocytes present in the dermis, and
includes superficial spreading, nodular, acral lentiginous, and lentigo maligna melanoma variants (Figure 1).
Melanoma in situ refers to malignant melanocytes that are contained within the epidermis and have not yet invaded
the dermis (i.e. intraepidermal), but are at risk of progression to melanoma if left untreated. Lentigo maligna, a
subtype of melanoma-in-situ in chronically sun-damaged skin, denotes another form of proliferation of abnormal
melanocytes. Lentigo maligna can progress to invasive melanoma if its growth breaches the dermo-epidermal
junction during a vertical growth phase (when it becomes known as 'lentigo maligna melanoma'), however its
malignant transformation is both lower and slower than for melanoma in situ (Kasprzak 2015
). Melanoma in situ and lentigo maligna are both atypical intraepidermal melanocytic
variants (also referred to as 'borderline evolving melanoma') (
www.seer.cancer.gov/tools/mphrules/2007/melanoma/terms_defs.pdf). Melanoma is one of the most dangerous forms
of skin cancer, with the potential to metastasise to other parts of the body via the lymphatic system and blood stream.
It accounts for only a small percentage of skin cancer cases but is responsible for up to 75% of skin cancer deaths (Boring
1994; Cancer Research UK 2017a).
In this diagnostic test accuracy review we define (a) cutaneous invasive melanoma and atypical intraepidermal melanocytic
variants as the primary target condition. We will also examine accuracy for target conditions of (b) cutaneous invasive
melanoma alone, and (c) any skin cancer or skin lesion with a high risk of progression to melanoma.
Prognosis: US data from 2007 to 2013 indicate five-year survival of 98.5% for localised melanoma, dropping to 62.9%
for those with regional spread (nodal disease) and 19.9% for disseminated disease (SEER 2017). Before the advent of
targeted and immuno-therapies, melanoma disseminated to distant sites and visceral organs was associated with
median survival of six to nine months, a one-year survival rate of 25%, and three-year survival of 15% (Balch 2009; Korn
2008). Between 1975 and 2010, five-year relative survival for melanoma in the US increased from 80% to 94%, with
survival for localised, regional, and distant disease estimated at 99%, 70%, and 18%, respectively in 2010 (Cho 2014).
Overall, mortality rates however showed little change, at 2.1 per 100,000 deaths in 1975 and 2.7 per 100,000 in 2010 (Cho
2014). Increasing incidence in localised disease over the same period (from 5.7 to 21 per 100,000) suggests that much
of the observed improvement in survival may be due to earlier detection and heightened vigilance (Cho 2014), however
targeted therapies for stage IV melanoma (e.g. BRAF inhibitors) have improved survival expectation and immunotherapies
are evolving such that long term survival is being documented (see below).
Treatment of melanoma
For primary melanoma, the mainstay of definitive treatment is wide local excision of the lesion, to remove both the
tumour and any malignant cells that might have spread into the surrounding skin (Garbe 2016; Marsden 2010; NICE 2015a; 
SIGN 2017; Sladden 2009). Recommended surgical margins vary according to tumour thickness (Garbe 2016) and
stage of disease at presentation (NICE 2015a).
Following histological confirmation of diagnosis, the lesion is staged according to the American Joint Committee on
Cancer (AJCC) Staging System to guide treatment (Balch 2009). Stage 0 refers to melanoma in situ; stages I to II
indicate localised melanoma; stage III occurs where there is regional metastasis; and stage IV indicates distant
metastasis (Balch 2009). The main prognostic indicators can be divided into histological and clinical factors.
Histologically, Breslow thickness is the single most important predictor of survival, as it is a quantitative measure of
tumour invasion which correlates with the propensity for metastatic spread (Balch 2001). Microscopic ulceration,
mitotic rate, microscopic satellites, regression, lymphovascular invasion, and nodular (rapidly growing) or amelanotic
(lacking in melanin pigment) subtypes (Moreau 2013; Shaikh 2012) are also associated with worse prognosis.
Independent of tumour thickness, prognosis is worse in: older people, males, those with recurrent lesions, and in
those with distant lymph node involvement (micro or macroscopic) and/or metastatic disease at the time of
primary presentation. There is debate regarding the prognostic effect from primary lesion site, with some evidence
suggesting a worse prognosis for truncal lesions or those on the scalp or neck (Zemelman 2014).
In terms of local or regional interventions beyond wide local excision for primary lesions, completion lymphadenectomy
(removal of all regional lymph nodes) is undertaken for those with clinically palpable lymph nodes and may be
considered if micrometastatic disease is identified on sentinel lymph node biopsy (NICE 2015a) although no survival
benefit has been shown to date for those undergoing sentinel node staging (Kyrgidis 2015; Morton 2014). Elective
lymph node dissection (Eggermont 2007), adjuvant radiotherapy or adjuvant systemic treatments are not recommended
for routine use in stage I, II or III disease in the UK (NICE 2015a), and in many parts of Europe (Garbe 2016), other
than interferon-alpha (licensed by FDA and EMEA) (Garbe 2016), which has been shown to be effective for the
treatment of high-risk groups in terms of both disease-free and overall survival in a Cochrane review found evidence
for its effectiveness for disease-free survival but not for overall survival (Mocellin 2013).
For stage IV melanoma, two distinct therapeutic approaches suggesting survival benefits in metastatic melanoma
are available: targeting mutated signal transduction in the RAS-RAF signalling pathway, e.g. BRAF-inhibitors (Chapman
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2012; Villanueva 2010) and MEK inhibitors (Dummer 2014; Larkin 2014), and immunomodulation (Chapman 2011; Hamid
2013; Hodi 2010). Molecular targeted therapies recommended in the UK for unresectable or metastatic BRAF V600
mutation-positive melanoma (around 45% of patients (Garbe 2016)) include BRAF-inhibitors dabrafenib (NICE 2014a),
vemurafenib (NICE 2012b) or trametinib (MEK inhibitor) in combination with dabrafenib (NICE 2016b). European
guidelines recommend combinations of BRAF- and MEK-inhibitors as standard treatment where indicated (Garbe 2016).
Immunotherapy-based approaches including ipilimumab (CTLA-4 inhibitor) and PD-1 inhibitors (nivolumab and
pembrolizumab) have been approved in the US and Europe (Hodi 2010) and by NICE in the UK both as single agents (NICE
2012a; NICE 2014b; NICE 2015b; NICE 2015c) and in combination (NICE 2016a; NICE 2016b). These have
shown high response rates, and demonstrate the potential for a durable clinical response for the first time in the
treatment of melanoma (Chapman 2011; Hamid 2013; Hodi 2010; Hodi 2016; Larkin 2015; Maio 2015; Sznol 2013).
An update of a Cochrane review comparing the efficacy of available systemic therapies for stage IIIc and stage IV
melanoma is currently underway (Pasquali 2014), as are a number of further NICE appraisals of new therapeutic
agents including binimetinib, talimogene laherparepvec (TVEC) and temozolomide (NICE 2017).
Index test(s)
Reflectance confocal microscopy (RCM), also known as confocal laser scanning microscopy or confocal
microscopy, was first developed for skin imaging in the early 1990s (Rajadhyaksha 1995) and is emerging as a potential
alternative or adjunct to dermoscopy for the diagnosis of skin cancer. It is a non-invasive technology, which can be used to
visualise horizontally sectioned images of the skin at a cellular lateral resolution of ~1micron, in vivo to the depth of the upper
dermis. The contrast for the monochrome images produced is achieved by the variation of the optical properties within the
skin when illuminated by a near-infrared light (830nm) (see Figure 2). The greatest contrast is achieved from melanin, so that
RCM is advocated as being particularly useful for assessing pigmented lesions.
The Caliber I.D. VivaScope® imaging systems are the only commercially available RCM devices (distributed by
MAVIG in Europe). The Vivascope 1500 (and the previously available 1000 version) is a console based unit with an
integrated dermoscope, whereas the Vivascope 3000 is a handheld device designed for superior ergonomics, allowing
imaging of lesions inaccessible for the 1500 version (Figure 3). Imaging can be undertaken by clinicians or
technicians following appropriate training (Edwards 2016). The length of time required for diagnosis has been
estimated at 15 minutes for Vivascope 1500 (10 minutes of a technician's time for imaging and 5 minutes of a
dermatologists for image interpretation) and 10 minutes for Vivascope 3000 (Edwards 2016). The company has
estimated the average cost per use of the 1500 system, including dermoscopy, as £120 based on 2014 NHS
reference costs and an indicative price for Vivascope 1500 of £95,224 (Edwards 2016).
Various algorithms have been proposed for the interpretation of RCM images, relying on either numeric thresholds
or qualitative indicators of test positivity according to the presence or absence of particular lesion characteristics.
The lesion characteristics that are accepted as being associated with melanomas are: absence of the normal
epidermis architecture, lack of delineation of the papillae (non-edged papillae), irregular nests of atypical
melanocytes, and the presence of large and highly refractile cells with prominent nuclei in higher epidermal layers (Edwards
2016; Pellacani 2007).
Clinical Pathway 
The diagnosis of melanoma occurs in primary, secondary, and tertiary care settings by both generalist and specialist
healthcare providers. People with concerns about a new or changing lesion will either present to their general
practitioner or directly to a specialist in secondary care, which could include a dermatologist, plastic surgeon, general
surgeon or other specialist surgeon (such as an ear, nose, and throat (ENT) specialist or maxillofacial surgeon), or
ophthalmologist (Figure 4). Current UK guidelines recommend that all suspicious pigmented lesions presenting in
primary care should be assessed by taking a clinical history and visual inspection using the seven-point checklist (MacKie
1990); lesions suspected to be melanoma should be referred for appropriate specialist assessment within two weeks (Chao
2013; Marsden 2010; NICE 2015d).
The specialist clinician will use history-taking, visual inspection of the lesion (in comparison with other lesions on the skin),
and usually dermoscopy to inform a clinical decision. If melanoma is suspected, then urgent excision is recommended. Other
lesions such as suspected dysplastic naevi or pre-malignant lesions such as lentigo maligna may also be referred for a
diagnostic biopsy, further surveillance or reassurance and discharge. This is the point at which RCM is generally thought to
have a role in patient management, most likely as an additional test to better identify patients with lesions that can
be monitored or reassured instead of being sent for urgent excision (Edwards 2016). RCM could also be considered as a
primary diagnostic test, i.e. as a potential replacement for dermoscopy.
Prior test(s)
Fundamental to the diagnosis of skin cancer is clinical examination and history-taking, however a range of
technologies have emerged to aid diagnosis to ideally reduce the number of excision biopsies. Dermoscopy in
particular has become the most widely used tool for clinicians to try and obtain an accurate assessment of
melanoma following visual inspection (Argenziano 1998; Argenziano 2012; Haenssle 2010; Kittler 2002).
Visual inspection of the skin is undertaken iteratively, using both implicit pattern recognition (non-analytical
reasoning) and more explicit ‘rules’ based on conscious analytical reasoning (Norman 2009), the balance of which
will vary according to experience and familiarity with the diagnostic question. Various attempts have been made to
formalise the "mental rules" involved in analytical pattern recognition for melanoma, ranging from a setting out of
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lesion characteristics that should be considered (Friedman 1985; Sober 1979) to formal scoring systems with explicit
numerical thresholds. The seven-point checklist, for example, assesses change in lesion size, shape, colour,
inflammation, crusting or bleeding, sensory change, or diameter ≥ 7 mm (MacKie 1985; MacKie 1990). Other
available tools include the ABCD(E) approach (Friedman 1985; Thomas 1998) and ugly duckling (Grob 1998).
Dermoscopy is a non-invasive, in vivo technique that uses a hand-held microscope and incident light (with or without oil
immersion) to reveal subsurface images of the skin at increased magnification of x 10 to x 100 (Kittler 2011). Although
widely used, the accuracy of dermoscopy largely depends on the experience and training of the examiner (Binder 1997; 
Kittler 2002; Kittler 2011). Pattern analysis (Pehamberger 1987; Steiner 1987) is thought to be the most specific and
reliable technique to aid dermoscopy interpretation when used by specialists (Maley 2014); however, dermoscopic
histological correlations have been established and diagnostic algorithms have been developed based on colour,
aspect, pigmentation pattern, and skin vessels, including the ABCD rule for dermoscopy (Nachbar 1994; Stolz 1994
), the Menzies approach (Menzies 1996), the seven-point dermoscopy checklist (Annessi 2007; Argenziano 1998; 
Argenziano 2001), and the three-point checklist (Gereli 2010).
The accuracy, and comparative accuracy, of visual inspection and dermoscopy and their associated scoring systems
is summarised in a further review in this series (Dinnes 2018).
Role of index test(s)
Used in conjunction with clinical and/or dermoscopic suspicion of malignancy in pigmented lesions, RCM is primarily
advocated as a tool to reduce the number of unnecessary excisions (Ferrari 2015), especially in lesions that may be
difficult to diagnose by clinical examination and dermoscopy alone (Guitera 2009). RCM features have been shown
to be strongly correlated with dermoscopic patterns (Pellacani 2014). Moreover, small diameter melanomas (less than
5 mm diameter) may demonstrate specific dermoscopic and confocal features, such as marked cytological atypia and
irregular nesting, which help to differentiate them from naevi (Pupelli 2013). One of the postulated advantages of RCM is its
ability to differentiate seborrheic keratosis or non-melanocytic lesions from a population of pigmented lesions.
Although the primary aim in diagnosing potentially life-threatening conditions such as melanoma is to minimise false negative
diagnoses (to avoid delay to diagnosis and even death), a test that can reduce false positive clinical diagnoses without
missing true cases of disease has patient and resource benefits. False-positive clinical diagnoses not only cause
unnecessary morbidity from the biopsy, but also increase patient anxiety. Pigmented lesions are common so the resource
implication for even a slight increase in the threshold to excise lesions in populations where melanoma rates are increasing,
will avoid a considerable healthcare burden to both patient and healthcare provider, as long as such lesions turn out to be
harmless.
RCM is also being explored for its ability to differentiate lentigo maligna from actinic or seborrhoeic keratosis (de Carvalho
2015; Menge 2016). RCM could also develop a future role in guiding definitive therapeutic margins (Edwards 2016) and to
evaluate response to topical chemotherapy for lentigo maligna, however these uses are not under consideration in this
review.
Alternative test(s)
A number of other tests are being reviewed as part of our series of Cochrane DTA reviews on the diagnosis of melanoma,
including visual inspection and dermoscopy, teledermatology, mobile phone applications, computer-aided diagnosis (CAD)
techniques, optical coherence tomography (OCT) and high frequency ultrasound (New Reference).
OCT is an emerging optical imaging technology based on interferometry using a near infra-red light source. It
exploits differences in the refractive index in the skin to create vertically sectioned images in vivo, in real time.
Vascular flow information can be extracted from the images, allowing neovascularisation to be visualised, which
has potential for earlier diagnosis of melanoma (Kokolakis 2012; Themstrup 2015). High frequency ultrasound has
shown good correlation with histology for measurement of melanoma thickness, but may also differentiate pigmented
lesions, particularly for colour Doppler (Scotto di Santolo 2015). CAD or artificial intelligence-based techniques
process and manipulate lesion images using predefined algorithms to identify the features that discriminate malignant
from benign lesions (Esteva 2017; Rajpara 2009). These techniques have been incorporated into commercially
available handheld devices for ease of use in a clinic setting, including SIAscopy™ (Moncrieff 2002; Walter 2012),
MelaFind® (Hauschild 2014; Monheit 2011; Wells 2012), and the Nevisense™ Electrical Impedance Spectroscopy
system (Malvehy 2014). CAD has however most commonly been applied to digital dermoscopy images (Esteva 2017; 
Rajpara 2009).
Evidence permitting, the accuracy of available tests will be compared in an overview review, exploiting within-study
comparisons of tests and allowing the analysis and comparison of commonly used diagnostic strategies where tests may be
used singly or in combination.
Other tests identified as potential candidates for review but for which no eligible studies were found include volatile
organic compounds (including canine odour detection) (Abaffy 2010; Church 2001; D'Amico 2008; Gallagher 2008; Kwak
2013; Williams 1989), and gene expression analysis (Ferris 2012; Wachsman 2011).
We also considered and excluded a number of tests from review including exfoliative cytology, which involves
microscopic examination of a scraping taken from a skin lesion stained with Giemsa (Ruocco 2011); tests used in the context
of monitoring people, such as total body photography of those with large numbers of typical or atypical naevi; and finally
histopathological confirmation following lesion excision. The latter is the established reference standard for melanoma
diagnosis and will be one of the standards against which the index tests are evaluated in these reviews.
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Rationale
Our series of reviews of diagnostic tests used to assist clinical diagnosis of melanoma aims to identify the most accurate
approaches to diagnosis and provide clinical and policy decision-makers with the highest possible standard of evidence
on which to base decisions. With increasing rates of melanoma incidence and the push towards the use of dermoscopy
and other high resolution image analysis in primary care, the anxiety around missing early cases needs to be balanced in
order to avoid referring too many people with benign lesions for a specialist opinion. It is questionable whether all skin
cancers picked up by sophisticated techniques, even in specialist settings, help to reduce morbidity and mortality or
whether newer technologies run the risk of increasing false-positive diagnoses. It is also possible that use of some
technologies, e.g. widespread use of dermoscopy in primary care with no training, could actually result in harm by
missing melanomas if they are used as replacement technologies for traditional history-taking and clinical examination of
the entire skin. Many branches of medicine have noted the danger of such 'gizmo idolatry' amongst doctors (Leff 2008).
To date, the use of RCM has been limited by expense (in terms of both equipment and staff time) and the need for
specialised training. Recent studies have demonstrated high sensitivity and specificity amongst experienced RCM
users, however, in at least one study, the accuracy of the group on average was higher than that of any one
individual observer (Farnetani 2015). A standardised system that is reproducible across users is therefore desirable.
Ultimately it is thought that although RCM may augment diagnostic sensitivity when used in conjunction with clinical
inspection and dermoscopy, its main contribution is an increase in specificity. However the exact contribution of
RCM as an adjunct to dermoscopy is not entirely clear (Edwards 2016; Stevenson 2013), and the number of RCM cases
required to offset an unnecessary excision biopsy has not been assessed in a UK setting.
Although a set of billing codes for the USA have been agreed since January 2016 (Rajadhyaksha 2017), RCM is not
recommended for routine use in the UK (Edwards 2016), Australia (Guitera 2017), or New Zealand (Sobarun 2015
). Available systematic reviews are limited by currency (Stevenson 2013) and methods (Xiong 2016 for example
failing to consider the nature of the target population, varying definitions of the target condition, and using an out of
date meta-analytic approach), or focus on selected studies considered to be more applicable to a UK setting (Edwards
2016). Furthermore, in a rapidly advancing field, there is a need for an up-to-date analysis of the accuracy of RCM in
comparison to dermoscopy at different points in the clinical pathway.
This is one of a series of Cochrane Diagnostic Test Accuracy (DTA) reviews on the diagnosis and staging of melanoma and
keratinocyte skin cancers as part of the National Institute for Health Research (NIHR) Cochrane Systematic Reviews
Programme. Appendix 1 shows the content and structure of the programme. As several reviews for each topic area
followed the same methodology, generic protocols were prepared in order to avoid duplication of effort, one for
diagnosis of melanoma (Dinnes 2015b) and one for diagnosis of keratinocyte skin cancers (Dinnes 2015a). The
Background and Methods sections of this review therefore use some text that was originally published in the protocol
concerning the evaluation of tests for the diagnosis of melanoma (Dinnes 2015b) and text that overlaps some of our
other reviews (Dinnes 2018). Table 1 provides a glossary of terms used.
Objectives 
To determine the diagnostic accuracy of reflectance confocal microscopy for the detection of cutaneous invasive melanoma
and atypical intraepidermal melanocytic variants in adults, and to compare its accuracy with that of dermoscopy.
Accuracy was estimated separately according to the point in the clinical pathway at which RCM is evaluated:
where it might be used as an alternative to dermoscopy in participants with any lesion suspicious for melanoma
where it might be used in addition to dermoscopy in participants with equivocal lesions in whom a clear management
decision could not be made following visual inspection and dermoscopy
Secondary objectives
To determine the diagnostic accuracy of reflectance confocal microscopy in comparison to dermoscopy for the detection of
cutaneous invasive melanoma alone
any skin cancer (melanoma or other skin cancer) or skin lesion with a high risk of progression to melanoma.
Accuracy was estimated separately according to the point in the clinical pathway at which RCM is evaluated:
where it might be used in addition to current practice (which may or may not include dermoscopy) in participants with any
lesion suspicious for melanoma
where it might be used as an addition to dermoscopy in participants with equivocal lesions in whom a clear management
decision could not be made following visual inspection and dermoscopy
For identifying cutaneous invasive melanoma and atypical intraepidermal melanocytic variants (the primary target condition):
To compare the accuracy of RCM to dermoscopy where both tests have been evaluated in the same studies (direct test
comparisons)
To determine the diagnostic accuracy of individual algorithms for RCM
To determine the effect of observer experience.
Investigation of sources of heterogeneity
We aimed to consider a range of potential sources of heterogeneity for investigation across the series of reviews, as
outlined in our generic protocol (Dinnes 2015b).
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i. Population characteristics
general versus higher risk populations
patient population: primary /secondary / specialist unit
lesion type: any pigmented; melanocytic
inclusion of multiple lesions per participant
ethnicity
ii. Index test characteristics
in-person versus remote image-based RCM interpretations
the nature of and definition of criteria for test positivity
observer experience with the index test
iii. Reference standard characteristics
reference standard used
whether histology-reporting meets pathology-reporting guidelines
use of excisional versus diagnostic biopsy
whether two independent dermatopathologists reviewed histological diagnosis
iv. Study quality
consecutive or random sample of participants recruited
index test interpreted blinded to the reference standard result
index test interpreted blinded to the result of any other index test
presence of partial or differential verification bias (whereby only a sample of those subject to the index test are verified by
the reference test or by the same reference test with selection dependent on the index test result)
use of an adequate reference standard
overall risk of bias
Methods 
Criteria for considering studies for this review
Types of studies 
We included test accuracy studies that allow comparison of the result of the index test with that of a reference standard,
including the following:
studies where all participants receive a single index test and a reference standard;
studies where all participants receive more than one index test(s) and reference standard;
studies where participants are allocated (by any method) to receive different index tests or combinations of index tests
and all receive a reference standard (between-person comparative studies (BPC));
studies that recruit series' of participants unselected by true disease status (referred to as case series for the purposes of
this review);
diagnostic case-control studies that separately recruit diseased and non-diseased groups (see Rutjes 2005);
both prospective and retrospective studies; and
studies where previously acquired clinical or dermoscopic images were retrieved and prospectively interpreted for study
purposes.
We excluded studies from which we could not extract 2x2 contingency data or if they included less than five melanoma
cases.
Participants
We included studies in adults with pigmented skin lesions or lesions suspicious for melanoma.
We excluded studies that recruited only participants with malignant diagnoses and studies that compared test results
in participants with malignancy compared with test results based on 'normal' skin as controls, due to the bias inherent
in such comparisons (Rutjes 2006).
We excluded studies with more than 50% of participants aged 16 and under.
Index tests
Studies evaluating reflectance confocal microscopy alone, or reflectance confocal microscopy in comparison to dermoscopy
were included.
All established algorithms or checklists to assist diagnosis were included. Studies developing new algorithms or
methods of diagnosis (i.e. derivation studies) were included if they used a separate independent 'test set' of participants
or images to evaluate the new approach. Studies that did not report data for a separate test set of patients or images
were included only if the lesion characteristics investigated had previously been suggested as associated with
melanoma and the study reported accuracy based on the presence or absence of particular combinations of
characteristics. Studies using a statistical model to produce a data driven equation, or algorithm based on multiple
diagnostic features, with no separate test set were excluded. Studies using cross-validation approaches such as 'leave-
one-out' cross-validation (Efron 1983) were excluded.
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No exclusions were made according to test observer.
Target conditions
The primary target condition was defined as the detection of:
any form of invasive cutaneous melanoma, or
atypical intraepidermal melanocytic variants (i.e. including melanoma in situ, or lentigo maligna, which has a risk of
progression to invasive melanoma).
Two additional definitions of the target condition were considered in secondary analyses, the detection of:
any form of invasive cutaneous melanoma alone, and
any skin cancer (melanoma or other skin cancer) or skin lesion with a high risk of progression to melanoma. This latter
definition includes other forms of skin cancer, such as basal cell carcinoma (BCC) and cutaneous squamous cell
carcinoma (cSCC), as well as melanoma in situ, lentigo maligna, and lesions with severe melanocytic dysplasia.
The diagnosis of the keratinocyte skin cancers, basal cell carcinoma, and squamous cell carcinoma as primary target
conditions are the subject of a separate series of reviews (New Reference).
Reference standards
The ideal reference standard was histopathological diagnosis of the excised lesion or biopsy sample in all eligible lesions. A
qualified pathologist or dermatopathologist should perform histopathology. Ideally, reporting should be standardised detailing
a minimum dataset to include the histopathological features of melanoma to determine the American Joint Committee on
Cancer (AJCC) Staging System (e.g. Slater 2014). We did not apply the reporting standard as a necessary inclusion
criterion, but extracted any pertinent information.
Partial verification (applying the reference test only to a subset of those undergoing the index test) was of concern given that
lesion excision or biopsy are unlikely to be carried out for all benign-appearing lesions within a representative population
sample. Therefore, we accepted clinical follow-up of benign-appearing lesions as an eligible reference standard, whilst
recognising the risk of differential verification bias (as misclassification rates of histopathology and follow-up will differ) in our
quality assessment of studies.
Additional eligible reference standards included cancer registry follow-up and 'expert opinion' with no histology or clinical
follow-up. Cancer registry follow-up is considered less desirable than active clinical follow-up, as follow-up is not carried out
within the control of the study investigators. Furthermore, if participant-based analyses as opposed to lesion-based analyses
are presented, it may be difficult to determine whether the detection of a malignant lesion during follow-up is the same lesion
that originally tested negative on the index test.
All of the above were considered eligible reference standards with the following caveats:
all study participants with a final diagnosis of the target disorder must have a histological diagnosis, either subsequent to
the application of the index test or after a period of clinical follow-up, and
at least 50% of all participants with benign lesions must have either a histological diagnosis or clinical follow-up to confirm
benignity.
Search methods for identification of studies 
Electronic searches 
The Information Specialist (SB) carried out a comprehensive search for published and unpublished studies. A single large
literature search was conducted to cover all topics in the programme grant (see Appendix 1 for a summary of
reviews included in the programme grant). This allowed for the screening of search results for potentially relevant
papers for all reviews at the same time. A search combining disease-related terms with terms related to the test
names, using both text words and subject headings was formulated (Appendix 2). The search strategy was designed to
capture studies evaluating tests for the diagnosis or staging of skin cancer. As the majority of records were related to the
searches for tests for staging of disease, a filter using terms related to cancer staging and to accuracy indices was applied to
the staging test search, to try to eliminate irrelevant studies, for example, those using imaging tests to assess treatment
effectiveness. A sample of 300 records that would be missed by applying this filter was screened and the filter adjusted to
include potentially relevant studies. When piloted on MEDLINE, inclusion of the filter for the staging tests reduced the overall
numbers by around 6000. The final search strategy, incorporating the filter, was subsequently applied to all bibliographic
databases as listed below. The final search result was cross-checked against the list of studies included in five systematic
reviews; our search identified all but one of the studies, and this study is not indexed on MEDLINE. The Information
Specialist devised the search strategy, with input from the Information Specialist from Cochrane Skin. No additional limits
were used.
We searched the following bibliographic databases to August 2016 for relevant published studies:
the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library;
the Cochrane Database of Systematic Reviews (CDSR) in the Cochrane Library;
Centre for Reviews and Dissemination (CRD) Database of Abstracts of Reviews of Effects (DARE);
CRD HTA (Health Technology Assessment) database;
MEDLINE via OVID (from 1946);
MEDLINE In-Process & Other Non-Indexed Citations via OVID;
EMBASE via OVID (from 1980); and
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CINAHL (Cumulative Index to Nursing and Allied Health Literature via EBSCO from 1960 to the present).
We searched the following databases for relevant unpublished studies:
CPCI (Conference Proceedings Citation Index) via Web of Science™ (from 1990);
Zetoc (from 1993); and
SCI Science Citation Index Expanded™ via Web of Science™ (from 1900, using the "Proceedings and Meetings
Abstracts" Limit function).
We searched the following trials registers:
The US National Institutes of Health Ongoing Trials Register (www.clinicaltrials.gov);
NIHR Clinical Research Network Portfolio Database (www.nihr.ac.uk/research-and-impact/nihr-clinical-research-
network-portfolio/);
The World Health Organization International Clinical Trials Registry Platform (apps.who.int/trialsearch/).
We aimed to identify all relevant studies regardless of language or publication status (published, unpublished, in press, or in
progress). No date limits were applied. Update searches will be time and resource dependent.
Searching other resources 
We have included information about potentially relevant ongoing studies in the 'Characteristics of ongoing studies' tables. We
have screened relevant systematic reviews identified by the searches for their included primary studies, and included any
missed by our searches. We have checked the reference lists of all included papers, and subject experts within the author
team have reviewed the final list of included studies. No citation searching has been conducted.
Data collection and analysis 
Selection of studies 
Titles and abstracts were screened by at least one author (JDi or NC), with any queries discussed and resolved by
consensus. A pilot screen of 539 MEDLINE references showed good agreement (89% with a kappa of 0.77)
between screeners. Primary test accuracy studies and test accuracy reviews (for scanning of reference lists) of any
test used to investigate suspected melanoma, BCC, or cSCC were included at initial screening. Inclusion criteria (Appendix
3) were applied independently by both a clinical reviewer (from one of a team of twelve clinician reviewers) and a
methodologist reviewer (JDi or NC) to all full text articles, disagreements were resolved by consensus or by a third party
(JDe, CD, HW, and RM). Authors of eligible studies were contacted when insufficient data were presented to allow for the
construction of 2x2 contingency tables.
Data extraction and management
One clinical (as detailed above) and one methodologist reviewer (JDi, NC or LFR) independently extracted data concerning
details of the study design, participants, index test(s) or test combinations and criteria for index test positivity, reference
standards, and data required to populate a 2x2 diagnostic contingency table for each index test using a piloted data
extraction form. Data were extracted at all available index test thresholds. Disagreements were resolved by consensus or by
a third party (JDe, CD, HW, and RM).
Authors of included studies were contacted where information related to the target condition (in particular to allow the
differentiation of invasive cancers from ‘in situ’ variants) or diagnostic threshold were missing. Authors of conference
abstracts published from 2013 to 2015 were contacted to ask whether full data were available. If no full paper was identified,
we marked conference abstracts as 'pending' and will revisit them in a future review update.
Dealing with multiple publications and companion papers
Where multiple reports of a primary study were identified, we maximised yield of information by collating all available data.
Where there were inconsistencies in reporting or overlapping study populations, we contacted study authors for clarification
in the first instance. If this contact with authors was unsuccessful, we used the most complete and up-to-date data source
where possible.
Assessment of methodological quality
We assessed risk of bias and applicability of included studies using the QUADAS-2 checklist (Whiting 2011), tailored to the
review topic (see Appendix 4). The modified QUADAS-2 tool was piloted on a small number of included full text articles. One
clinical (as detailed above) and one methodologist reviewer (JDi, NC or LFR) independently assessed quality for the
remaining studies; any disagreement was resolved by consensus or by a third party where necessary (JDe, CD, HW, and
RM).
Statistical analysis and data synthesis
For the primary outcome of detection of invasive melanoma or atypical intraepidermal melanocytic variants, we conducted
separate analyses according to the point in the clinical pathway that RCM was applied. Three groups of studies were formed:
i. RCM used as a replacement for dermoscopy in participants with lesions suspicious for melanoma, i.e. no attempt to
exclude those diagnosed as definite melanomas or as obviously benign on dermoscopy was described (denoted as studies
in 'any lesion suspicious for melanoma' or 'any potential melanoma').
ii. RCM used as an addition to dermoscopy in participants with equivocal lesions in whom a clear management decision
could not be made following visual inspection and dermoscopy (denoted as studies in ‘equivocal’ lesions).
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iii. ‘Other’ studies which did not fit into either of these categories.
Our unit of analysis was the lesion rather than the person. This is because (i) in skin cancer initial treatment is directed to the
lesion rather than systemically (thus it is important to be able to correctly identify cancerous lesions for each person), and (ii)
it is the most common way in which the primary studies reported data. Although there is a theoretical possibility of
correlations of test errors when the same people contribute data for multiple lesions, most studies include very few people
with multiple lesions and any potential impact on findings is likely to be very small, particularly in comparison with other
concerns regarding risk of bias and applicability. For each analysis, only one dataset was included per study to avoid multiple
counting of lesions.
For each analysis undertaken, only one dataset was included per study to avoid over-counting of lesions. Where multiple
algorithms were assessed in an individual study, datasets were selected on the following preferential basis:
i. ‘no algorithm’ reported; data presented for clinician’s overall diagnosis or management decision
ii. pattern analysis or pattern recognition
iii. Pellacani’s RCM score
iv. Segura algorithm
v. Presence of statistically significant lesion characteristics
Where multiple thresholds per algorithm were reported, we included the standard or most commonly used threshold. If data
for multiple observers was reported, data for the most experienced observer was used, and data for a single observer’s
diagnosis was used in preference to a consensus or average across observers. If we were unable to choose a dataset based
on the above ‘rules’, a random selection of one dataset per study was made.
For each index test, algorithm or checklist under consideration, estimates of sensitivity and specificity were plotted on
coupled forest plots and in receiver operating characteristic (ROC) space. For tests where commonly used thresholds
were reported we estimated summary operating points (summary sensitivities and specificities) with 95% confidence and
prediction regions using the bivariate hierarchical model (Chu 2006; Reitsma 2005). Where inadequate data were
available for the model to converge the model was simplified, first by assuming no correlation between estimates
of sensitivity and specificity and secondly by setting estimates of near zero variance terms to zero (Takwoingi 2015). Where
all studies reported 100% sensitivity (or 100% specificity) the number with disease (or no disease) was summed across
studies and used to compute a binomial exact 95% confidence interval. Heterogeneity in estimates of sensitivity and
specificity was assessed by inspection of the magnitude and statistical significance of the estimates of variance terms in the
bivariate model.
We made comparisons between tests and in investigating heterogeneity by comparing summary ROC curves using
the hierarchical summary receiver-operator curves (HSROC) model (Rutter 2001). This allowed incorporation of data at
different thresholds and from different algorithms or checklists. We used an HSROC model that assumed a constant SROC
shape between tests and subgroups, but allowed for differences in threshold and accuracy by addition of covariates. The
significance of the differences between tests or subgroups was assessed by the likelihood ratio test assessing differences in
both accuracy and threshold, and by a Wald test on the parameter estimate testing for differences in accuracy alone. Simpler
models were fitted when convergence was not achieved due to small numbers of studies, first assuming symmetric SROC
curves (setting the shape term to zero), and then setting random effects variance estimates to zero.
Data on the accuracy of dermoscopy, to allow comparisons of tests, was included only if reported in the studies of
RCM due to the known substantial unexplained heterogeneity in all studies of the accuracy of dermoscopy (Dinnes 2018
). Comparisons were made between dermoscopy results with RCM data from all RCM studies, and then only using
RCM data from studies that also reported dermoscopy data for the same patients to enable a robust direct
comparison (Takwoingi 2013).
Estimates of accuracy from HSROC models are presented as diagnostic odds ratios (estimated where the SROC curve
crosses the sensitivity=specificity line) with 95% confidence intervals. Differences between tests and subgroups from
HSROC analyses are presented as relative diagnostic odds ratios with 95% confidence intervals. To facilitate interpretation
in terms of rates of false positive and false negative diagnoses, values of specificity at the point on the SROC curve with 90%
sensitivity have been computed. This value was chosen as it lies within the estimates for the majority of analyses. Results
should only be considered as illustrative examples of possible specificities and differences in specificities that could be
expected.
For computation of likely numbers of true positive, false positive, false negative and true negative findings in the 'Summary of
findings' tables, these indicative values were applied to lower quartile, median and upper quartiles of the prevalence
observed in the study groups.
Bivariate models were fitted using the meqrlogit command in STATA 13 and HSROC models fitted using the NLMIXED
procedure in the SAS statistical software package (SAS 2012, version 9.3; SAS Institute, Cary, NC, USA) and the
metadas macro (Takwoingi 2010).
Investigations of heterogeneity
We examined heterogeneity between studies by visually inspecting the forest plots of sensitivity and specificity and summary
ROC plots. Where a sufficient number of studies were identified, meta-regression was performed by adding the potential
source of heterogeneity as a covariate to a hierarchical model.
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Sensitivity analyses
No sensitivity analyses were done.
Assessment of reporting bias
Because of uncertainty about the determinants of publication bias for diagnostic accuracy studies and the inadequacy
of tests for detecting funnel plot asymmetry (Deeks 2005), no tests to detect publication bias were performed.
Results 
Results of the search
A total of 34,347 unique references were identified and screened for inclusion. Of these, 1051 full text papers were
reviewed for eligibility for any one of the suite of reviews of tests to assist in the diagnosis of melanoma or keratinocyte
skin cancer. Of the 1051 full text papers assessed, 848 were excluded from all reviews in our series (Figure 5 documents a
PRISMA flow diagram of search and eligibility results). A total of 85 studies were tagged as potentially eligible for the two
RCM reviews; ultimately, 22 publications were included, 18 in this review and 10 in the review of RCM for the detection of
keratinocyte skin cancers (6 were included in both). Reasons for exclusion included publications not being primary test
accuracy studies (n = 13), lack of test accuracy data (12 studies), because they were derivation studies developing new
algorithms or approaches to diagnosis without the use of separate training and test sets of data (n = 8), included ineligible
populations, e.g. including only malignant lesions (n = 6), did not assess eligible target conditions or did not adequately
define the target condition (n = 10), inadequate sample size (n = 15), assessed the accuracy of individual RCM
characteristics (n = 5) or used ineligible reference standards (i.e. less than 50% of benign group with final diagnosis
established by histology or follow-up; n = 3). A list of the 67 studies excluded from this review with reasons for exclusion is
provided in Characteristics of excluded studies, with a list of all studies excluded from the full series of reviews available as a
supplementary file.
The corresponding authors of five studies were contacted and asked to supply further information for this review. Responses
were received from two authors who provided additional data in relation to Pupelli 2013 and Alarcon 2014. Professor
Pellacani further provided information on lesion overlap between several included studies that were co-authored by him.
This review reports on a total of 19 cohorts of participants with lesions suspected of melanoma, published in 18
study publications, and providing 67 datasets for RCM and 7 for dermoscopy. A total of 2838 lesions were included,
658 with a diagnosis of melanoma. The total number of study participants cannot be estimated due to lack of
reporting in study publications. Two publications were split into two cohorts for the purposes of this review, one by
Pellacani and colleagues (Pellacani 2014a (cons) and Pellacani 2014b (doc)) and one by Guitera and colleagues (Guitera
2009a (Modena); Guitera 2009b (Sydney)). One of the 18 study publications (Pellacani 2007) was based on a combined
analysis of the two cohorts of lesions reported in the Guitera 2009 study and was included only to allow analysis of additional
algorithm thresholds and was not included in the main analyses. A description of the various algorithms and thresholds used
for diagnosis across the studies is provided in Appendix 5.
Methodological quality of included studies
The overall methodological quality of all included study cohorts is summarised in Figure 6 and Figure 7. The
denominator for this section is 20 cohorts because of the inclusion of two reports for the same group of lesions (Pellacani
2007; Guitera 2009). Studies were generally at high or unclear risk of bias across all domains and of high or unclear concern
regarding applicability of the evidence.
Just under 50% (n = 8) were at high risk of bias for participant selection due to inappropriate participant exclusions
Exclusions were variously made according to imaging failure, image quality or particular lesion types such as lentigo maligna.
Those at unclear risk of bias (n = 4) did not clearly describe participant recruitment as random or consecutive. All cohorts
were at high (n = 17) or unclear (n = 3) concern regarding included participants and setting, due to restricted study
populations (with 16 studies including only participants with melanocytic lesions, or even more narrowly defined populations
such as nodular lesions) and inclusion of multiple lesions per patient (with seven including over 5% more lesions than
participants and four not reporting the number of patients). Sixteen of the 20 cohorts included lesions selected for excision
based on the clinical or dermoscopic diagnosis or selected retrospectively from histopathology databases; this was not
considered of high concern regarding applicability for RCM studies as the primary role for RCM is to reduce unnecessary
excisions.
Three quarters of cohorts were at low risk of bias in the index test domain; all studies reported blinding of RCM interpretation
to the reference standard diagnosis and 16 reported pre-specification of the diagnostic threshold. Over half of studies were at
high concerns around the applicability of the index test, due to blinded interpretation of RCM images (fully blinded in six and
providing only information on patient age and lesion site in four), lack of detail regarding the diagnostic threshold used (n =
2), or interpretation by a non-expert observer (n = 1). It is of note that 15 of the 20 cohorts were produced by, or in
collaboration with, the same expert research team, led by Prof Pellacani which may further reduce the generalisability of
results.
Almost all cohorts reported use of an acceptable reference standard (n = 16), but only two clearly reported blinding of the
reference standard to the RCM result. None of the cohorts reported blinding of histology to the referral diagnosis (based on
clinical examination or dermoscopy), but this was not incorporated into the overall risk of bias for this domain. For the
applicability of the reference standard, two reported using expert diagnosis for some lesions and 13 were unclear regarding
histopathology interpretation by an experienced histopathologist or by a dermatopathologist.
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Six cohorts did not use the same reference standard for all participants (differential verification), 11 were unclear on the
interval between the application of the index test and excision for histology, and seven did not include all participants in the
analysis primarily due to technical difficulties in imaging.
For the 6 cohorts comparing RCM with dermoscopy, three reported blinding between tests and three reported no blinding,
but this did not contribute to the overall assessment of risk of bias. One study did not clearly report the interval between tests.
The clinical applicability of the application of the tests was of high concern due to reporting of average results for both tests
(n = 1) and of unclear concern due to the image-based nature of test interpretation (n = 5).
Findings
Primary target condition: invasive melanoma and atypical intraepidermal melanocytic variants
In this section we present the results for studies of RCM versus dermoscopy for the primary target condition of invasive
melanoma and atypical intraepidermal melanocytic variants, i.e. invasive malignant melanoma and melanoma in situ or
lentigo maligna, according to the study population: studies in all those with 'any lesion suspicious for melanoma' versus those
in participants with equivocal lesions. A number of different algorithms to assist RCM diagnosis were used across the
included studies; these are described in detail in Appendix 5.
Studies using RCM in any lesion suspicious for melanoma
The following section documents studies where RCM was used in all participants with lesions scheduled for excision. These
populations include both clinically or dermoscopically obvious melanomas, along with some lesions that are likely to be
benign, and a proportion of more difficult to diagnose (equivocal) lesions so that RCM was being evaluated as an addition to
current practice (which may or may not have included dermoscopy).
Eight publications provided data for 9 evaluations of RCM alone (Curchin 2011; Guitera 2009a (Modena); Guitera 2009b
(Sydney); Guitera 2012; Koller 2011; Langley 2007; Pellacani 2014b (doc); Rao 2013; Segura 2009) 3 of which also
included dermoscopy (Guitera 2009b (Sydney); Guitera 2009a (Modena); Langley 2007) (Table 2 and Figure 8). All
studies were case series (seven prospective in design and two unclear). Studies were undertaken in Europe (n = 4;
44%), Oceania (n = 2; 22%), North America (n = 2; 22%), or in more than one continent (n = 1; 11%). Four studies
(44%) were undertaken in a secondary care setting, 3 (33) in specialist skin cancer units and two (22%) in mixed
secondary care and specialist units. Six cohorts reported inclusion of lesions scheduled for excision on the basis of
clinical (Guitera 2012; Langley 2007) or dermoscopic (Guitera 2009a (Modena); Guitera 2009b (Sydney); Guitera 2012; 
Pellacani 2014b (doc)) suspicion of melanoma or due to lesions changes on follow-up (Guitera 2009a (Modena); Guitera
2009b (Sydney); Langley 2007; Segura 2009). Two further cohorts included lesions scheduled for excision but did
not describe any prior testing of participants (Curchin 2011; Rao 2013) and one (Koller 2011) provided no information as to
lesion selection. Two studies reported including any type of lesion (22%), three restricted to pigmented lesions only (33%),
and four restricted to melanocytic (44%) lesions only. Three studies (33%) excluded acral or awkwardly sited lesions and five
(56%) reported excluding on RCM image quality.
The median sample size was 137 patients (range 42 to 195; reported in 6 studies) and 131 lesions (range 50 to 323). The
median lesion to patient ratio was 1.07 (range 1 to 1.19) in 7 studies (and not stated in Koller 2011 or Rao 2013). Mean
age was given in five studies and ranged from 41 to 53 years and mean percentage of male participants ranged from
39.9 to 54.3%. The mean prevalence of disease was 27.6% (range 2.8% to 41.5%). On average melanoma in situ
lesions made up 25% of the disease positive group, ranging from 7.7% to 51.4%. The spectrum in the disease negative
groups also varied between studies with three studies including only benign melanocytic naevi (Koller 2011; Langley 2007; 
Segura 2009), three also including Spitz naevi (ranging from 3% (Guitera 2009b (Sydney)) to over 10% (Guitera 2009a
(Modena); Guitera 2012)), and the three remaining studies including BCC, SCC, and seborrhoeic and/or actinic
keratosis (Curchin 2011; Pellacani 2014b (doc); Rao 2013) amongst others (Pellacani 2014b (doc); Rao 2013).
More than half of studies used the Vivascope 1500 imaging system (n = 5), two used Vivascope 1000, and the remaining two
initially used the 1000 and moved on to the 1500 model during the course of the study. Six studies reported the use of
dermoscopic images to help guide acquisition of RCM images. In all studies, diagnosis was reported for a single observer
rather than for a consensus of observers or average value. Observers were dermatologists in four studies (44%), with three
studies reporting observers to be expert or with high levels of experience in practice and six (67%) with high levels of
experience with RCM. These characteristics were not reported in the remaining studies. In three studies diagnosis was
undertaken in-person with real time interpretation of RCM images; in the remaining six, test interpretation was undertaken
remotely based on RCM images alone (n = 2), alongside the dermoscopic image of the same lesion (n = 1), or with
information provided only on lesion site, patient age or gender (n = 3).
In 8 studies the reference standard diagnosis was made by histology alone (i.e. all lesions either excised or biopsied)
and in the remaining study expert diagnosis opinion based on “unequivocal clinical and conventional dermoscopic
criteria” was used to establish the final diagnosis for 46% (n = 31) of the disease negative group (Koller 2011).
Reflectance confocal microscopy
The 9 evaluations of RCM reported using Pellacani’s RCM score for four datasets (50%). One of these (Curchin 2011
) also applied the Guitera score (Guitera 2010) for lesions suspected of lentigo maligna of the face. One study
developed and applied the Segura algorithm (Segura 2009). The remaining studies reported test accuracy for
selected RCM characteristics (Langley 2007) or for observer diagnosis of melanoma (Koller 2011; Rao 2013).
Estimates of sensitivities ranged from 63% to 100% and specificities from 57% to 95% (Figure 8). The low sensitivity of 63%
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in Koller 2011 appeared as an outlier, all other studies having values at or above 86%. Similarly, specificities were above
82% in all studies except Pellacani 2014b (doc) (57%), Guitera 2009a (Modena) (58%), and Guitera 2012 (62%). Guitera
2009a (Modena) and Guitera 2012 both had higher than expected percentages of Spitz nevi (19% and 11% respectively)
whereas Koller 2011 was one of two studies to use the Vivascope 1000 throughout. The lower specificity in Pellacani 2014b
(doc) is more difficult to explain, but may be related to the fact that all included lesions were considered to require excision
based on dermoscopy alone, which may have affected the case-mix of lesions in a way that we are not able to identify.
Correctly identified basal cell carcinoma lesions were considered true negatives for the purposes of these calculations for
Guitera 2012 and Rao 2013.
Results were pooled across algorithms and thresholds as a summary ROC curve (Figure 9). Estimates of accuracy
obtained from the curve suggest that the specificity of RCM would be 82% at a fixed threshold of 90% sensitivity (Table 3).
Comparison of RCM versus dermoscopy
The three evaluations of dermoscopy that were included in these RCM studies reported using pattern analysis to
assist dermoscopy interpretation; two were conducted in-person (Guitera 2009a (Modena); Langley 2007) and one
was based on dermoscopic images with information on lesion site and patient age only (Guitera 2009b (Sydney)).
Sensitivities for dermoscopy ranged from 86% to 91%; specificities ranged from 28% to 84% (Figure 8). The accuracy
of dermoscopy was compared with the accuracy of RCM estimated from (a) all 9 RCM studies (Figure 9) and
estimated from direct comparisons in (b) with the subset of 3 studies that evaluated both RCM and dermoscopy (Figure 10
). In both comparisons the accuracy of RCM exceeded that of dermoscopy (Table 3). In (a) the diagnostic odds ratio
(DOR) for RCM was 4.82 (95% CI 2.16 to 10.8; P = 0.0001) times that of the dermoscopy, in (b) it was 4.96 (95% CI
1.1 to 21.5; P = 0.03) times that of the dermoscopy. These effects correspond to predicted differences in specificity of
(a) 40% (82% versus 42%) and (b) 52% (93% versus 41%) at a fixed sensitivity of 90% (Table 3).
Equivocal lesion studies
We defined equivocal lesion studies as those in which RCM was used in participants with equivocal lesions in whom a clear
management decision could not be made following visual inspection and/or dermoscopy, i.e. RCM was being evaluated as a
potential addition to dermoscopy.
Seven publications provided data for 7 evaluations of RCM alone (Alarcon 2014; Farnetani 2015; Ferrari 2015; Lovatto 2015;
Pellacani 2012; Pellacani 2014a (cons); Stanganelli 2015) and 3 of dermoscopy (Alarcon 2014; Ferrari 2015; Stanganelli
2015) (Table 3 and Figure 11). All studies were case series; three (43%) were prospective in design and four (57%)
retrospective, three of which prospectively reinterpreted previously acquired RCM images. Studies were all
undertaken in Europe (100%). Three studies (43%) were undertaken in a secondary care setting and four (57%) in
specialist skin cancer units. All studies reported some degree of prior testing of participants, with two (29%)
selecting lesions that were equivocal on either clinical examination or dermoscopy (Farnetani 2015; Pellacani 2012),
three (43%) with all lesions equivocal on dermoscopy (Alarcon 2014; Ferrari 2015; Pellacani 2014a (cons)), and two
(29%) selecting lesions showing changes on digital follow-up (Lovatto 2015; Stanganelli 2015). One study reported including
any type of lesion (14%), one restricted to pigmented lesions only (14%) and five restricted to melanocytic (71%) lesions
only. Three (43%) studies reported excluding lesions on RCM image quality.
The median sample size was 70 patients (range 62 to 264; reported in 5 studies) and 100 lesions (range 60 to 308), giving a
median lesion to patient ratio of 1.05 (range 1 to 1.22). Mean age was reported in 5 studies and ranged from 39 to 54.7 years
and mean percentage of male participants was from 44.0 to 54.0%. The mean prevalence of the primary target condition of
18.2% (range 1.9% to 34.8%) was lower compared to the studies in any lesion suspicious for melanoma as would be
expected in a group of more difficult to diagnose lesions. On average melanoma in situ lesions made up 28.6% of the
disease positive group, ranging from 8.3% to 61.5% (breakdown reported for four datasets). The spectrum in the
disease negative groups also varied with four studies including only (Lovatto 2015) or primarily (Ferrari 2015; Pellacani 2012;
Stanganelli 2015) benign naevi, although in one of these non-dysplastic naevi made up 41% of the disease negative
group. Three included BCC and a range of other diagnoses including seborrheic or actinic keratosis (Alarcon 2014; 
Farnetani 2015) or Spitz naevi (Pellacani 2014a (cons)).
All studies in this group used the Vivascope 1500 imaging system (100%); none reported the use of dermoscopic images to
help guide acquisition of RCM images. Diagnosis was reported for a single observer in 71% of studies (n = 5), for a
consensus of three observers in one study and was not reported in the remaining study. Observers were qualified
dermatologists in five studies (71%), and four studies reported observers to have high levels of experience in practice and
five (71%) reported high levels of experience with (or training in) RCM. These observer characteristics were not reported in
the remaining studies. In one study, diagnosis was undertaken in-person with real time interpretation of RCM images; in the
remaining six, test interpretation was undertaken remotely based on RCM images alone (n = 3) or alongside the
dermoscopic image of the same lesion (n = 3), with information provided only on lesion site, patient age or gender in one of
these.
In six studies the reference standard diagnosis was made by histology alone (i.e. all lesions either excised or
biopsied) and in the remaining study 227 of 308 lesions referred for RCM consultation underwent surveillance using
sequential digital dermoscopy follow-up and cancer registry searches for those lost to follow-up; 28 lesions were
excised during follow-up and found to be benign (Pellacani 2014a (cons)).
Reflectance confocal microscopy
The 7 evaluations of RCM reported using Pellacani’s RCM score (Lovatto 2015) or use of the RCM score was
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assumed due to study authorship (Pellacani 2014a (cons)), the Segura algorithm (Alarcon 2014) or the Pellacani
two step algorithm for dysplastic naevi and melanoma (Pellacani 2012; Stanganelli 2015). The remaining studies
reported test accuracy for the presence of statistically significant RCM characteristics (Ferrari 2015) or for observer
diagnosis of melanoma (Farnetani 2015).
Estimates of sensitivities ranged from 80% to 100% and specificities from 67% to 95% (Figure 11). There were no obvious
outliers or heterogeneity in sensitivities, and no consistent differences to potentially explain the observed heterogeneity in
specificities. Correctly identified BCC lesions were considered true negatives for the purposes of these calculations for
Farnetani 2015 and Pellacani 2014a (cons).
Results were pooled across algorithms and thresholds as a summary ROC curve (Figure 12). Estimates of accuracy
obtained from the curve suggest that specificity would be 86% at a fixed threshold of 90% sensitivity (Table 3). These values
for specificity are higher than those observed in studies in any lesion suspicious for melanoma, reflecting the marginally
higher values and lower variability of sensitivities in the equivocal lesion studies.
Comparison of RCM versus dermoscopy
The three evaluations of dermoscopy that were included in these RCM studies reported using the seven point
checklist for dermoscopy (Ferrari 2015) or a revised version thereof (Stanganelli 2015), or did not report the approach
to dermoscopy interpretation (Alarcon 2014). All were image-based diagnoses; two studies provided the RCM image
with (Alarcon 2014) or without (Ferrari 2015) additional patient or lesion information to assist diagnosis, and one
providing a baseline dermoscopic image (Stanganelli 2015).
The accuracy of dermoscopy was compared with the accuracy of RCM estimated from (a) all 7 RCM studies (Figure 12
) and estimated from direct comparisons in (b) with the subset of 3 studies that evaluated both RCM and dermoscopy (
Figure 13). The meta-analytical model for the paired analysis (b) required assumptions of a symmetrical SROC curve and
fixed effects for accuracy and threshold to obtain convergence.
It is notable that the accuracy of dermoscopy in these studies (DOR=3.0 (95% CI 1.3 to 6.8)) is much lower than in
those in any lesion suspicious for melanoma (DOR = 14.4 (95% CI 2.7 to 77.6)), as would be expected given by
definition these studies are those in where diagnoses involving dermoscopy are equivocal, i.e. they include lesions to
be excised because a clear diagnosis could not be reached on clinical examination or dermoscopy. In both
comparisons the accuracy of RCM exceeded that of dermoscopy (Table 3). In (a) the diagnostic odds ratio (DOR) for
RCM was 20.1 (95% CI 6.6 to 61.3; P<0.001) times that for dermoscopy, in (b) it was 22.1 (95% CI 1.7 to 283.6; P =
0.03) times that of the dermoscopy. These effects correspond to predicted differences in specificity of (a) 37% (86%
versus 49%) and (b) 50% (94% versus 44%) at a fixed sensitivity of 90% (Table 3).
Analyses by algorithms used to assist RCM – all studies
The 18 included studies provided 25 datasets evaluating the accuracy of different algorithms or approaches to diagnosis with
RCM at a number of different thresholds for test positivity for the detection of invasive melanoma or atypical intraepidermal
melanocytic variants. A description of the various algorithms and thresholds is provided in Appendix 5. One dataset
from Pellacani and colleagues (Pellacani 2007) was excluded due to overlap in study population, algorithm and
threshold with a study by Guitera and colleagues (Guitera 2009a (Modena); Guitera 2009b (Sydney)).
Figure 14 provides forest plots of all algorithms for the detection of invasive melanoma or atypical intraepidermal melanocytic
variants, with meta-analytical estimates at each threshold presented in Table 4. We did not formally make any
comparisons between the algorithms due to the small number of studies available evaluating each algorithm. Whilst the
specificity of the computer–assisted approach to analysis of RCM images (Koller 2011) appears to be much lower than any
other algorithm, the ranges of values for different algorithms are largely comparable.
Pellacani’s RCM score
Pellacani’s RCM score (Pellacani 2005; Pellacani 2007) was the most commonly evaluated formal algorithm for the
detection of melanoma (8 studies; 10 datasets), with data reported at thresholds of ≥ 2, ≥ 3 and ≥ 4. One study (Pellacani
2014b (doc); Pellacani 2014a (cons)) did not report the threshold used and contact with authors was unsuccessful;
as it cited one of the original Pellacani and colleagues papers (Pellacani 2007), the recommended threshold of ≥ 3
was assumed. The majority of datasets were image-based, with only two studies providing data for in-person
evaluations (Curchin 2011; Pellacani 2014b (doc); Pellacani 2014a (cons)). The majority of datasets were from
studies in any lesion suspicious for melanoma (Curchin 2011; Guitera 2012; Guitera 2009a (Modena); Guitera 2009b
(Sydney); Guitera 2012; Pellacani 2007; Pellacani 2014b (doc)) with only two from studies of equivocal lesions (Lovatto
2015; Pellacani 2014a (cons)). One study provides two datasets at different thresholds (Pellacani 2007); hence, the total
number of datasets is 10.
The pooled accuracy combining data from all 6 studies reporting (or assumed to be) at RCM score ≥ 3 was a sensitivity
of 92% (95% CI 87% to 95%) and specificity of 72% (95% CI 62% to 81%). Lower thresholds had higher sensitivity but
lower specificity, higher thresholds had lower sensitivity but higher specificity (Table 4).
Segura score
The Segura algorithm, developed in Segura 2009 was evaluated in three further studies (Alarcon 2014; Guitera 2012; 
Lovatto 2015) at the standard threshold of >-1. All datasets were image-based; test interpretation was blinded to any
further information in two (Lovatto 2015; Segura 2009), two one provided the observer with patient age and lesion
site (Alarcon 2014; Guitera 2012), one of which also provided the dermoscopic image (Alarcon 2014). Two studies
#164b Reflectance confocal microscopy for the diagnosis of cutaneous melanoma in adults
15 / 163
were conducted in equivocal lesions (Alarcon 2014; Lovatto 2015) and two in 'any lesion suspicious for melanoma'
populations (Segura 2009; Guitera 2012). The pooled accuracy combining data from all four studies was a sensitivity of
92.6% (76.2% to 98.0%) and specificity of 87.5% (72.2% to 95.0%) (Table 4).
Other formally developed algorithms
Guitera 2012 reported a two-step algorithm to firstly differentiate BCC from other lesions and then melanoma from the
remaining lesions. In this single study the melanoma component of the algorithm demonstrated a sensitivity of 78% (95% CI
69% to 86%) and specificity of 84% (95% CI 79% to 88%).
Pellacani 2012 also developed a two-step algorithm, this time to differentiate dysplastic from non-dysplastic lesions and then
melanoma from dysplastic lesions. The same algorithm was evaluated in Stanganelli 2015. Combined accuracy was a
sensitivity of 96% (95% CI 72% to 100%) and specificity of 71% (95% CI 61% to 79%) (Table 4).
Finally, Koller 2011 reports a computer–assisted approach to analysis of RCM images. This demonstrated a perfect
sensitivity of 100% (95% CI 86% to 100%) but a very poor specificity of 24% (95% CI 14% to 35%) (Table 4).
‘No algorithm’ evaluations
Seven studies reported accuracy data for RCM without the use of a formally developed algorithm.
The three datasets reporting accuracy based on the presence of statistically significant characteristics (Ferrari 2015; Pupelli
2013) or selected lesion characteristics (Langley 2007), had sensitivities ranging from 89% to 97% and specificities from
70% to 90%.
The four datasets reporting accuracy for observer diagnosis of melanoma were all image-based (all except one (Koller 2011
) also providing the dermoscopic image to test interpreters), two conducted in 'any lesion suspicious for melanoma'
populations (Koller 2011; Rao 2013), one in equivocal lesions (Farnetani 2015) and one in ‘other’ populations (Figueroa
Silva 2016). The pooled accuracy of the four studies gave an estimated sensitivity of 81% (95% CI 65% to 91%) and
specificity of 88% (95% CI 78% to 94%).
Rao 2013 also provides a direct comparison of image-based test interpretation by an experienced observer to in-person real-
time diagnosis by a less experience observer. Sensitivity was lower for the in-person evaluation (67%, 95% CI 30% to 93%)
compared to image-based (89%, 95% CI 52% to 100%), although confidence intervals were wide and overlapping.
Specificities were almost identical for the two approaches (96% versus 95%).
Overall, observed sensitivities appeared higher for studies reporting the use of a ‘named’ algorithm and were very similar
(92%) between studies using the most widely used algorithms (Pellacani’s RCM score and the Segura score). Summary
specificity was higher for the Segura algorithm (87.5%) compared to the RCM score (72%), although it was used in fewer
studies (4 versus 6), the number of lesions evaluated was higher (784 versus 420).
Investigations of heterogeneity
Results for formal investigations of heterogeneity are presented in Table 5, investigating the effects of use of any RCM
scale versus no scale (Figure 15), in-person versus image-based (Figure 16), and whether RCM is used in all lesions
or only equivocal lesions (Figure 17). Although RCM appeared to be more accurate when interpreted using a scale
(relative diagnostic odds ratio (DOR) compared to studies not reporting use of a scale of 1.81, 95% CI 0.41 to 8.03),
from in-person studies (relative DOR in comparison to image-based studies 4.77, 95% CI 0.56 to 40.8), and when used
on equivocal lesions (relative DOR in comparison to 'any lesion suspicious for melanoma' populations 2.88, 95% CI
0.80 to 10.4), none of the differences reached levels of statistical significance (Table 5).
The impact of observer experience on RCM accuracy is shown in Figure 18 for equivocal lesions and Figure 19 for
'any lesion suspicious for melanoma' populations. Overall, only three studies classified any observer as having low
experience (Curchin 2011; Farnetani 2015; Rao 2013), too few to allow any conclusive analyses.
We were unable to undertake investigations of heterogeneity for other characteristics listed in the protocol due to lack of
variation in characteristics, or absence of information in the study reports.
Target condition: invasive melanoma alone
In this section we present the results for studies of RCM for the target condition of invasive melanoma only; no comparisons
with dermoscopy were identified for this target condition. All studies were conducted in 'any lesion suspicious for melanoma'
populations, i.e. no attempt was described to exclude those diagnosed as definite melanomas or as obviously benign on
dermoscopy.
Three study cohorts provided data for 3 evaluations of RCM (Curchin 2011; Guitera 2012; Segura 2009) (Figure 20). All
studies were case series (two prospective in design and one unclear). Studies were undertaken in Europe (n = 1), Oceania
(n = 1), or in more than one continent (n = 1). All studies were undertaken in a secondary care setting (n = 2) or a mixed
secondary care specialist unit setting (n = 1). Two studies reported including any type of lesion and one restricted to
melanocytic lesions only. One study excluded keratotic lesions. The sample size ranged from 42 to 330 patients and 50 to
356 lesions. The mean lesion to patient ratio was 1.11 (range 1.07 to 1.19). Mean age was given in two studies and ranged
from 49.5 to 53 years; the percentage of male participants ranged from 39.9 to 53.4%. The mean prevalence of disease was
20.4% (range 14.3% to 24.0%). The percentage of melanoma in situ lesions in the disease negative group ranged from 2.6%
to 17.7%.
All studies used the Vivascope 1500 imaging system; two reporting the use of dermoscopic images to help the guide
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acquisition of RCM images. All studies reported diagnosis for a single observer, though only one clearly reported that this
was by an experienced dermatologist. One reported in-person real time interpretation of RCM images and two reported RCM
interpretation remotely from the patient (one blinded to any other information an done supplied details of patient age and
lesion site). The reference standard diagnosis was made by histology alone in all studies.
Segura 2009 developed and applied a new algorithm (denoted the Segura algorithm) to a set of melanocytic lesions at
a threshold of >-1 (BCCs and benign non melanocytic lesions were excluded); sensitivity was 96% (95% CI 78% to
100%) and specificity 84% (95% CI 74% to 92%) (Figure 21).
One study (Curchin 2011) used Pellacani’s RCM score at a threshold of ≥ 3 and also applied the Guitera score (Guitera
2010) for lesions suspected of lentigo maligna of the face; sensitivity was 100% (95% CI 74% to 100%) and
specificity 92% (95% CI 79% to 98%). The remaining study (Guitera 2012) reported the melanoma component of a two-step
algorithm to have a sensitivity of 78% (95% CI 65% to 89%) and specificity of 86% (95% CI 81% to 90%). Correctly identified
melanoma in situ, BCC and SCC were considered true negative results for the purposes of these calculations.
Insufficient data were available to make any overall summary of test accuracy for this target condition.
Target condition: any skin cancer (melanoma or other skin cancer) or skin lesion with a high risk of progression
to melanoma
In this section we present the results for studies of RCM versus dermoscopy for the target condition of any skin cancer
(melanoma or other skin cancer) or skin lesion with a high risk of progression to melanoma, i.e. any invasive skin cancer,
melanoma in situ or lentigo maligna and lesions with severe dysplasia, according to the study population: studies in any
lesion suspicious for melanoma versus those in participants with equivocal lesions.
Studies in any lesion suspicious for melanoma
Four study cohorts provided data for four RCM evaluations (Curchin 2011; Guitera 2012; Pellacani 2014b (doc); Rao 2013
) (Figure 20). All studies were case series (two prospective in design and two unclear). Studies were undertaken in Europe (n
= 1), North America (n = 1), Oceania (n = 1), or in more than one continent (n = 1). All studies were undertaken in a
secondary care setting (n = 2) or a mixed secondary care specialist unit setting (n = 2). Three studies included all lesion
types and Pellacani 2014b (doc) included pigmented lesions only. The sample size ranged from 42 to 330 patients
(reported in three studies) and 50 to 356 lesions. The lesion to patient ratio ranged from 1.07 to 1.19. Mean age was
given in three studies and ranged from 41 to 53 years; the percentage of male participants was ranged from 44% to 54%
(n = 3). The mean prevalence of disease was 33.8% (range 22.9% to 44.1%). The percentage of invasive melanoma or
melanoma in situ lesions in the disease positive group was 12% (Rao 2013), 46% (Pellacani 2014b (doc); 59% (Curchin
2011) and 63% (Guitera 2012); invasive SCCs were included as disease positive for both Rao 2013 (5% of disease positive
group) and Guitera 2012 (54% of disease positive group) but could not be differentiated from sebhorrheic keratoses in
Curchin 2011 and were therefore included in the disease negative group (n = 6; or 21% of disease negative group). Pellacani
2014b (doc) did not report including any cSCCs.
All studies used the Vivascope 1500 imaging system and reported the use of dermoscopic images to help the guide
acquisition of RCM images. All studies reported diagnosis for a single observer, though only one clearly reported that
this was by an experienced dermatologist. Two reported in-person real time interpretation of RCM images (Curchin 2011; 
Pellacani 2014b (doc)) and two reported RCM interpretation remotely from the patient (Guitera 2012 supplied details of
patient age and lesion site and Rao 2013 presented the dermoscopic image to aid interpretation). The reference standard
diagnosis was made by histology alone in all studies.
Curchin 2011 and Pellacani 2014b (doc) used Pellacani’s RCM score at a threshold of ≥ 3, Guitera 2012 reported data for
their new two-step algorithm for detection of BCC or melanoma and Rao 2013 reported observer diagnosis. Estimates of
sensitivities ranged from 85% to 100% and specificities from 52% to 89%.
Equivocal lesion studies
Three studies provided data for three evaluations of RCM alone (Farnetani 2015; Pellacani 2012; Pellacani 2014a (cons)
) (Figure 20). All studies were case series (two prospective in design and one retrospective with prospective
reinterpretation of images). All studies were undertaken in Europe, all in Italy. Two studies were undertaken in a
secondary care setting (n = 2) and one in a specialist clinic. One study recruited any lesion type, one restricted to
pigmented lesions and one to melanocytic lesions only. The sample size ranged from 62 to 252 patients (reported in
two studies) and 60 to 308 lesions. The lesion to patient ratios where reported were 1.03 (Pellacani 2012) and 1.22
(Pellacani 2014a (cons)). Mean age was given in two studies and ranged from 41 to 47.7 years; the percentage of male
participants ranged from 44% to 52% (2 studies). The mean prevalence of disease was 24.9% (range 8.1% to 35.0%). The
mean percentage of invasive melanoma or melanoma in situ lesions in the disease positive group was 51.6% (range 24% to
73.6%).
All studies used the Vivascope 1500 imaging system and reported diagnosis for a single observer. Observers were
described as dermatologists in two studies. One reported in-person real time interpretation of RCM images (Pellacani 2014a
(cons)) and two reported RCM interpretation remotely from the patient (one blinded (Pellacani 2012) and one
appeared to supply dermoscopic image to aid interpretation (Farnetani 2015), although this was not well reported).
The reference standard diagnosis was made by histology alone in two studies and was supplemented by clinical
and cancer registry follow-up in the other (Pellacani 2014a (cons)).
One study developed a two step algorithm to differentiate dysplastic from non-dysplastic lesions and then
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melanomas from dysplastic lesions (Pellacani 2012), one reported the observers overall diagnosis (Farnetani 2015
), and one did not report the algorithm used but was assumed to have used Pellacani’s RCM score, based on study
authorship (Pellacani 2014a (cons)). Estimates of sensitivities ranged from 86% to 100% and specificities from 80% to 91%.
Analyses by algorithms used to assist RCM – all studies
The 6 included studies provided 11 datasets evaluating the accuracy of different algorithms or approaches to diagnosis with
RCM at different thresholds for test positivity for the detection of any skin cancer or skin lesion with a high risk of progression
to melanoma. A description of the various algorithms and thresholds used for diagnosis across the studies is provided in
Appendix 5. One dataset from Pellacani and colleagues (Pellacani 2007) was excluded due to overlap in study
population, algorithm and threshold with a study by Guitera and colleagues (Guitera 2009a (Modena); Guitera 2009b
(Sydney)).
Figure 22 provides forest plots of all algorithms and thresholds, with meta-analytical estimates at each threshold presented in
Table 4. We did not formally make any comparisons between the algorithms due to the small number of studies available
evaluating each algorithm.
Pellacani’s RCM score
Pellacani’s RCM score was evaluated in three datasets, one (Curchin 2011 in an ‘any potential melanoma’
population) reported results at a threshold of ≥ 3 and two (from a single study in equivocal lesions (Pellacani 2014b (doc); 
Pellacani 2014a (cons)) that did not report the threshold used but the recommended threshold of ≥ 3 was assumed,
as discussed above. All three datasets were from in-person evaluations of RCM, one with interpretation by an RCM
novice (Curchin 2011), and the other two by members of a ‘confocal unit’ assumed to be expert in RCM use.
RCM sensitivities were relatively high in all studies (≥ 86%), with lower specificities in the two studies of
dermoscopically equivocal lesions (Pellacani 2014b (doc); Pellacani 2014a (cons)). The pooled accuracy combining
data from all 3 datasets reporting (or assumed to be) at RCM score ≥ 3 was a sensitivity of 98% (95% CI 91% to 99%)
and specificity of 75% (95% CI 54% to 89%) (Table 4).
Other formally developed algorithms
Three other algorithms were each evaluated in a single dataset each for detection of any skin cancer (melanoma or other
skin cancer) or skin lesion with a high risk of progression to melanoma. The Segura algorithm and Guitera two-step algorithm
were both evaluated in Guitera 2012, and the Pellacani two-step algorithm in Pellacani 2012.
All studies used image-based evaluations of RCM, one study conducted in equivocal lesions was blinded to any
further information (Pellacani 2012) and the other (in an any potential melanoma population) provided details of
patient age and lesion site only (Guitera 2012).
Guitera 2012 reported a sensitivity of 92% and specificity of 68% for their two-step algorithm (with 9 SCCs considered as
disease positive) compared to a sensitivity of 80% and specificity 70% for the Segura algorithm (the 9 SCCs could only be
considered disease negative for this calculation due to lack of disaggregated data however, classing the 9 SCCs as disease
negative for the Guitera two-step algorithm made very little difference to the estimate of sensitivity and specificity). Pellacani
2012 estimated sensitivity and specificity for their two-step algorithm as 89% and 80% respectively.
‘No algorithm’ evaluations
Two studies reported accuracy data for observer diagnosis with RCM without the use of a formally developed algorithm by
different observers and at more than one threshold.
Farnetani 2015 reports data for in-person diagnosis of malignancy by nine different observers with varying levels of
experience. Rao 2013 provides a comparison of image-based test interpretation by an experienced observer to in-person
real-time diagnosis by a less experienced observer in an 'any lesion suspicious for melanoma' population for the diagnosis of
any malignancy and for the decision to excise a lesion. There was a slight discrepancy in the number of lesions between in-
person (n = 318) and image-based (n = 323) interpretations. For the diagnosis of any malignancy, the sensitivity was 78%
(95% CI 67% to 87%) for in-person diagnosis and 85% (95% CI 75% to 92%) for image-based; specificities were 85% (95%
CI 80% to 89%) and 86% (95% CI 81% to 90%), respectively. For the decision to excise a lesion, the sensitivity was 85%
(95% CI 75% to 92%) for in-person diagnosis and 90% (95% CI 81% to 95%) for image-based; specificities were 61% (95%
CI 55% to 68%) and 79% (95% CI 73% to 84%), respectively.
For the diagnosis of malignancy by an experienced observer, the pooled data across the two studies (using the image-based
data from Rao 2013) gave an estimated sensitivity of 85% (95% CI 77% to 90%) and specificity of 87% (95% CI 83% to
90%).
Evaluations of RCM in other study populations
Three evaluations of RCM in other study populations were identified.
Pupelli 2013 selected confocal images of 24 melanomas of < 5 mm diameter and three histologically proven small-diameter
naevi controls per melanoma (n = 72) that were excised within the same time frame. Images were interpreted alongside the
dermoscopic image plus information on patient age and site. The presence of three statistically significant lesion
characteristics led to an estimated sensitivity of 83% (95% CI 63% to 95%) and specificity of 90% (95% CI 81% to 96%) for
the detection of invasive melanoma and atypical intraepidermal melanocytic variants.
Figueroa Silva 2016 included a series of 63 images of pigmented lesions with a clear-cut ‘dermoscopy island’, defined as “a
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well-circumscribed area showing a uniform dermoscopic pattern, different from the rest of the lesion”. A single observer
assessed the RCM images (blinded to all other information apart from dermoscopy) for the presence or absence of a number
of lesion characteristics and provided an overall diagnosis. The estimated sensitivity and specificity for the detection of
invasive melanoma and atypical intraepidermal melanocytic variants was 89% (95% CI 71% to 98%) and 89% (95% CI 74%
to 97%). For the detection of invasive melanoma only (n = 7) and considering the 19 melanoma in situ lesions as disease
negative, the sensitivity is 88% and specificity 62%.
Longo 2013 examined the use of RCM for the diagnosis of nodular melanoma. A series of images of clinically nodular lesions
(defined as cutaneous palpable or superficial seated lesions) were interpreted by a single dermatologist blinded to all other
information. For the diagnosis of invasive nodular lesions, the sensitivity was 100% and specificity 91%.
Discussion 
Summary of main results
RCM has been evaluated in a range of study populations and using a number of different algorithms. Sensitivity is generally
high across studies and target conditions, but there is considerable heterogeneity in specificity. Studies were generally at
high or unclear risk of bias across almost all domains and of high or unclear concern regarding applicability of the evidence,
limiting the strength of conclusion that can be drawn. The Summary of findings table 1 presents key results for the primary
target condition of cutaneous invasive melanoma or atypical intraepidermal melanocytic variants.
Across all algorithms and thresholds assessed, the Pellacani RCM score at a threshold of ≥ 3 has the largest number of
datasets for any one threshold; sensitivity was estimated at 92% and specificity at 72%. RCM accuracy was similar between
'any lesion suspicious for melanoma' studies and equivocal lesion studies, with sensitivities consistently around or above
90% but with much greater variation in specificities. In comparison to dermoscopy, RCM was found to be more accurate in
both participant groups, i.e. those with all lesions suspected of melanoma, and in equivocal lesion populations. Due to
differences in the algorithms and thresholds used between studies, analysis required use of a summary ROC curve, and to
aid interpretation we quote ‘typical’ summary results assuming a fixed sensitivity of 90% for both tests. The Summary of
findings table 1 translates these estimates to a hypothetical cohort of 1000 lesions. For 'any lesion suspicious for melanoma'
studies, specificities were 82% for RCM and 42% for dermoscopy at a sensitivity of 90% for both tests. At disease
prevalences of 26, 30 and 36%, using RCM as an alternative to dermoscopy would reduce false positives (or number of
excisions that would be performed) by 296, 280 and 256 per 1000 compared with dermoscopy alone. Both tests would miss
26, 30 and 36 melanomas at each respective prevalence of melanoma. For equivocal lesion studies, specificities were 86%
for RCM and 49% for dermoscopy at a sensitivity of 90% for both tests. At disease prevalences of 10%, 20% and 23%, using
RCM in addition to dermoscopy would reduce the number of excisions by 333, 296 and 285 per 1000. Both tests would miss
10, 20 and 23 melanomas at each respective prevalence of melanoma. Investigations of heterogeneity were limited due to
paucity of data but suggested higher RCM accuracy in equivocal lesions and from in-person evaluations of RCM images.
Strengths and weaknesses of the review
The strengths of this review include an in-depth and comprehensive electronic literature search, systematic review methods
including double extraction of papers by both clinicians and methodologists, and contact with authors to allow study inclusion
or clarify data. A clear analysis structure according to patient pathway was adopted to allow test accuracy in different study
populations to be estimated and a detailed and replicable analysis of methodologic quality was undertaken.
The main concerns for the review are a result of the poor reporting of primary studies, in particular forcing some assumptions
to be made to allow studies to be split by pathway and in separating studies by the different definitions of the target condition.
In terms of the separation of studies by pathway, although some assumptions were made, it emerged that the studies in each
group could almost have been separated by disease prevalence, with higher rates in the 'any lesion suspicious for
melanoma' group (ranging from 26% to 42% with one outlier at 3%), as would be expected in studies that included more
obvious melanomas, and lower rates in the equivocal lesion group (ranging from 2% to 27%), again as would be expected
with more clinically difficult lesions.
Clear identification of the target condition was not provided in three of the 16 cohorts included in our primary analyses
for detection of invasive melanoma or atypical intraepidermal melanocytic variants. The inclusion of melanoma in situ
lesions as disease positive was eventually discerned from the text of two papers (Alarcon 2014; Ferrari 2015) and
was assumed for the third study (Farnetani 2015). Where studies included other invasive skin cancers in the study
population, we attempted to class any that were correctly identified as true negative results as opposed to false positives, on
the basis that removal of any skin cancer in the attempt to identify melanomas would not be a negative consequence of the
test. This relied on studies providing a disaggregation of test results according to final lesion classification and was not
always possible, particularly when invasive SCCs were not separated from ‘in situ’ lesions such as Bowen’s disease.
Finally, observer expertise is key for any diagnostic process based on visual inspection, with both non-analytical
pattern recognition (implicit identification) and analytical pattern recognition (using more explicit ‘rules’ based on
conscious analytical reasoning) employed to varying extents between clinicians, according to factors such as
experience and familiarity with the diagnostic question (Norman 2009). Notably, research in this field has been dominated by
a single expert group and results obtained from a more typical range of specialists in different countries, health care systems
and settings are needed. A lack of clear reporting of observer training and experience in RCM made analysis difficult.
Given these limitations, our results should be considered as exploratory rather than conclusive. Our results are
however, generally in accord with those of other recently published systematic reviews (Xiong 2016; Edwards 2016),
one of which was conducted as part of a technology assessment report for NICE (Edwards 2016), despite differences in
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methodological approaches. Xiong 2016 did not consider varying definitions of the target condition in their primary
analysis but pooled all studies regardless of detection of melanoma, BCC or SCC (our examination of RCM for the
diagnosis of keratinocyte skin cancers is reported in a separate systematic review in our series (Dinnes 2015a)). In a
secondary analysis, eight studies with melanoma as the ‘focus’ were pooled, producing estimates of sensitivity of
92.7% (95% CI 90.0 to 94.9) and specificity of 78.3% (95% CI 0.76 to 0.81) (Xiong 2016). No consideration was given
to differences in patient populations, two studies were excluded from our review (Gerger 2005; Guitera 2010) and two
of the included studies reported on the same set of lesions (Guitera 2009; Pellacani 2007).
The Edwards 2016 review did not conduct a meta-analysis, instead selecting studies considered to be more applicable to a
UK setting. Using studies with ‘optimistic’ accuracy data (sensitivity 97% and specificity 94% in Alarcon 2014) and with ‘less
favourable’ (sensitivity 100% and specificity 51% from Pellacani 2014) accuracy, deterministic incremental cost-
effectiveness ratios (ICER) for RCM in comparison to ‘usual practice’ were estimated for patients with
dermoscopically equivocal lesions (assuming that two thirds of lesions would be excised and the remainder
monitored). Resulting QALYs ranged £8877 using ‘optimistic’ data to £19,095 (Edwards 2016). The report concluded that
data are lacking to allow generalisability to a UK setting.
Applicability of findings to the review question
The data included in this review is generally applicable to the clinical setting. Most of the studies used the current version of
the only commercially available RCM system, the Vivascope 1500. Narrow definitions of the eligible study populations and
lack of clarity regarding the patient pathway and any prior testing may restrict applicability, and the use of remote image-
based diagnosis largely by RCM experts further restrict the transferability of results to a clinical setting.
Authors' conclusions 
Implications for practice 
RCM may have a potential role in clinical practice, particularly for the assessment of melanocytic lesions identified as
equivocal following visual inspection and dermoscopy, where the evidence suggests that RCM may be both more sensitive
and specific in comparison to dermoscopy. Given the paucity of data to allow comparison with dermoscopy, we presented
illustrative data assuming that both tests are similarly sensitive. On this basis, for all lesions suspicious for melanoma, with
RCM essentially used as a replacement for dermoscopy, the number of inappropriate excisions could potentially be reduced
by up to two thirds. Given the additional expense and training required for RCM, the evidence for improved accuracy is
insufficient to support its widespread use in a general population of people with lesions suspicious for melanoma. For an
equivocal lesion population, the evidence for equivalent sensitivity between RCM and dermoscopy is more tenuous (with
RCM likely to be the more sensitive test given that this group of lesions has already been identified as equivocal on
dermoscopy), but even assuming equivalent sensitivity, inappropriate excisions could be reduced by as much as three
quarters. If superior sensitivity of RCM could be demonstrated for this group, considerable patient benefit could be gained in
terms of fewer missed melanomas and reduced morbidity. Digital monitoring in those considered negative on RCM could
further reduce harms from any missed cases; however, resource implications and patient impact from such a policy would
have to be taken into account.
Implications for research 
Further prospective evaluation of RCM in a standard healthcare setting with a clearly defined and representative
population of participants with dermoscopically equivocal lesions and with RCM results interpreted in a usual practice
setting by observers representative of those who would normally interpret images is appropriate in order to confirm
the suggested increase in accuracy over dermoscopy. A multicentre approach would allow confirmation that results
are replicable across centres and that the technology can be implemented across a health service. Prospective
recruitment of consecutive series of participants, with test interpretation blinded to the reference standard diagnosis
and with pre-specified and clearly defined diagnostic thresholds for determining test positivity are easily achieved.
Systematic follow-up of non-excised lesions avoids over-reliance on a histological reference standard and allows
results to be more generalisable to routine practice. A standardised approach to diagnosis, and clear identification of
the level of training and experience required to achieve good results is also required. Any future research study
needs to be clear about the diagnostic pathway followed by study participants prior to study enrolment, and should
conform to the updated Standards for Reporting of Diagnostic Accuracy (STARD) guideline (Bossuyt 2015).
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Differences between protocol and review 
Inclusion criteria amended to remove inclusion of participants "at high risk of developing melanoma, including those with a
family history or previous history of melanoma skin cancer, atypical or dysplastic naevus syndrome, or genetic cancer
syndromes" as these are not a target population for RCM use.
Primary objectives and primary target condition have been changed from detection of invasive melanoma alone, to the
detection of cutaneous invasive melanoma and atypical intraepidermal melanocytic variants, as the latter is more clinically
relevant to the practicing clinician.
For the primary objective, study populations that could not be clearly identified as either 'any lesion suspicious for
melanoma ' or 'equivocal lesions' were considered separately as 'other lesion' studies.
Secondary objectives have been tailored to the individual test, with three objectives added: to compare the accuracy of
RCM to dermoscopy where both tests have been evaluated in the same studies; to determine the diagnostic accuracy of
individual algorithms for RCM; and to determine the effect of observer experience. Heterogeneity investigations were
limited by the data available.
Studies using cross-validation, such as ’leave-one-out’ cross-validation were excluded rather than included as these
methods are not sufficiently robust and are likely to produce unrealistic estimates of test accuracy. To improve clarity
of methods, this text from the protocol “We will include studies developing new algorithms or methods of diagnosis
(i.e. derivation studies) if they use a separate independent 'test set' of participants or images to evaluate the new
approach. We will also include studies using other forms of cross validation, such as 'leave-one-out' cross-validation
(Efron 1983). We will note for future reference (but not extract) any data on the accuracy of lesion characteristics
individually, e.g. the presence or absence of a pigment network or detection of asymmetry” has been replaced with
“All established algorithms or checklists to assist diagnosis were included. Studies developing new algorithms or
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methods of diagnosis (i.e. derivation studies) were included if they used a separate independent 'test set' of
participants or images to evaluate the new approach. Studies that did not report data for a separate test set of
patients or images were included only if the lesion characteristics investigated had previously been suggested as
associated with melanoma and the study reported accuracy based on the presence or absence of particular
combinations of characteristics. Studies using a statistical model to produce a data driven equation, or algorithm
based on multiple diagnostic features, with no separate test set were excluded. Studies using cross-validation
approaches such as 'leave-one-out' cross-validation (Efron 1983) were excluded.”
We proposed to supplement the database searches by searching the annual meetings of appropriate organisations (e.g.
British Association of Dermatologists Annual Meeting, American Academy of Dermatology Annual Meeting, European
Academy of Dermatology and Venereology Meeting, Society for Melanoma Research Congress, World Congress of
Dermatology, European Association of Dermato Oncology), however due to volume of evidence retrieved from database
searches and time restrictions we were unable to do this.
For quality assessment, the QUADAS-2 tool was further tailored according to the review topic. In terms of analysis,
restriction to analysis of per patient data was not performed due to lack of data. Sensitivity analyses were not performed
as planned due to lack of data.
Published notes 
Characteristics of studies
Characteristics of included studies 
Alarcon 2014
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective. Recruitment: 1
June 2011 and 30 May 2012; Country: Spain
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Dermoscopically equivocal pigmented
lesions, assumed to be melanocytic, seen at Melanoma
Unit
Setting: Specialist unit (skin cancer/pigmented lesions
clinic) Melanoma Unit of the Hospital Clinic of Barcelona.
Prior testing: Dermatoscopic suspicion in all cases
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: Non-melanocytic appearance and
lesions referred for immediate excision or scheduled for
digital follow-up based on dermoscopy.
Sample size (patients): No. eligible: unclear, No.
included: unclear
Sample size (lesions): No. eligible: 343, No. included:
264
Participant characteristics: 
Age: Mean: unknown; Median: 54.7; Range: 8-89 (for
264 excised)
Gender: Male: 136 (51.5% of 264 excised)
Fitzpatrick phototype: Type I to II 42 (46%) of melanoma;
Type III to IV 50 (54%) of melanoma
Lesion characteristics: Pigmented: 100%
Lesion site: Head/Neck: 73 (27.7%); Trunk: 135 (51.1%);
Limbs: 49 (18.6%); Acral 7 (7%).
Thickness/depth: ≤ 1 mm: 86 of 92 melanoma; 6 > 1 mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Dermoscopy No algorithm used
Method of diagnosis: Dermoscopic images
Prior test data: Clinical examination and/or case notes site and age; dermoscopy and RCM
interpretation appear to have been conducted by same observer with no indication of blinding
Diagnostic threshold: Not reported; no details
Diagnosis based on: Single observer; 1 of 3 examiners
Observer qualifications: Dermatologist.
Experience in practice: Not described
Experience with index test: High experience/‘Expert’ users; three dermatologists with expertise in RCM
Any other detail All of the lesions were imaged with a digital camera (Canon PowerShot G10; Canon,
Tokyo, Japan) and a high-resolution dermatoscope dermatoscope (DermLite Photo; 3Gen LLC, Dana
Point, CA, U.S.A.).
Reflectance confocal microscopy (RCM) Segura algorithm used. RCM-VivaScope Vivascope 1500
Method of diagnosis: Confocal images (remote)
Prior test data: Lesion site and/or patient age only; dermoscopy and RCM intepretation appear to have
been conducted by same observer with no indication of blinding
Diagnostic threshold: > -1(The presence of two protective criteria in the basal layer with a score of -1
was considered (i) edged papillae and (ii) presence of typical cells in the basal layer; and the presence
of two risk criteria with a score of 1 was also considered: (i) presence of round pagetoid cells in upper
layers of the epidermis; and (ii) presence of the nucleated cells found within the dermal papillae. A
threshold score >-1 was used to obtain a diagnosis of melanoma)
Diagnosis based on: Single observer; 1 of 3 examiners
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’
Experience with index test: High experience /‘Expert’ users
Other detail: In vivo confocal microscopy was performed with a commercially available reflectance
confocal microscope (Vivascope 1500; Caliber Imaging and Diagnostics, Rochester, NY, U.S.A.),
which uses a near-infrared laser at a wavelength of 830 nm with a maximum power of 35 mW
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were sufficient details of diagnostic thresholds provided? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were sufficient details of diagnostic thresholds provided? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histology and
clinical follow-up of one year
Details: Histology of excision: 264; follow-up:
79
Target condition (Final diagnoses): 
Melanoma (in situ and invasive, or not
reported): 92; BCC: 12;
Benign naevus: 107; other (including
sebhorrheic keratosis and actinic keratosis:
53); plus 79 followed up with no histological
classification .
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: Following the use of
dermoscopy, 343 of the lesions classified as
equivocal would eventually have been excised.
After the addition of RCM, 77% of lesions
(264/343) were judged as suggestive of
malignancy according to the criteria followed in
the study, and therefore were excised. The 79
lesions without criteria of malignancy upon
RCM examination were scheduled for clinical
or digital follow-up; these were not included in
accuracy calculations by the authors but data
provided to allow their inclusion.
Time interval between index test(s) and
reference standard: Histology undertaken on
the same day as RCM. Unclear time gap from
dermoscopy.
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
Was the minimum clinical follow-up after application of index test(s)
adequate?
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
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A. Risk of Bias
Comparative
Time interval between index test(s): Not
specified but appears consecutive
Was each index test result interpreted without knowledge of the results of other
index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Unclear
Are there any concerns that the test comparison could have introduced bias? Unclear risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No
Are there concerns that the test comparison differs from the review question? High
Notes
Notes —
 
Curchin 2011
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective; Period of data
collection Jan 2010 to May 2010
Country Australia
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Consecutive patients from
dermatology department's minor excision booking
list.
Setting: Secondary (general dermatology)
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (patients): No. included: 42
Sample size (lesions): No. included: 50
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Reflectance confocal microscopy (RCM) RCM-VivaScope Vivascope 1500
RCM score Used RCM score and LM score for suspected lentigo maligna of the face (Guitera 2010)
Method of diagnosis: In person
Prior test data: Dermoscopy "dermoscopic and RCM images were aligned over the top of each other
so that correlation between the two could be made"
Diagnostic threshold: RCM score: ≥ 3; LM score for suspected lentigo maligna of the face (Guitera
2010); threshold NR
Diagnosis based on: Single observer; Number of examiners 1?
Observer qualifications: Not reported
Experience in practice: Not described
Experience with index test: Low experience / novice users; analysis was performed by a novice to
RCM analysis after completing a RCM analysis course in Modena, Italy.
Other detail Macroscopic images were obtained using a 14.7 megapixeldigital camera (Canon Power
Shot G10, Canon, Tokyo,Japan). A dermoscopic image was taken using the dermoscopic camera
attached to the Vivascope 1500 RCM System. RCM images were then captured using the Vivascope
1500 (Lucid Inc, Rochester, NY, USA).
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were sufficient details of diagnostic thresholds provided? Yes
Was the test interpretation carried out by an experienced examiner? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological diagnosis
alone
Details: No. patients/lesions: Disease positive: 21;
Disease negative: 29
Target condition (Final diagnoses) Melanoma
(invasive): 12; Melanoma (in situ): 1; BCC: 9; cSCC:
6 (includes SK and/or AK); 'Benign' diagnoses: 23
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of
the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Time interval to reference test: patients
asked to come to the clinic (for imaging)
1h prior to their scheduled surgery.
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Was the minimum clinical follow-up after application of index test(s) adequate?
If more than one algorithm evaluated for the same test, was the interval between
application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes —
 
Farnetani 2015
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series series of cases
consecutively and retrospectively selected by an
expert dermoscopist for a web-based inter-
observer reliability study
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection: not reported
Country: Italy (lesion image acquisition);
Observers were located in the US (3), Europe (4),
Australia (1) and Israel (1).
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Diagnostically equivocal lesions
excised due to clinical or dermoscopic suspicion of
melanoma, where a specific clinical and
dermoscopic diagnosis could not be rendered with
certainty. Lesions selected by an expert
dermoscopist blinded to final diagnosis
Setting: Secondary (general dermatology) All
included RCM images were collected at the
Department of Dermatology of the University of
Modena and ReggioEmilia (Modena, Italy),
Prior testing: Clinical and/or dermatoscopic
suspicion
Setting for prior testing: Secondary (general
dermatology)
Exclusion criteria: Poor quality index test image; No
additional selection criteria were considered in case
selection
Sample size (patients): No. included: NR
Sample size (lesions): No. included: 100
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? Unclear
Index Test
Index tests
Reflectance confocal microscopy (RCM): No algorithm. Vivascope 1500
Method of diagnosis: Confocal images (remote) 3 RCM mosaic images presented per lesion
Prior test data: Dermoscopy "Each case for evaluation had a high-resolution dermoscopic image
obtained with a dermoscopic lens that was attached to a digital camera"; "No additional clinical
information (eg, age and melanoma or lesion history) was provided to evaluators."
Diagnostic threshold: Evaluators completed a ‘pattern description’ (presence/absence of a number of
RCM features) and gave an overall diagnosis of malignant (melanoma or BCC) or benign; no specific
threshold used.
Derivation aspect to study: Discriminant analysis used to identified RCM features independently
associated with malignancy, melanoma and BCC.
Three of 6 discriminatory RCM features were more frequently observed in melanoma: the presence of
pagetoid cells, the presence of atypical cells at the DEJ, and irregular epidermal architecture; 3 of 6
discriminatory RCM features were more frequently observed in BCCs: basaloid cord–like structures,
presence of ulceration, and a specific DEJ pattern. Accuracy was not estimated for combinations of
these particular features
Diagnosis based on: Results presented for each of 9 observers and for majority diagnosis; i.e.
consensual diagnosis by ≥5 of 9 evaluators. Also present average across 9 observers and across 6
more experienced and 3 less experienced observers.
Number of examiners: 9. Fifteen individuals were invited to participate, 9 of whom agreed. Between
June 15, 2010, and August 24, 2010, participants were asked to evaluate 10 cases per week for 10
consecutive weeks.
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with index test: 
Low experience/novice users: 3 with < 3 years RCM experience
High experience/‘Expert’ users: 6 with ≥ 3 years RCM experience
Reflectance confocal microscopy
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were sufficient details of diagnostic thresholds provided? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological diagnosis
alone
Details: none reported
No. patients/lesions: Disease positive: 35 Disease
negative: 65
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not reported): 20;
BCC: 15
Sebhorrheic keratosis: 7; melanocytic nevi 55 ; actinic
keratoses 3.
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of
the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: Excised lesions only
included
Time interval to reference test: not reported
Time interval between index test(s): N/A
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Was the minimum clinical follow-up after application of index test(s) adequate?
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative
#164b Reflectance confocal microscopy for the diagnosis of cutaneous melanoma in adults
30 / 163
B. Concerns regarding applicability
Notes
Notes —
 
Ferrari 2015
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection: 2010
Country: Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Melanocytic lesions with equivocal
clinical and/or dermoscopic features that underwent
excision and had a complete set of dermoscopy and RCM
images with histopathology report. Only dermoscopically
featureless (retrospectively scoring 0-2 on 7-point
checklist) or equivocal lesions (those scoring 3-4 on
dermoscopy 7-point checklist) were included in RCM
evaluation.
Setting: Secondary (general dermatology)
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Secondary (general dermatology)
Exclusion criteria: non-melanocytic appearance;
unequivocal appearance - 90 ‘positive-clear cut’ lesions
(scoring 5 or more on 7-point checklist) were excluded
from RCM evaluation; poor quality index test image "Only
lesions with high quality dermoscopic images, a complete
set of confocal images and histopathology report
available were included in the study"; Other characteristic:
incomplete histopathathology report.
Sample size (patients): No. included: NR
Sample size (lesions): No. eligible: 322 / No. included:
322* for dermoscopy; 232 for RCM (*232 for each test
included in this review)
Participant characteristics: None reported
Lesion characteristics: Thickness/depth - Overall mean
1.05 +/16 mm, range 0–10 mm (70 melanomas); Those
scoring 0-2 on 7-point checklist: mean 0.18 +/0.42 mm;
range 0–0.94 mm) (6 melanomas)Those scoring 3-4 on 7-
point checklist: mean 0.36 +/-0.42, range 0-1.4mm (17
melanomas)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Dermoscopy 7-point checklist
Method of diagnosis: Dermoscopic images
Prior test data: lesion site and age provided; dermoscopy and RCM interpretation appear to have been
conducted by same observer with no indication of blinding
Diagnostic threshold: All thresholds reported. Data extracted using standard threshold ≥ 3
Diagnosis based on: Single observer; Number of examiners 1 of 3
Observer qualifications: Dermatologist. All the images were interpreted independently by one of the
three dermatologists with expertise in RCM
Experience in practice: Not described
Experience with index test: High experience /‘Expert’ users; three dermatologists with expertise in
RCM
Any other detail All of the lesions were imaged with a digital camera (Canon PowerShot G10; Canon,
Tokyo, Japan) and a high-resolution dermatoscope dermatoscope (DermLite Photo; 3Gen LLC, Dana
Point, CA, U.S.A.).
#
Reflectance confocal microscopy (RCM). No algorithm (presence of significant characteristics); criteria
taken from Pellacani (Two step) - four features described as ‘melanoma clues’, referenced to
Pellacani 2012. Final criteria tested on data and only those predictive used.
RCM-VivaScope Vivascope 1500
Method of diagnosis: Confocal images (remote)
Prior test data: Dermoscopy "Dermoscopic and confocal microscopic images were evaluated, in blind
from histological diagnosis, by a dermatologist trained in dermoscopy and RCM."
Diagnostic threshold: 
2x2 data for chosen qualitative threshold
For featureless lesions (score 0 to 2 on dermoscopy 7PCL), presence of at least one of:
≥ 5 round pagetoid cells
architectural disorder.
For equivocal lesions (score 3 to 4 on dermoscopy 7PCL), presence of at least one of:
any number of round pagetoid cells
five or more atypical cells at the junction
Derivation aspect to study: 
Previously published RCM parameters demonstrated useful for melanoma detection were selected.
Evaluated confocal features were as follows:
presence of pagetoid cells,
cell shape (roundish or dendritic) and number (< 5 or > 5 cells per mm2),
overall DEJ architecture (ringed, meshwork, clods and non-specific pattern);
architectural disorder (irregular alternation of different RCM patterns, non-edged papillae extended
over the 10% of lesion, and/or angled filaments/dendrites crossing the papillae),
presence of cytological atypia (> 5 cells per mm2) and
atypical nucleated cells arranged in nests
Selection of characteristics indicative of skin cancer: Logistic regression
Characteristics selected: as above
Diagnosis based on: Consensus (3 observers)
Number of examiners 3
Observer qualifications: Dermatologists
Experience in practice: High/Expert
Experience with index test: High/Expert
Other detail Confocal imaging was performed with near-infrared reflectancemode confocal laser
scanning microscope (Vivascope1500 ; MAVIG GmbH, Munich, D)
Reflectance confocal microscopy
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were sufficient details of diagnostic thresholds provided? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were sufficient details of diagnostic thresholds provided? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological diagnosis
alone
Details: not further described
No. patients/lesions: 232 out of originally selected
322; Disease positive: 23 Disease negative: 209
Target condition (Final diagnoses): Melanoma (in situ
or invasive): 23
Benign nevus: 195; Spitz nevus 14;
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Yes
Were the reference standard results interpreted without knowledge of
the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: 90 ‘positive-clear cut’
lesions scoring 5 or more were excluded
from RCM evaluation
Time interval to reference test: Images taken
'before excision'
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Was the minimum clinical follow-up after application of index test(s) adequate?
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative
Dermoscopy and RCM interpretation appear to
have been conducted by same observer with
no indication of blinding
Was each index test result interpreted without knowledge of the results of
other index tests or testing strategies? Unclear
Was the interval between application of the index tests less than one
month? Yes
Are there any concerns that the test comparison could have introduced
bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No
Are there concerns that the test comparison differs from the review question? High
Notes
Notes —
 
Figueroa Silva 2016
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection/Prospective
interpretation
Period of data collection January 2010 and February 2015
Country Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: All pigmented lesions with a clear-
cut dermoscopy island (DI) and available
dermoscopic and RCM images were included
Setting: Secondary (general dermatology)
Prior testing: Dermatoscopic suspicion in all cases
Setting for prior testing: Secondary (general
dermatology)
Exclusion criteria: None reported
Sample size (patients): No. eligible: not reported/
No. included: 61
Sample size (lesions): No. eligible: 1964 pigmented
lesions / No. included: 63
Participant characteristics: mean age 44.1
(SD=14.8); % Male 43%
Lesion characteristics: Lesion site - trunk: 37 lesions
(60%)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Reflectance confocal microscopy (RCM) No algorithm (observer diagnosis)
RCM-VivaScope Vivascope 1500
Method of diagnosis: Confocal images (remote)
Prior test data: Dermoscopic image provided but blinded to histology and clinical information
Diagnostic threshold: Melanoma or not based on pattern analysis. RCM mosaics were evaluated for
the presence/absence of: cobblestone pattern, pagetoid cells, architecture type (ringed, meshwork or
clod prevalent pattern at DEJ, regular/irregular) and atypical cells at the DEJ. All RCM criteria were
evaluated on both the DI and the rest of the lesion
Diagnosis based on: Single observer (n = 1). One investigator reviewed all RCM images and rendered
a diagnosis; two other investigators separately reviewed the dermoscopic images according to four DI
patterns.
Observer qualifications: Not reported - probably dermatologist given setting
Experience in practice: Not described
Experience with index test: Not described
Other detail: Dermoscopic images had previously been collected by using a digital camera
(Canon Powershot; Canon, New York, NY, USA) equipped with a contact, nonpolarized
dermatoscope (DermLite Photo 3Gen, San Juan Capistrano, CA, USA) using a 20-fold
magnification. RCM images were acquired with a near-infrared, reflectance mode, confocal
microscope (VivaScope1500 MAVIG GmbH, Munich, Germany). A minimum of three
mosaics were obtained per lesion at three different skin level (superficial epidermal layers,
dermo-epidermal junction (DEJ) and papillary dermis) as described elsewhere (Debarbieux 2013).
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were sufficient details of diagnostic thresholds provided? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological
diagnosis plus follow up
Details: 
Histology (not further described): Disease
positive: 27; Disease negative: 19
Clinical FU plus histology of suspicious lesions:
Lesions were followed up on the basis of original
RCM interpretation, i.e. at time of patient
presentation. All lesions would have been
excised on basis of dermoscopy alone; Length
of FU: ≥ 1 year (mean 22 months); No. patients:
17 lesions (47% of all disease negative)
Target condition (Final diagnoses) 
Melanoma (invasive): 8; Melanoma (in situ): 19
Benign naevus: 36
Is the reference standards likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: not reported
Time interval to reference test: not reported
Time interval between index test(s): N/A
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
Was the minimum clinical follow-up after application of index test(s) adequate?Yes
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
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Notes —
 
Guitera 2009a (Modena)
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series (random sample of
50% of benign lesions included to increase the
prevalence of melanoma)
Data collection: Prospective
Period of data collection Sept 2004 Aug 2007
Country Italy and Australia; NB data have been
separated by country for the purposes of this
review due to mixed use of imaged based and
in-person dermoscopy interpretation according
to country. Guitera 2009a (Modena) reports
data for lesions recruited in Modena, Italy
* The dataset also overlaps Pellacani 2007
which reports data for RCM only but at
alternative RCM score thresholds.
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Melanocytic lesions suspicious of
melanoma based on dermatoscopic diagnostic criteria
or lesion change; only 50% of observed benign
lesions included
Setting: Secondary (general dermatology).
Prior testing: Clinical and/or dermatoscopic suspicion
or changes on digital monitoring
Setting for prior testing: Secondary (general
dermatology)
Exclusion criteria: lesions on soles/palms excluded;
Lentigo maligna excluded; lesions used in previous
assessments or RCM model development
Sample size (patients): No. included: 195
Sample size (lesions): No. eligible: 195
Participant characteristics: Median age : 42 (7-88yrs);
IQR 32, 59 yrs; Male: 54.3%
Lesion characteristics: Pigmented: 92%; Non-
pigmented: 8% (included amelanotic lesions or those
with tan, light gray, or pale blue pigment only); Lesion
thickness/depth: median 0.65mm (IQ 25, 75: 0.23,
1.01)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Dermoscopy: Pattern analysis
Method of diagnosis: In person; dermoscopy diagnosis made at time of first consultation, prior to RCM
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: Not reported
Diagnosis based on: Single observer (n = 1).
Observer qualifications: Dermatologist (described as Modena expert based in Dermatology Dept)
Experience in practice: High experience or ‘Expert’
Experience with index test: High experience /‘Expert’ users 'Expert'; no further details
Other detail: hand-held dermoscope (Delta 10, Heine, Herrsching, Germany).
Reflectance confocal microscopy (RCM): Pellacani RCM score
RCM-VivaScope Vivascope 1000 and Vivascope 1500, Lucid Inc., Henrietta, NY
Method of diagnosis: Confocal images (remote)
Prior test data: Lesion site and/or patient age only were provided. Confocal images from Modena were
scored by PG (located inSydney) retrospectively and blinded to dermoscopy and pathological
diagnosis, but not to information of site and age.
Diagnostic threshold: Six diagnostic features scored: non-edged papillae and cytological atypia at the
dermal-epidermal junction scored 2each; round pagetoid cells intraepidermally, widespread pagetoid
infiltration in the epidermis, nucleated cells found within the dermal papillae, and cerebriform nests in
the dermis scored 1 each. Total score >3 indicated MM.
Diagnosis based on: Single observer (n = 1)
Observer qualifications: NR; presumed dermatologist based on study setting and expert nature of
observers
Experience in practice: NR; based on study setting
Experience with index test: NR, but both observers co-authored studies developing RCM
Other detail Some differences between Vivascope 1000 and Vivascope 1500 exist. "The former is a
more cumbersome instrument, as 4 mm images required laborious reprocessing. Furthermore,single
capture images were slightly smaller in size, however,showing a similar quality with respect to the
Vivascope 1500."
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were sufficient details of diagnostic thresholds provided? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were sufficient details of diagnostic thresholds provided? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
#164b Reflectance confocal microscopy for the diagnosis of cutaneous melanoma in adults
38 / 163
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological
diagnosis alone
Details: None provided. Disease positive:
79; Disease negative: 116
Target condition (Final diagnoses) 
Melanoma (invasive): 61; Melanoma (in
situ): 18
Benign naevus: 94; Spitz nevus 22
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: imaged prior
to biopsy
Time interval between index test(s): imaged
prior to biopsy
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Was the minimum clinical follow-up after application of index test(s) adequate?
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative
Confocal images from Modena were scored in
Sydney retrospectively and blinded to dermoscopy
but not age and lesion site
Was each index test result interpreted without knowledge of the results
of other index tests or testing strategies? Yes
Was the interval between application of the index tests less than one
month? Yes
Are there any concerns that the test comparison could have introduced
bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? Unclear
Are there concerns that the test comparison differs from the review question? Unclear
Notes
Notes —
 
Guitera 2009b (Sydney)
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection Sept 2004 Aug 2007
Country Italy and Australia
NB data have been separated by country for
the purposes of this review due to mixed use of
imaged based and in-person dermoscopy
interpretation according to country. Guitera
2009b (Sydney) reports data for lesions
recruited in Sydney, Australia
* The dataset also overlaps Pellacani 2007
which reports data for RCM only but at
alternative RCM score thresholds.
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Melanocytic lesions suspicious of
melanoma based on dermatoscopic diagnostic criteria or
lesion change
Setting: Specialist unit (skin cancer/pigmented lesions
clinic) Australia Melanoma Diagnostic centre
Prior testing: Clinical and/or dermatoscopic suspicion or
changes on digital monitoring
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: lesions on soles/palms excluded;
Lentigo maligna excluded; lesions used in previous
assessments or RCM model development; 25 lesions
out of 156 were rejected for poor quality dermoscopy
image,
Sample size (patients): No. included: 156
Sample size (lesions): No. eligible: 156; No included:
131
Participant characteristics: Median age : 52 (19-90yrs);
IQR 40, 63 yrs; Male: 59%
Lesion characteristics: Pigmented: 75%; Non-
pigmented: 25% (included amelanotic lesions or those
with tan, light gray, or pale blue pigment only); Lesion
thickness/depth: median 0.40mm (IQ 25, 75: 0, 0.84)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Dermoscopy Pattern analysis
Method of diagnosis: Dermoscopic images
Prior test data: lesion site and age available
Diagnostic threshold: Not reported
Diagnosis based on: Single observer (n = 1); Dermoscopy diagnosis of Sydney lesions
was made retrospectively on the images in a random order, blinded to RCM and
pathological diagnosis but not to information of site and age, by a Modena expert (GP)
using pattern analysis (Pehamberger 1993).
Observer qualifications: Dermatologist; Not clearly reported, but described as Modena expert based in
Dermatology Dept
Experience in practice: High experience or ‘Expert’
Experience with index test: High experience /‘Expert’ users 'Expert'; no further details
Other detail: high-resolution digital oil immersion dermoscopy camera (Sentry, Polartechnics Ltd,
Sydney, NSW, Australia).
Reflectance confocal microscopy (RCM): Pellacani RCM score
Vivascope 1000 and Vivascope 1500, Lucid Inc., Henrietta, NY
Method of diagnosis: Confocal images (remote)
Prior test data: Lesion site and/or patient age only. Confocal images from Sydney were scored by GP
(located in Modena), retrospectively and blinded to dermoscopy and pathological diagnosis, but not to
information of site and age.
Diagnostic threshold: Six diagnostic features scored: non-edged papillae and cytological atypia at the
dermal-epidermal junction scored 2each; round pagetoid cells intraepidermally, widespread pagetoid
infiltration in the epidermis, nucleated cells found within the dermal papillae, and cerebriform nests in
the dermis scored 1 each. Total score >3 indicated MM.
Diagnosis based on: Single observer (n = 1)
Observer qualifications: NR - Dermatologist assumed based on study setting and expert nature of
observers
Experience in practice: NR; based on study setting
Experience with index test: NR, but both observers co-authored studies developing RCM
Other detail Some differences between Vivascope 1000 and Vivascope 1500 exist. "The former is a
more cumbersome instrument, as4 4 mm images required laborious reprocessing. Furthermore,single
capture images were slightly smaller in size, however,showing a similar quality with respect to the
Vivascope 1500."
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were sufficient details of diagnostic thresholds provided? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were sufficient details of diagnostic thresholds provided? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological
diagnosis alone
Details: None provided. Disease positive:
44; Disease negative: 87
Target condition (Final diagnoses): 
Melanoma (invasive): 28; Melanoma (in
situ): 16
Benign naevus: 84; Spitz nevus 3
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 25 lesions out of 156
were rejected for poor quality dermoscopy
image, blinded to the diagnostician
Time interval to reference test: NR
Time interval between index test(s): NR
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Was the minimum clinical follow-up after application of index test(s)
adequate?
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
Confocal images from Sydney were scored by GP
(located in Modena), retrospectively and blinded
to dermoscopy and pathological diagnosis, but not
to information of site and age.
Was each index test result interpreted without knowledge of the results
of other index tests or testing strategies? Yes
Was the interval between application of the index tests less than one
month? Yes
Are there any concerns that the test comparison could have introduced
bias? Low risk
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B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? Unclear
Are there concerns that the test comparison differs from the review question? Unclear
Notes
Notes —
 
Guitera 2012
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported
Period of data collection NR
Country Australia and Italy
Test set derived: randomly split into
training and test sets
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Consecutive Patients presenting or
found with suspicious lesions, including all macules of
the face and neck suspicious for lentigo maligna, and
which would be subjected to biopsy or excision to rule
out an epithelial tumor or an MM following conventional
clinical and dermoscopy diagnosis and with lesion
location amenable to RCM; described as predominantly
melanocytic or suspicious for BCC
Setting: Mixed, lesions recruited from Modena (general
dermatology) and Sydney (skin cancer/pigmented
lesions clinic)
Prior testing: Clinical and/or dermatoscopic suspicion
Exclusion criteria: Location/site of lesion keratotic, sole,
and palm lesions were excluded
Sample size (patients): No. eligible: 663
Sample size (lesions): No. eligible: 710 / No included:
356 in test set, 253 melanocytic
Participant characteristics: Median age (full sample): 53,
IQR 39 to 66 (for full sample), Range: 6-90; Male: 354;
53.4% (of full sample)
Lesion characteristics: Not reported
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Reflectance confocal microscopy (RCM): RCM score and Segura algorithm; also derived own
independently significant features for MM and BCC.
Vivascope 1500
Method of diagnosis: Confocal images (remote)
Prior test data: Lesion site and/or patient age only "RCM features were described by two expert
observers (GP and PG), blinded from any clinical information, dermoscopy, and clinical aspects, but
not for the location and age of the patient"
Diagnostic threshold: Pellacani RCM score (Pellacani 2007): >3 and >2; Segura (Segura 2009)
"calculated with a threshold of zero"; own new two step model identified 7 independently significant
features for MM (assume presence of any one indicated T+): - cerebriform nests,- atypical cobblestone
pattern with small nucleated cells in the epidermis, - marked cytological atypia, and - pagetoid cells,
and- disarranged epidermal layer with no honey comb - Large inter-papillae spaces filled with
honeycomb- Dense nest. 8 independently significant features for BCC: - Polarized in the honeycomb -
Linear telangiectasia-like horizontal vessels- Basaloid cord or nodule - Epidermal shadow - Convoluted
glomerular-like vessels - Non-visible papillae - Cerebriform nests- Disarray of the epidermal layer
Derivation aspect to study: 
Lesion characteristics assessed A series of 48 features, corresponding to previous
observations (Pellacani 2007; Guitera 2009), and new descriptors were considered at three different
depth levels. Descriptions and definitions provided.
Selection of characteristics indicative of skin cancer by multivariate discriminant analysis performed on
the training set
Diagnosis based on: Single observer (n = 2)
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’
Experience with index test: High experience /‘Expert’ users
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were sufficient details of diagnostic thresholds provided? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological diagnosis
alone
Details: not further described; full sample Disease
positive: 335 / disease negative 375
Target condition (Final diagnoses): Test set only
Melanoma (in situ and invasive, or not reported):
105; BCC: 52; cSCC: 9
Benign nevus 132; SPitz nevus 16; actinic keratosis
8; 31 benign macule of the face and 3
dermatofibroma
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of
the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
No exclusions
Imaged prior to biopsy
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Was the minimum clinical follow-up after application of index test(s) adequate?
If more than one algorithm evaluated for the same test, was the interval between
application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes —
 
Koller 2011
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective (retrospective image
selection / prospective interpretation for training
set)
Period of data collection: July 2007 to June 2008
Country Austria
Training set lesions were evaluated
retrospectively (also reported in Gerger 2005)
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Melanocytic skin lesions recruited
from department of dermatology; lesions were not
selected according to presence or absence of
particular RCM features
Setting: Secondary (general dermatology)
Prior testing: Unclear; some assessment conducted
as only melanocytic lesions included
Setting for prior testing: Secondary (general
dermatology)
Exclusion criteria: non-melanocytic appearance
Sample size (patients): No. included: NR
Sample size (lesions): No. included: 92 (test set only)
Participant characteristics: None reported
Lesion characteristics: Ulcerated : 1/24 melanomas;
mean thickness/depth: 0.75mm (SD 1.06; range in
situ to 3.7 mm)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Reflectance confocal microscopy (RCM): No algorithm overall diagnosis and development of new CAD
model using training set of lesions
Vivascope 1000
Method of diagnosis: Confocal images (remote)
Prior test data: No further information used observer was blinded with regard to the clinical or
histopathological diagnosis
Diagnostic threshold: 
Human observer: diagnosis based on 'expert experience'; RCM characteristics not reported
CAD interpretation: 30.47% (set for sensitivity of 100%)
Derivation aspect to study: 
Lesion characteristics assessed: In each RCM image, a set of 39 analysis parameters were measured.
Selection of characteristics indicative of skin cancer classification: procedure was performed by the
CART (Classification and Regression Trees) analysis software from Salford Systems (San Diego, CA,
USA).
Characteristics selected N/A
Diagnosis based on: Single observer (n = 1)
Observer qualifications: Independent clinical dermatologist interpreted RCM images but image
acquisition not described in detail.
Experience in practice: Not described
Experience with index test: High experience /‘Expert’ users
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were sufficient details of diagnostic thresholds provided? Unclear
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological
diagnosis plus expert diagnosis
Details: 
Histology (not further described): Disease
positive: 24 / Disease negative: 37
Expert opinion based on unequivocal clinical
and conventional dermoscopic criteria:
Disease positive: 0 / Disease negative: 31
Target condition (Final diagnoses) 
Melanoma invasive: 18; Melanoma in situ: 6
Benign naevus: 68
Is the reference standards likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard No
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
A. Risk of Bias
Flow and timing
Suspicious lesions were excised after clinical,
dermoscopic
and confocal examination and subjected to standard
histopathological
assessment.
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
Was the minimum clinical follow-up after application of index test(s)
adequate?
If more than one algorithm evaluated for the same test, was the
interval between application of the different algorithms 1 month or
less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes —
 
Langley 2007
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection February 2002 to
May 2005
Country Canada
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with suspicious pigmented
lesions scheduled for biopsy due to clinical suspicion of
malignancy determined by clinical appearance or a
history of change in the lesion.
Setting: Specialist unit (skin cancer/pigmented lesions
clinic) Division of Dermatology Pigmented Lesion Clinic
and the Plastic Surgery Clinics
Prior testing: Clinical suspicion of malignancy without
dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: non-pigmented; poor quality index test
image; lesion site or previous diagnostic biopsy
Sample size (patients): No. eligible: 127 / No. included:
125
Sample size (lesions): No. eligible: 127 / No. included:
125
Participant characteristics: Mean age: 44.2y (16 to 84)
Lesion characteristics: median thickness 0.62 mm 0.20
mm to 7.92 mm)
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not
match the review question? Unclear
Index Test
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Index tests
Dermoscopy Pattern analysis
Method of diagnosis: In person
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: Qualitative pattern analysis; no further details
Diagnosis based on: Single observer (n = 1)
Observer qualifications: Not reported likely dermatologist
Experience in practice: Not described
Experience with index test: Not described
Any other detail: dermoscopy was performed and a diagnosis rendered using the pattern analysis
method. A clinical photograph was obtained with a Nikon D1X digital camera, and with a Nikon F401s
camera with a 60-mm lens with dermatophot attachment
Reflectance confocal microscopy (RCM): No algorithm - selected characteristics based on the
criteria described in authors’ initial series (Langley 2001)
Vivascope 1000
Method of diagnosis: In person
Prior test data: "Clinical, dermoscopic and confocal examinations were conducted sequentially by a
single reviewer (R.L.)."
Diagnostic threshold: Any one of: epidermal disarray with loss of the normal honeycomb pattern; a
grainy image; pagetoid cells in the epidermis; complex branching dendrites or dendritic cells; atypical
and pleomorphic refractile cells, and the presence of bright, highly refractile particles.
Diagnosis based on: Single observer (n = 1). A single observer with experience in CSLM performed
the imaging and examined all images in real-time (R.L.)
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with index test: High experience /‘Expert’ users
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were sufficient details of diagnostic thresholds provided? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were sufficient details of diagnostic thresholds provided? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological diagnosis alone
Details: Definitive diagnosis was made by a
dermatopathologist. Disease positive: 37 / Disease
negative: 88
Target condition (Final diagnoses) 
Melanoma (invasive): 22; Melanoma (in situ): 15
Benign naevus: 88
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Were the reference standard results interpreted without
knowledge of the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: Two patients were
excluded from the database due to technical
difficulties with the imaging.
Interval: When CSLM imaging was complete,
the lesions were removed by excisional
biopsy.
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Was the minimum clinical follow-up after application of index test(s) adequate?
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
Clinical, dermoscopic and confocal
examinations were conducted sequentially by a
single reviewer
Was each index test result interpreted without knowledge of the results of
other index tests or testing strategies? No
Was the interval between application of the index tests less than one
month? Yes
Are there any concerns that the test comparison could have introduced
bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? Yes
Are there concerns that the test comparison differs from the review question? Lowconcern
Notes
Notes —
 
Longo 2013
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Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection NR
Country Italy
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Clinically nodular lesions (defined as
cutaneous palpable/superficial seated lesions and not
subcutaneous ones) that underwent excision
Setting: Department of Dermatology, University of Modena
and Reggio Emilia and Dermatology and Skin Cancer Unit,
Arcispedale S. Maria Nuova IRCCS, Reggio
Prior testing: Selected for excision (no further detail)
Exclusion criteria: None reported
Sample size (patients): No. included: 140
Sample size (lesions): No. included: 140
Participant characteristics: Mean age: 50 years (SD 19.7);
45.7% male
Lesion characteristics: 'most' lesions on the trunk;
dermatofibroma mainly located on extremities; mean
thickness 16mm (SD 1.82); 23 'pure' nodular melanomas
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Reflectance confocal microscopy (RCM): No algorithm (correct diagnosis of each histological
category); also identifies independently significant features [cannot include data for MM as does not
give breakdown of nodular melanoma and melanoma metastases; no response to author contacted]
VivaScope Model NR; likely Vivascope 1500 given publication date
Method of diagnosis: Confocal images (remote)
Prior test data: No further information used; blinded to dermoscopic image
Diagnostic threshold: 'RCM pattern analysis' (referenced to Longo 2011; Pellacani 2007; amongst
others).
Multivariate analysis id 3 positive independent significant features for MM+Mets [- widespread
pagetoid distribution (graded as focal, localized, widespread); - many atypical cells; - cerebriform
nests] and 4 positive independent significant features for BCC [- tumour islands (dark silhouettes or
tightly packed basaloid islands); - cauliflower architecture; - bright filaments within the tumour islands;
and - presence of bright collagen.]
Derivation aspect to study: Each of 36 criteria were also scored for presence or absence.
MM - Epidermis: Honeycombed or cobblestone pattern; Disarray of epidermis; Pagetoid spread;
Pagetoid cell shape; Pagetoid cell distribution Dermo epidermal junction: Nonspecific architecture;
Cytological atypia (moderate, severe); Dermis: Sheet-like structures; Dermal nesting; Prominent
vascularity (enlarged vessels covering more than 50% of the lesion surface); Inflammatory infiltrate
covering more than 50% of the lesion surface
BCC - Epidermis: Honeycombed or cobblestone pattern; Disarray of epidermis; Ulceration or erosions;
Dermo epidermal junction: Cauliflower architecture; Nonspecific architectureDermis: Dark silhouettes;
Tightly packed cells; Bright filaments within tumour islands; Prominent vascularity (enlarged vessels
covering more than 50% of the lesion surface); Inflammatory infiltrate (covering more than 50% of the
lesion surface.
SCC - Epidermis: Honeycombed or cobblestone pattern; Disarray of epidermis; Ulceration or erosions;
Scales; Keratin inclusion/plugsDermis: Prominent vascularity ( enlarged vessels covering more than
50% of the lesion surface); Inflammatory infiltrate (covering more than 50% of the lesion surface)
Selection of characteristics indicative of skin cancer : Univariate and then multivariate discriminant
analysis was also performed to identify independently significant RCM criteria for NM+Mets vs. all
other diagnoses, BCC vs. all other diagnoses, SCC vs. all other diagnoses.
Diagnosis based on: Single observer (n = 1)
Observer qualifications: Dermatologist
Experience in practice: 5 years’ experience in RCM and therefore presumably in practice
Experience with index test: 5 years’ experience in RCM
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were sufficient details of diagnostic thresholds provided? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological
diagnosis alone
Details: (not further described); Disease
positive: 23 nodular melanoma
Disease negative: 117
Target condition (Final diagnoses) 
Melanoma (invasive): 23 nodular; BCC: 28;
cSCC: 6; Other malignant: 9 melanoma
metastases
Benign naevus: 25 (14 compound, 8
intradermal, 3 blue naevi); 7 Spitz naevi;
Sebhorrheic keratosis: 14; 5 vascular and 6
other benign lesions;
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 8 not evaluable and 3
‘nonspecific’ RCM results reported (appear to be
excluded from derivation of independently
significant characteristics)
Not evaluable: lesions where all the three levels
(epidermis, DEJ and upper dermis) were not
explorable for any reason that hampered the
collection of quality images or the exploration of
DEJ/superficial dermis. 2 Nonspecific: lesions
where a diagnosis could not be formulated, despite
the possibility of exploring all three levels, because
of the impossibility of recognizing diagnostic
features with enough confidence."
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Unclear
Was the minimum clinical follow-up after application of index test(s)
adequate?
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes —
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Lovatto 2015
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection January 2006 to
January 2009
Country Spain
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Consecutive high risk patients with atypical
melanocytic lesions excised because of change following
sequential digital dermoscopy follow-up. Required to have at
least two of the following characteristics: >100 melanocytic
naevi; high number of atypical melanocytic lesions under
dermoscopy; personal or familial history of melanoma; or,
predisposing genetic mutations for melanoma (i.e. CDKN2A
mutation-carriers, xeroderma pigmentosum).
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: Changes on digital monitoring FU with total body
photography and digital dermoscopy
Setting for prior testing: Specialist unit (skin cancer/pigmented
lesions clinic)
Exclusion criteria: Unequivocal appearance/diagnosis
Sample size (patients): No. included: 51
Sample size (lesions): No. included: 64
Participant characteristics: Mean age: 42y (25-69), SD 11.7;
Male: 47%; History of melanoma/skin cancer 25%; Family
history of melanoma 24%; Genetic predisposition 4%
(CDKN2A mutation); 20% with both personal and familial
history of melanoma. Fitzpatrick phototype I to II 71%; Type III
to IV 15; 29%
Lesion characteristics: Mean total dermoscopy score at follow-
up (ie. on excision): 5.44 for neavus group and 5.55 for
melanoma group. Lesio thickness 5 ≤ 1 mm (3 with Breslow
0.5 mm, and one each at 0.6 and 0.7 mm)
Are the included patients and chosen study setting
appropriate? No
Did the study avoid including participants with multiple
lesions? No
Are there concerns that the included patients and setting do
not match the review question? High
Index Test
#164b Reflectance confocal microscopy for the diagnosis of cutaneous melanoma in adults
55 / 163
Index tests
Reflectance confocal microscopy (RCM): RCM score; Segura algorithm
Vivascope 1500
Method of diagnosis: Confocal images (remote)
Prior test data: No further information used; blinded to dermoscopy and histopathologic diagnosis
Diagnostic threshold: 
Segura algorithm (Segura 2009) includes four diagnostic features: two protective criteria in the basal
layer with a score of -1 these are i) edged papillae and (ii2) typical cells in the basal layer; and two risk
criteria with a score of +1, these are (i) roundish pagetoid cells in upper layers of the epidermis and (ii)
nucleated cells within the dermal papillae. Melanoma must be considered when the total score is ≥0.
RCM score (Pellacani 2007): two major criteria scoring two points; these are (i) presence of cytologic
atypia and (ii) non-edged papillae at basal layer and four minor criteria scoring 1 point; these are (i)
presence of roundish cells in superficial layers spreading upward in a pagetoid fashion (ii) pagetoid
cells widespread throughout the lesion, (iii) cerebriform clusters in the papillary dermis and (iv)
nucleated cells within dermal papilla. Score ≥ 3
Diagnosis based on: Unclear; could be consensus or average (n = 3)
Observer qualifications: Not reported - Likely dermatologists (based in Dept Dermatology)
Experience in practice: Not described
Experience with index test: Not described
Other detailAny other detail (Vivascope 1500; Lucid Inc, Henrietta, NY, USA).
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were sufficient details of diagnostic thresholds provided? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological diagnosis alone
Details: consensus of 3 skilled histopathologists with
experience in the field of melanocytic skin lesions;
reviewed at the dermatopathology conference. Disease
positive: 13; Disease negative: 51
Target condition (Final diagnoses) 
Melanoma (invasive): 5; Melanoma (in situ): 8
Benign naevus: 51 melanocytic naevus with variable
degree of atypia
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Were the reference standard results interpreted without
knowledge of the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? Unclear risk
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B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: NR
Time interval to reference test: consecutive;
Images taken 'before excision'
Time interval between index test(s): N/A
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Was the minimum clinical follow-up after application of index test(s)
adequate?
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less? Yes
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes —
 
Pellacani 2007
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection NR
Country Italy and Australia
Test set derived For multivariate analysis, the
study sample was randomly divided into a
training set and a test set, each comprising
50% of the lesions. Data included relate to
full sample.
* The dataset also overlaps Guitera 2009
which reports data for dermoscopy as well as
RCM; have only included Pellacani 2007
data related to alternative RCM score
thresholds; not included in primary analysis
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: All melanocytic lesions excised to
exclude melanoma, based upon dermoscopy, sequential
digital monitoring, or history of change in standard
clinical practice, were included
Setting: Secondary (general dermatology) Italy;
Specialist unit (skin cancer/pigmented lesions clinic)
Australia
Prior testing: Clinical and/or dermatoscopic suspicion;
Changes on digital monitoring
Exclusion criteria: lesions of palms and soles were not
included; non-melanocytic appearance; lesions excised
for cosmetic reasons or solely due to a patient request;
lentigo maligna excluded
Sample size (patients): No. included: 332
Sample size (lesions): No. included: 351; 156 from
Australia and 195 from Italy
Participant characteristics: Median age: 47.7 (IQR 35.9,
60.4); Male: 52%
Lesion characteristics: Lesion site - Head/Neck: 15;
Trunk: 68; abdomen and chest: 135 on the back;Upper
limbs/shoulder: 50; Lower limbs/hip: 83. ≤ 1 mm
thickness: 66% (62/136); 1.01-2.00 mm: 25% (23);
2.01-4.00 mm: 9% (8); median thickness 0.49mm (IQR:
0, 0.89 mm)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
1. Reflectance confocal microscopy (RCM): RCM score
Also identifies features independently correlated with malignancy by means of discriminant analysis on
the training set, unable to include as only AUC presented.
Vivascope 1000s and Vivascope 1500s
Method of diagnosis: Confocal images (remote)
Prior test data: Lesion site and/or patient age only
Diagnostic threshold: Data presented for all RCM scores from ≥ 1 to ≥ 8; data extracted for ≥ 2, ≥ 3
and ≥ 4 (included here only for ≥ 2, ≥ 3).
Diagnosis based on: Single observer (n = 2); one from the University of Modena evaluated the Sydney
cases, and one from Sydney evaluated the Modena cases
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with index test: High experience /‘Expert’ users
Other detail Vivascope 1000s and Vivascope 1500s, Lucid Inc., Henrietta, New York
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were sufficient details of diagnostic thresholds provided? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological
diagnosis alone
Details: not further described; Disease
positive: 136; Disease negative: 215
Target condition (Final diagnoses) 
Melanoma (invasive): 94; Melanoma (in
situ): 42
Benign naevus: 215
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
RCM images were acquired before
biopsy
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Was the minimum clinical follow-up after application of index test(s) adequate?
If more than one algorithm evaluated for the same test, was the interval between
application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes —
 
Pellacani 2012
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection Jan 1-March 31
2008
Country Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Melanocytic lesions with equivocal clinical
and/or dermatoscopic features
Setting: Secondary (general dermatology) not mentioned in
text, just in author institution details
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Secondary (general dermatology) [it is
inferred that the patient was evaluated in the same unit]
Exclusion criteria: non-melanocytic appearance; Unequivocal
appearance/diagnosis; Disagreement between evaluators on
tumour histological classification
Sample size (patients): No. included: 62
Sample size (lesions): No. eligible: 64 /No. included: 60
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting
appropriate? No
Did the study avoid including participants with multiple
lesions? Yes
Are there concerns that the included patients and setting
do not match the review question? High
Index Test
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Index tests
Reflectance confocal microscopy (RCM) Pellacani (Two step) Own new algorithm based on evaluation
of a list of previously published parameters and some new descriptors (cites Pellacani 2009 and
Pellacani 2009a, and Scope 2007);
Vivascope 1500
Method of diagnosis: Confocal images (remote)
Prior test data: No further information used "blinded from any clinical, dermatoscopic, or
histopathologic information"
Diagnostic threshold: (≥ 3 chars present, two at step 1 and one at step 2). Step 1: to identify dysplastic
nevus - Presence of cytologic atypia (≥ 1 present) including - round pagetoid cells - atypical cells at
DEJ. Presence of architectural atypia (≥ 1 present)- irregular junctional nests - short interconnections
between junctional nests - nonhomogenous cellularity within junctional nests. Step 2: to identify
melanoma from dysplastic nevus (≥ 1 present) - widespread (≥ 50% of lesional area) round pagetoid
cells, - widespread (≥ 50% of lesional area) atypical cells at the DEJ, and - nonedged papillae (≥ 10%
of the lesional area)
Derivation aspect to study: Lesions were evaluated for a list of previously published parameters and
for some new descriptors specifically introduced for this study.
Selection of characteristics indicative of skin cancer: For multivariate analysis, binary logistic
regression was performed for the identification of the independently significant features in
distinguishing among nondysplastic nevi, dysplastic nevi, and MM.
Stepwise forward selection and goodness-of-fit statistics were used to select the features and
determine whether the model adequately described the data.A P value less than .01 was considered
significant for the correlation tests, whereas a P less than .05 was used for the other statistical tests.
Diagnosis based on: Single observer (n = 1)
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’
Experience with index test: High experience /‘Expert’ users
Other detail. Any other detail RCM uses a low-power 830-nmlaser beam that generates horizontal
sections of the skin of 1.0-um lateral resolution up to approximately200 um in depth.15 A minimum of 3
mosaics, with a maximum area of 8 3 8 mm,were obtained per lesion, one in the superficial epidermis
(stratum granulosum/spinosum), one at the dermoepidermal junction (DEJ), and one in papillary
dermis.
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were sufficient details of diagnostic thresholds provided? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
#164b Reflectance confocal microscopy for the diagnosis of cutaneous melanoma in adults
61 / 163
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological
diagnosis alone
Details: Disease positive 14; Disease negative
46
Target condition (Final diagnoses) 
Melanoma (invasive): 10; Melanoma in situ 4
Benign: Severe dysplasia: 5; 7 showed mild
dysplasia, 15 moderate; 19 nondysplastic nevi
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 4 lesions were excluded as
dermatopathologists could not agree on pathology (in two
cases discordance was for MM versus dysplastic nevus
diagnosis, and in the other two between dysplastic and
nondysplastic nevus)
Time interval to reference test: Before excision, all lesions
were recorded
by means of digital dermatoscopy and RCM
Was there an appropriate interval between index test and
reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Was the minimum clinical follow-up after application of index
test(s) adequate?
If more than one algorithm evaluated for the same test, was
the interval between application of the different algorithms 1
month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes —
 
Pellacani 2014a (cons)
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection January 2010 to
December 2010
Country Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients requesting a mole check or
with suspicion of melanoma who were referred to
pigmented lesion clinic and who were then found to have
atypical lesions on dermoscopy. Those in whom
diagnosis could not be determined on dermoscopy were
referred for an 'outcome decision' (consultation group).
Patients were referred on the basis of both urgent
access (melanoma suspected in a single lesion by GP or
other dermatologist) and scheduled access (referred for
dermoscopy and total body examination).
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Dermatoscopic suspicion in all cases. All
patients underwent dermoscopy in the PLC; those with
dermoscopically atypical lesions were referred for RCM,
either to document a lesion already selected for excision
(documentation group, reported in Pellacani 2014b
(doc)) or for an 'outcome decision' (consultation group),
i.e. diagnosis could not be determined on dermoscopy
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: Clinically and/or dermatoscopically
clear-cut epithelial tumours were not enrolled; Poor
quality index test image - In nine cases RCM could not
be performed (five RCM documentation and four RCM
consultation) due to the presence of artefacts,
hyperkeratosis, and/or ulcerations, impeding imaging.
Sample size (patients): No. eligible: 1005 examined with
dermoscopy; No. included: 252 referred for RCM
consultation
Sample size (lesions): No. eligible: NR; No. included:
308 for RCM documentation
Participant characteristics: Median age 41.7 (IQR 31.9,
52.1); For all referred patients (n = 1005): 443 male
(44%); Consultation group only: History of
melanoma/skin cancer 23 (7%); Family history of
melanoma 30 (10%). Fitzpatrick phototype I to II: 150
(49%); Type III to IV 116 (38%)
Lesion characteristics: Lesion site (full sample)
Head/Neck: 9%; Trunk: 59%; Upper limbs/shoulder:
12%; Lower limbs/hip: 20%
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Reflectance confocal microscopy (RCM). RCM score
Vivascope 1500
Method of diagnosis: In person
Prior test data: Patients were "referred to confocal unit"; confocal reader was blinded to the patient
pathway and aware that lesions were dermoscopically atypical for ‘RCM documentation’ or for ‘RCM
consultation’.
Diagnostic threshold: Not reported Pellacani 2005 cited
Diagnosis based on: Single observer (n = 1)
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with index test: Not described but 'confocal unit' described
Other detail Any other detail Dermatoscopy examinations were conducted using the Dermlite HR
(3Gen LLC, San Juan Capistrano, CA, U.S.A.). Lesions that were scheduled for digital monitoring
were also acquired by means of FotoFinder (TeachScreen GmbH, Bad Birnbach, Germany) using 20-
fold magnification.
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were sufficient details of diagnostic thresholds provided? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological diagnosis
plus FU and cancer registry follow-up
Histology (not further described): 81 (consultation
group) [overall dataset 292 excised (see Pellacani
2014a (cons))
Clinical FU: 227, 28 of which were subsequently
excised (incl above) because of observed
dermatoscopic changes (all benign). Most non
excised lesions (89.4% 178/199) were followed up
for 1 year; the others were lost at the 1-year follow-
up.
Cancer registry FU: Those lost to clinical follow-up
were checked on the tumour registry; no melanomas
were diagnosed in patients scheduled for follow-up
after baseline examinations.
Target condition (Final diagnoses) 
Melanoma (invasive): 13; Melanoma (in situ): 9;
BCC: 19; 1 melanoma metastasis
Clark naevus 71; Spitz nevus 5; solar lentigo,
seborrhoeic keratosis
or lichen planus-like keratosis 0; other benign 207 (8
with histological diagnosis (25 Clark naevi, two Spitz
naevi and one benign nonmelanocytic lesion) and
199 benign on FU)
Is the reference standards likely to correctly classify the target
condition? No
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of
the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 9 excluded due to
RCM failure
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
Was the minimum clinical follow-up after application of index test(s) adequate?Yes
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes —
 
Pellacani 2014b (doc)
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Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection January 2010 to
December 2010
Country Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients requesting a mole check or
with suspicion of melanoma who were referred to
pigmented lesion clinic and who were then found to have
atypical lesions on dermoscopy. Those in whom excision
was required on dermoscopy were referred for RCM
documentation (documentation group). Patients were
referred on the basis of both urgent access (melanoma
suspected in a single lesion by GP or other
dermatologist) and scheduled access (referred for
dermoscopy and total body examination).
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Dermatoscopic suspicion in all cases. All
patients underwent dermoscopy in the PLC; those with
dermoscopically atypical lesions were referred for RCM,
either to document a lesion already selected for excision
(documentation group, as reported here) or for an
'outcome decision' (consultation group, reported in
Pellacani 2014a (cons)), i.e. diagnosis could not be
determined on dermoscopy.
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: Clinically and/or dermatoscopically
clear-cut epithelial tumours were not enrolled; Poor
quality index test image - In nine cases RCM could not
be performed (five RCM documentation and four RCM
consultation) due to the presence of artefacts,
hyperkeratosis, and/or ulcerations, impeding imaging.
Sample size (patients): No. eligible: 1005 examined with
dermoscopy; No. included: 171 referred for RCM
documentation
Sample size (lesions): No. eligible: NR; No. included:
183 for RCM documentation
Participant characteristics: Median age 41.2 (IQR 35,
63); For all referred patients (n = 1005): 443 male (44%);
History of melanoma/skin cancer 8 (5%); Family history
of melanoma 13 (8%). Fitzpatrick phototype I to II: 99
(58%); Type III to IV 72 (42%)
Lesion characteristics: Lesion site (full sample)
Head/Neck: 9%; Trunk: 59%; Upper limbs/shoulder:
12%; Lower limbs/hip: 20%
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Reflectance confocal microscopy (RCM). RCM score
Vivascope 1500
Method of diagnosis: In person
Prior test data: Patients were "referred to confocal unit"; confocal reader was blinded to the patient
pathway and aware that lesions were dermoscopically atypical for ‘RCM documentation’ or for ‘RCM
consultation’.
Diagnostic threshold: Not reported; Pellacani 2005 cited
Diagnosis based on: Single observer (n = 1)
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with index test: Not described but 'confocal unit' described
Other detail Any other detail Dermatoscopy examinations were conducted using the Dermlite HR
(3Gen LLC, San Juan Capistrano, CA, U.S.A.). Lesions that were scheduled for digital monitoring
were also acquired by means of FotoFinder (TeachScreen GmbH, Bad Birnbach, Germany) using 20-
fold magnification.
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were sufficient details of diagnostic thresholds provided? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histology alone for
documentation group; 227 from consultation group were
referred for follow-up (see Pellacani 2014a (cons))
Target condition (Final diagnoses) 
Melanoma (invasive): 13; Melanoma (in situ): 9; BCC:
19; 1 melanoma metastasis
Clark naevus 121; Spitz nevus 8; solar lentigo,
seborrhoeic keratosis
or lichen planus-like keratosis 7; other benign 5
(haemosiderotic dermatofibroma, xanthogranuloma, viral
wart and two nonspecific inflammatory dermatoses)
Is the reference standards likely to correctly classify the target
condition? No
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Were the reference standard results interpreted without
knowledge of the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? High risk
#164b Reflectance confocal microscopy for the diagnosis of cutaneous melanoma in adults
67 / 163
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 9 excluded due to
RCM failure
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
Was the minimum clinical follow-up after application of index test(s) adequate?Yes
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes —
 
Pupelli 2013
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective
Period of data collection 2007-2011
Country Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Melanomas <5 mm consecutively
excised; plus 3 histologically proven small-diameter
naevi per included melanoma
Setting: Specialist unit (skin cancer/pigmented lesions
clinic) [from Author institution]
Prior testing: Selected for excision (no further detail) All
had undergone dermoscopy and RCM in order to be
included
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: lesion size > 5 mm excluded;
disagreement between evaluators on tumour histological
classification
Sample size (patients): No. included: 96
Sample size (lesions): No. included: 96
Participant characteristics: Mean age: MM 48 (IQR 17,
77); Naevi 41 (IQR 6, 82); Male: MM 54% / naevi 58%
Lesion characteristics: Lesion site: Trunk: 62% naevi;
Lower limbs/hip: 46% melanomas. Mean thickness 0.37
mm (SD 0.44 mm); Melanoma diameter in situ MM: 10 <
1 mm, 3 ≥ 1 mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Dermoscopy 7-point checklist
Method of diagnosis: Dermoscopic images
Prior test data: body site and age provided; RCM images may also have been available at time of
image interpretation
Diagnostic threshold: ≥ 3
Diagnosis based on: likely single observer (n = NR)
Observer qualifications: Not reported likely dermatologist
Experience in practice: Not described
Experience with index test: Not described
Any other detail Dermoscopic images were acquired by means of a polarized dermatoscope (DermLite
FOTO; 3Gen Inc., San Juan Capistrano, CA, U.S.A.)."
Reflectance confocal microscopy (RCM): No algorithm independently significant features
Vivascope 1500
Method of diagnosis: Confocal images (remote)
Prior test data: Lesion site and/or patient age only. "Dermoscopic and confocal microscopic images
were evaluated – in blind from histological diagnosis, but not from the body site or the age of the
patient."
Diagnostic threshold: appears to be ≥ 1 characteristic present. 3 characteristics were identified as
independently significant (presence of at least five pagetoid cells per mm2, tangled lines within the
epidermis, and atypical roundish cells at the dermoepidermal junction). Sensitivity and specificity to
allow 2x2 estimation were obtained from authors
Derivation aspect to study: 
Lesion characteristics assessed. RCM parameters as published previously (all described).
Selection of characteristics indicative of skin cancer multivariate analysis (logistic regression)
Diagnosis based on: likely single observer (n = NR)
Observer qualifications: Not reported likely dermatologist
Experience in practice: Not described
Experience with index test: Not described
Other detailAny other detail Confocal imaging was performed with a near-infrared reflectance-mode
confocal laser scanning microscope (Vivascope1500 ; Lucid Inc., Rochester, NY, U.S.A.). The
instrument and acquisition methods have been describedelsewhere.16,18
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were sufficient details of diagnostic thresholds provided? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were sufficient details of diagnostic thresholds provided? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological
diagnosis alone
Details: Disease positive: 24 / Disease
negative: 72
Target condition (Final diagnoses) 
Melanoma (invasive): 13; Melanoma (in
situ): 11
Benign naevus: 65 (29 junctional, 19
compound, intra-dermal, eight blue, four
lentigo simplex) ; Spitz nevus 7.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: not reported
Time interval to reference test: not reported
Time interval between index test(s): not
reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Was the minimum clinical follow-up after application of index test(s) adequate?
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative
"Dermoscopic and confocal microscopic images
were evaluated – in blind from histological
diagnosis, but not from the body site or the age
of the patient."
Was each index test result interpreted without knowledge of the results of
other index tests or testing strategies? No
Was the interval between application of the index tests less than one
month? Yes
Are there any concerns that the test comparison could have introduced
bias? Low risk
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B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? Unclear
Are there concerns that the test comparison differs from the review question? Unclear
Notes
Notes —
 
Rao 2013
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported; appear to be
prospective but not explicitly stated
Period of data collection Jun 2010-Sep
2011
Country US
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Lesions removed for cosmetic or
medical reasons (no further detail; 'teleconsultation
setting'
Setting: Secondary (general dermatology); Private
(Based on author institutions)
Prior testing: Not reported; unclear whether selection
for excision was based on clinical assessment alone
or including dermoscopy
Setting for prior testing: Unspecified
Exclusion criteria: Six cases were excluded due to
"insufficient information"
Sample size (patients): NR
Sample size (lesions): No. eligible: 340; No. included:
334. 318/334 reported for Reader 1; 323/334
reported for Reader 2
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? Unclear
Index Test
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Index tests
Reflectance confocal microscopy (RCM). No algorithm; Overall observer diagnosis
Vivascope 1500
Method of diagnosis: 
In person US (Reader 1; less experienced)
Confocal images (remote) Modena, Italy; Reader 2 (more experienced) (*data used for primary
analysis and QUADAS scoring)
Prior test data: Clinical examination and/or case notes and dermoscopy "diagnosis was based on the
dermoscopic image and confocal microscopy evaluation before excision."
Diagnostic threshold: Not reported Observers gave diagnosis and excise decision (no further details)
Diagnosis based on: Single observer (n = 2)
Observer qualifications: Not reported Presume dermaologists
Experience in practice: Not described
Experience with index test: Low experience / novice users Reader 1 (US) had 1 year of experience at
the beginning of the study
High experience /‘Expert’ users Reader 2 (Italy) had over 9 years of experience with RCM.
Other detail Images were sent via Vivanet (CaliberID, Rochester, NY), a Health Insurance Portability
and Accountability Act-compliant server.15
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were sufficient details of diagnostic thresholds provided? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological
diagnosis alone
Details: not further described; Disease
positive: 78; Disease negative: 256
Target condition (Final diagnoses) 
Melanoma (invasive): 8; Melanoma (in situ);
1; BCC: 27; cSCC: 42
Benign nevi 176; sebhorrheic keratosis 22;
actinic keratosis 24; 23 other
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
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B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 6 described as
excluded because of insufficient information;
318/334 reported for Reader 1323/334
reported for Reader 2
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Was the minimum clinical follow-up after application of index test(s) adequate?
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes —
 
Segura 2009
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series. Authors separately describe recruitment
of 'possibly malignant' and clinically/dermoscopically benign but
seem to be from same overall population
Data collection: Prospective
Period of data collection November 2005 to June 2006
Country Spain
Was a consecutive or random sample of patients
enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: All patients attending dermatology dept
or melanoma unit with a lesion
suggestive of malignancy (study participation did not
affect the clinical decision or the excision schedule) and
patients with lesions known to be clinically and
dermatoscopically benign; only melanocytic included in
2x2
Setting: Mixed (Dermatology Department and the
Melanoma Unit of the Hospital Clinic, Barcelona, Spain)
Prior testing: Clinical and/or dermatoscopic suspicion
Exclusion criteria: None reported
Sample size (patients): No. eligible: 143
Sample size (lesions): No. eligible: 154 / No. included:
100 (melanocytic only)
Participant characteristics: Mean age: 49.45 years; Male:
39.9%; 13 had personal or family history of melanoma;
'most' described as having dysplastic mole syndrome
and 'most' with dermatoscopic changes recorded during
follow-up examinations
Lesion characteristics: Lesion site Head/Neck: 34 (22%);
Trunk: 82 (53%); Lower limbs/hip: 22 (14%) head2
(1.3%) neck
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Reflectance confocal microscopy (RCM). Segura Own new algorithm
Vivascope 1500
Method of diagnosis: Confocal images (remote)
Prior test data: No further information used "stored confocal images were evaluated afterward, without
regard to clinical or dermatoscopic data"
Diagnostic threshold: Cutoff of >-1 = 'most probable melanoma' Within melanocytic lesions (ML) 2
protective features associated with benign lesions (score -1 each) - typical basal cells and - edged
papillae 2 risk features associated with melanoma (score +1 each) - roundish pagetoid cells and -
atypical dermal nucleated cells. Lesions were assigned a value from -2 to 2 according to the presence
or absence of these factors
Derivation aspect to study: 
Lesion characteristics assessed - Superficial layer: honeycombed pattern, cobblestone pattern,
epidemral disarray, pagetoid cellsDermoepidermal junction: visible dermal papilla, typical basal cells,
marked atypia basal cells, cells in sheet like structures, junctional clustersPapillary dermis: dermal
nests, nucleated dermal cells, plump bright cells, bright hyper reflecting spots, enlarged dermal
vessels
Selection of characteristics indicative of skin cancer Multivariate analysis using logistic regression to
develop an algorithm in which benign (protective) features given a value of -1 and malignant (risk)
features a value of +1
Diagnosis based on: Single observer (n = NR)
Observer qualifications: Not reported Two observers described for the interobserver reproducibility
study (120 images) but this appears separate to RCM interpretations used for the accuracy study.
Experience in practice: Not described
Experience with index test: Not described
Other detail Study participation (RCM) did not affect the clinical decision or the excision schedule.
Study aimed to develop a 2-step process, firstly to differentiate melanocytic from nonmelanocytic
lesions, then to differentiate malignant from benign within the melanocytic group. The first step has not
been extracted but note that relatively poor accuracy was observed (sensitivity for detection of ML
59%. specificity 96.7%)
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were sufficient details of diagnostic thresholds provided? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological diagnosis plus
expert diagnosis
Details: Both diagnostic and therapeutic excisions
performed
No. patients/lesions: 139 in total; including 92
melanocytic lesions
Disease positive: Melanocytic: 36 melanomas;
Nonmelanocytic: 27 BCC
Disease negative: Melanocytic: 56; Non melanocytic: 20
Expert opinion: of the 154 included lesions, 15 clinically
and dermatoscopically benign did not undergo excision:
8 were melanocytic benign nevi and 7 were non-
melanocytic
Target condition (Final diagnoses) T
Melanoma (invasive): 23; Melanoma (in situ): 13; BCC 0
(27 BCC in non melanocytic lesion group; not included in
2x2)
Benign naevus: 64 (32 dysplastic, 20 common, 7
congenital, 2 blue,2 Reed, and 1 Meyerson nevi)
27 benign NML not included in 2x2 (8 SK, 5 solar
lentigines, 4 benign lichenoid keratoses, 4 vascular
lesions, 3 actinic keratoses, 2 dermatofibromas, and 1
sebaceous hyperplasia)
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Were the reference standard results interpreted without
knowledge of the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard No
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: All non-melanocytic (n
= 54)
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
Was the minimum clinical follow-up after application of index test(s) adequate?
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes —
 
Stanganelli 2015
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Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective
Period of data collection July 2010 to July 2012
Country Italy
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Lesions excised at the Skin Cancer Unit on
the basis of clinical and/ or dermoscopic changes at follow-up
suggesting a malignancy and with available dermoscopy, RCM
and histological images and reports.
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: Lesions showing clinical or dermoscopic changes
on follow-up
Setting for prior testing: Specialist unit (skin cancer/pigmented
lesions clinic)
Exclusion criteria: Unequivocal appearance/diagnosis
Sample size (patients): No. included: 70
Sample size (lesions): No. included: 70
Participant characteristics: Mean age: women: 39 years, men:
40 years; Male: 38 (54%). History of melanoma/skin cancer 26
(37%). Total naevus counts, 27 (39%) > 50 melanocytic naevi,
33 (47%) 10–50 naevi; and 10 (14%) <10 naevi. Fitzpatrick
phototype Type I to II 19 (27%); Type III to IV 50 (73%)
Lesion characteristics: Lesion site Head/Neck: 5; Trunk: 56;
Upper limbs/shoulder: 1; Lower limbs/hip: 8. Median thickness
0.4mm (0.2-1 mm).
Mean diameter at baseline 8 mm (range 2–22 mm) mean at FU
9 mm (range 3–24 mm)
Are the included patients and chosen study setting
appropriate? No
Did the study avoid including participants with multiple
lesions? Yes
Are there concerns that the included patients and setting do
not match the review question? High
Index Test
#164b Reflectance confocal microscopy for the diagnosis of cutaneous melanoma in adults
78 / 163
Index tests
Dermoscopy. Revised 7-point checklist
Method of diagnosis: Dermoscopic images. Appears to be image-based comparison of follow-up
images with baseline images to determine criteria indicating significant change
Prior test data: Baseline and follow-up dermoscopic images were compared to detect structural or
chromatic changes or the development of new dermoscopic features indicative of melanoma
Diagnostic threshold: A score of ‘no change’ was assigned if all variables remained constant, with
a tolerance of major axis change of 2 mm (Beer 2011; Terushkin 2012); ‘minor change’ if there was
only symmetrical change in structural or chromatic pattern; ‘moderate change’ if either structural or
chromatic changes were asymmetrical, but there were no melanoma-specific criteria; and ‘major
change’ if there were asymmetrical structural and chromatic changes, or the appearance of
melanoma-specific criteria.
Diagnosis based on: Unclear; NR for dermoscopy
Observer qualifications: Not reported likely dermatologists (RCM images in same study were
evaluated jointly by three expert dermatologists who had no knowledge of the clinical, dermoscopic or
histopathology information)
Experience in practice: Not described
Experience with index test: Not described
#
Reflectance confocal microscopy (RCM). Pellacani (Two step algorithm). Methods cites RCM
score (Pellacani 2005); also refers to weighting according to extent and distribution for
differential diagnosis with dysplastic naevus (Pellacani 2012). From discussion: "We were
able to distinguish benign and malignant lesions accurately using a previously proposed
algorithm for differentiating dysplastic naevus and melanoma that considers the extent and
distribution of RCM parameters (Pellacani 2012).
Vivascope 1500
Method of diagnosis: Confocal images (remote)
Prior test data: No further information used observers "had no knowledge of the clinical, dermoscopic
or histopathology information, and reached a consensus or majority opinion"
Diagnostic threshold: Not reported in detail. "Each lesion was classified considering the main
melanoma features (Pellacani 2005) and weighted according to extent and distribution for
differential diagnosis with dysplastic naevus (Pellacani 2012)."
Diagnosis based on: Consensus three expert dermatologists (n = 3)
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’
Experience with index test: High experience /‘Expert’ users
Other detailAny other detail RCM images were obtained with a Vivascope 1500 (Lucid Inc.,
MAVIG GmbH, Munich, Germany) using an 830-nm laser at a maximum power of 20 mW.
Methods and acquisition settings have been described previously (Pellacani 2007). RCM images of
0.5 x 0.5 mm were acquired with a lateral resolution of 1 lm and an axial resolution of 3–5 lm and
assembled into composite images that covered 4–8 mm2 mosaics (Pellacani 2009). Composite
images were obtained at three different depths, corresponding to the stratum granulosum/spinosum,
the dermo-epidermal junction and the papillary dermis.
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were sufficient details of diagnostic thresholds provided? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy
#164b Reflectance confocal microscopy for the diagnosis of cutaneous melanoma in adults
79 / 163
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were sufficient details of diagnostic thresholds provided? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological diagnosis
alone
Details: not further described. Disease positive: 12;
Disease negative: 58
Target condition (Final diagnoses) 
Melanoma (invasive): 11, Melanoma (in situ): 1
55 melanocytic naevi (79%) and three
nonmelanocytic lesions (4%)
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of
the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
RCM imaging performed before surgical
excision
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Was the minimum clinical follow-up after application of index test(s) adequate?
If more than one algorithm evaluated for the same test, was the interval between
application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
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A. Risk of Bias
Comparative
(RCM) observers "had no knowledge of the
clinical, dermoscopic or histopathology
information, and reached a consensus or majority
opinion"
Was each index test result interpreted without knowledge of the results
of other index tests or testing strategies? Yes
Was the interval between application of the index tests less than one
month? Yes
Are there any concerns that the test comparison could have introduced
bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No
Are there concerns that the test comparison differs from the review question? High
Notes
Notes —
 
Footnotes
NR – not reported; PSL – pigmented skin lesion; PLC – pigmented lesion clinic; MM – malignant melanoma; MiS – melanoma
in situ (or lentigo maligna); BCC – basal cell carcinoma; cSCC – cutaneous squamous cell carcinoma; LS – lentigo simplex;
SK – seborrheic keratosis; SN – Spitz nevi; AK – actinic keratosis; BN – benign naevi; BD – Bowen’s disease; DF –
dermatofibroma; FU – follow-up; R –retrospective; P – prospective; CS – case series; CCS – case control study; WPC –
within person comparison (of tests); BPC – between person comparison (of tests); NC – non comparative; RCM – reflectance
confocal microscopy; CAD – computer-assisted diagnosis; Cons - consensus diagnosis; exp - experience; obs - observer; VI
visual inspection.
Characteristics of excluded studies 
Agero 2006
Reason for exclusion EXCLUDE on sample size
only 5 lesions
 
Ahlgrimm-Siess 2010
Reason for exclusion EXCLUDE on study population ~EXCLUDE on sample size. Two cases of BCC.
 
Ahlgrimm-Siess 2011
Reason for exclusion EXCLUDE on study population ~EXCLUDE on sample size. Two cases of SCC.
 
Alarcon 2014a
Reason for exclusion EXCLUDE on sample size
 
Amjadi 2011
Reason for exclusion EXCLUDE on study population - Includes only BCC (82)/SCC (48) and 8 AK/SK
lesions; primary aim appears to be to differentiate BCC and SCC despite describing
inclusion of clinically difficult to diagnose non-pigmented lesions.
 
Bassoli 2012
Reason for exclusion EXCLUDE on target condition
The aim of this study was to identify criteria for specific diagnosis of LPLK using in vivo
RCM.
 
Benati 2015
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Reason for exclusion EXCLUDE if individual lesion characteristics
 
Braga 2009
Reason for exclusion EXCLUDE on sample size
case reports
 
Carrera 2015
Reason for exclusion EXCLUDE not a primary study
 
Castro 2015
Reason for exclusion EXCLUDE on target condition; eligible for keratinocyte review only
 
de Carvalho 2015
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE on 2x2 data
 
de Carvalho 2016
Reason for exclusion EXCLUDE on target condition
EXCLUDE on sample size
 
Edwards 2016
Reason for exclusion EXCLUDE not a primary study
systematic review
 
Eichert 2010
Reason for exclusion Review/comment paper
 
Gareau 2009
Reason for exclusion EXCLUDE on study population
Only BCC cases 
 
Gerger 2005
Reason for exclusion EXCLUDE on reference standard
only 1/3 of disease negative group had adequate ref test
EXCLUDE duplicate or related publication; data reported as training set in Koller 2011
(#860)
 
Gerger 2006
Reason for exclusion EXCLUDE on reference standard
Only 30/120 benign were excised (30/90 benign nevi and 0/30 SK)
 
Gerger 2008a
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Reason for exclusion EXCLUDE on reference standard
all MMs were excised plus 14/50 benign; remainder diagnosed on clinical/dermoscopic
criteria
 
Gerger 2008b
Reason for exclusion EXCLUDE on reference standard; includes 70 melanocytic lesions - 20 MM (all
histologically verified); 70 benign naevi (28% histologically verified, and the rest
diagnosed with dermoscopy only). 
 
Giambrone 2015
Reason for exclusion EXCLUDE on target condition
EXCLUDE but contact authors
they do not give information on the target condition-only state malignant/benign
cutaneous lesions??? Contacted 8-5-17
 
Gill 2014
Reason for exclusion EXCLUDE if derivation study; looking for correlation with histological features
EXCLUDE on 2x2 data; Looks at correlation between RCM features and histological
features; not test accuracy
EXCLUDE duplicate or related publication; Same lesions reportedly included in
Pellacani 2012
 
Gonzalez 2002
Reason for exclusion EXCLUDE on study population. BCC only.
 
Gonzalez 2013
Reason for exclusion EXCLUDE not a primary study
 
Guida 2015
Reason for exclusion EXCLUDE not a primary study
systematic review
 
Guitera 2010
Reason for exclusion EXCLUDE on target condition; only looking at LM and not LMM
 
Guitera 2013
Reason for exclusion EXCLUDE on study population; LM and LMM only
EXCLUDE on target condition; data only available for LM
EXCLUDE on 2x2 data
 
Haenssle 2006
Reason for exclusion EXCLUDE on index test; surveillance study estimating accuracy of different
approaches to follow-up
 
Hennessy 2010
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Reason for exclusion EXCLUDE on 2x2 data
 
Hoogedoorn 2014
Reason for exclusion EXCLUDE conference abstract
 
Hoogedoorn 2015
Reason for exclusion EXCLUDE on sample size
 
Humphrey 2006
Reason for exclusion EXCLUDE on study population
EXCLUDE as derivation study - assesses lesion vascularity
 
Incel 2015
Reason for exclusion EXCLUDE on 2x2 data ~EXCLUDE but contact authors. se/sp given in Table 3 but not
clear how the disease negative groups are comprised (i.e. BCC vs what? the 37
benign or some other definition?) and not clear what threshold was used.
 
Kadouch 2015
Reason for exclusion systematic review
 
Kadouch 2015a
Reason for exclusion EXCLUDE not a primary study
clinical trial protocol
 
Kose 2014
Reason for exclusion EXCLUDE not a test accuracy study
EXCLUDE on 2x2 data
 
Langley 2001
Reason for exclusion EXCLUDE on 2x2
EXCLUDE but contact authors; contact authors for RCM 2x2 data can only get 2x2 for
clinical diagnosis 
 
Langley 2006
Reason for exclusion EXCLUDE on sample size
 
Losi 2014
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE on 2x2 data
 
Maier 2013
Reason for exclusion EXCLUDE on study population; all study participants had final diagnosis of melanoma
 
Malvehy 2012
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Reason for exclusion EXCLUDE not a primary study; review article
 
Menge 2016
Reason for exclusion EXCLUDE on target population; includes participants with primary possible recurrent
and/or previously treated lesions and does not disaggregate results. Also includes
multiple lesions per participant (63 'sites' from 17 participants; unclear how many of
the 39 LM positive on histology had melanoma). 
 
Miller 2011
Reason for exclusion EXCLUDE on target condition
EXCLUDE on 2x2 data; not an accuracy study
 
Nobre 2011
Reason for exclusion EXCLUDE on sample size; case report
 
Nori 2004
Reason for exclusion EXCLUDE on target condition; eligible for keratinocyte review only
 
Pellacani 2005
Reason for exclusion EXCLUDE if derivation study; uses leave one out
 
Pellacani 2007a
Reason for exclusion EXCLUDE if individual lesion characteristics; looking at blue hue not overall diagnosis 
EXCLUDE if derivation study
 
Pellacani 2008
Reason for exclusion EXCLUDE on 2x2 data; no accuracy data provided in the study, looking at correlation
of RCM features to dermoscopy and histology
 
Pellacani 2009
Reason for exclusion EXCLUDE on 2x2 data; Study is testing concordance of terminology used in
RCM...not accuracy. 
 
Peppelman 2013
Reason for exclusion EXCLUDE on study population; only present data for subtypes of BCC
EXCLUDE on 2x2 data; does not give accuracy data 
 
Peppelman 2015
Reason for exclusion EXCLUDE if derivation study
EXCLUDE on 2x2 data; no data for overall accuracy
 
Peppelman 2016
Reason for exclusion EXCLUDE not a primary study; RCT protocol
 
Puig 2012
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Reason for exclusion EXCLUDE on sample size; case report
 
Reggiani 2015
Reason for exclusion EXCLUDE not a primary study; systematic review
 
Rishpon 2009
Reason for exclusion EXCLUDE on sample size; only 3 invasive SCC
EXCLUDE if derivation study RCM characteristics for SCC
 
Röwert-Huber 2007
Reason for exclusion Review/comment paper
 
Salerni 2011
Reason for exclusion EXCLUDE on sample size; <5 cases 
 
Scope 2009
Reason for exclusion EXCLUDE on sample size
 
Scope 2014
Reason for exclusion EXCLUDE not a primary study; editorial paper 
 
Soyer 2013
Reason for exclusion EXCLUDE not a primary study; comment on a primary study (Longo 2013)
 
Steiner 1992
Reason for exclusion EXCLUDE on sample size
only two melanomas 
 
Stephens 2013
Reason for exclusion EXCLUDE on sample size
 
Stevenson 2013
Reason for exclusion EXCLUDE not a primary study
systematic review of RCM
 
Tannous 2009
Reason for exclusion EXCLUDE on sample size; only two malignant melanomas 
 
Willard 2011
Reason for exclusion EXCLUDE on sample size; case study
 
Witkowski 2016
Reason for exclusion EXCLUDE on target condition; eligible for keratinocyte review only
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Xiong 2016
Reason for exclusion EXCLUDE not a primary study
systematic review of RCM
 
Yelamos 2016
Reason for exclusion EXCLUDE not a primary study
 
Footnotes
Characteristics of studies awaiting classification 
Borsari 2016
Patient Sampling —
 
Patient characteristics and setting —
 
Index tests —
 
Target condition and reference
standard(s)
—
 
Flow and timing —
 
Comparative —
 
Notes Published October 2016; after search dates
 
Guitera 2016
Patient Sampling —
 
Patient characteristics and setting —
 
Index tests —
 
Target condition and reference
standard(s)
—
 
Flow and timing —
 
Comparative —
 
Notes Published October 2016; after search dates
 
Jain 2017
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Patient Sampling —
 
Patient characteristics and setting —
 
Index tests —
 
Target condition and reference
standard(s)
—
 
Flow and timing —
 
Comparative —
 
Notes Published March 2017; conference abstract only
 
Ludzik 2016
Patient Sampling —
 
Patient characteristics and setting —
 
Index tests —
 
Target condition and reference
standard(s)
—
 
Flow and timing —
 
Comparative —
 
Notes Published September 2016; after search dates
 
Footnotes
Characteristics of ongoing studies 
Footnotes
Summary of results tables
1 Summary of findings table
Question: What is the diagnostic accuracy of reflectance confocal microscopy for the detection of cutaneous invasivemelanoma and atypical intraepidermal melanocytic variants in adults?
Population: 
 
Adults with lesions suspicious for melanoma, including:
Any lesion excised due to suspicion of melanoma, and
Equivocal lesions where a clear management decision could not be made following visual inspection or
dermoscopy
Index test: Reflectance confocal microscopy (RCM)
Comparator
test: Dermoscopy
Target
condition: Cutaneous invasive melanoma and atypical intraepidermal melanocytic variants
Reference
standard: Histology with or without long term follow-up
Action: If accurate, negative results of RCM will stop patients having unnecessary excision of skin lesions
Quantity of evidence
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Question: What is the diagnostic accuracy of reflectance confocal microscopy for the detection of cutaneous invasivemelanoma and atypical intraepidermal melanocytic variants in adults?
Number of
cohorts 19
1 Total lesions
with test results
2838
Total with
melanoma
658
Limitations
Risk of bias: High risk for patient selection from exclusion of some difficult to diagnose types of lesion (8/20). High risk for
the index test from data driven RCM threshold (4/20). High risk from inadequate reference standard (4/20)
and unclear risk as it was not clear that the reference standard was interpreted blind to the RCM results in
18/20 studies. High risk from differential verification (6/20), timing of tests was not mentioned in 11/20.
Applicability of
evidence to
question:
High concern from narrowly defined populations (12/20) and multiple lesions per patient (7/20). High
concern for RCM applicability from blinded interpretation of images (10/20). Studies are dominated by one
particularly expert research group (15/20). Little information was given concerning the expertise of the
histopathologist.
Findings: All analyses are undertaken on subgroups of the studies
Test: 
RCM – using ‘RCM score’ algorithm at threshold ≥3 or likely ≥3 regardless of population 
Datasets Lesions Melanomas Sensitivity (95% CI) Specificity (95% CI)
6 1209 296 92% (87, 95) 72% (62, 81)
Consistency: Significant heterogeneity in specificity between studies. Includes both equivocal (4) and 'any suspicious lesion'
(2) populations; both in-person (3) and image based 3).
Numbers observed in a cohort of 1000 lesions being tested2
 
True positive False negative False positive True negative
(receive necessary
excision)
(do not receive required
excision)
(inappropriately receive
excision)
(appropriately do not receive
excision)
At prevalence
13% 120 10 244 626
At prevalence
23% 212 18 216 554
At prevalence
39% 359 31 171 439
Test: 
RCM versus dermoscopy3 – any algorithm or threshold in 'any lesion suspicious for melanoma' populations [dermoscopy
data denoted in brackets]
Datasets Lesions Melanomas
Sensitivity (fixed)
RCM [Dermoscopy]
Specificity
RCM [Dermoscopy]
9 [3] 1452 [451] 370 [160] 90% [90%] 82% [42%]
Numbers observed in a cohort of 1000 lesions being tested2,3,4
 
True positive False negative False positive True negative
(receive necessary
excision)
(do not receive required
excision)
(inappropriately receive
excision)
(appropriately do not receive
excision)
At prevalence
26% 234 26
133 [429]
↓296
607 [311]
↑296
At prevalence
30% 270 30
126 [406]
↓280
574 [294]
↑280
At prevalence
36% 324 36
115 [371]
↓256
525 [269]
↑256
Test:
RCM versus dermoscopy – any algorithm or threshold in equivocal lesion populations [dermoscopy data denoted in
brackets]
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Question: What is the diagnostic accuracy of reflectance confocal microscopy for the detection of cutaneous invasivemelanoma and atypical intraepidermal melanocytic variants in adults?
Datasets Lesions Melanomas
Sensitivity (fixed)
RCM [Dermoscopy]
Specificity
RCM [Dermoscopy]
7 [3] 1177 [645] 180 [127] 90% [90%] 86% [49%]
Numbers observed in a cohort of 1000 lesions being tested2
 
True positive False negative False positive True negative
(receive necessary
excision)
(do not receive required
excision)
(inappropriately receive
excision)
(appropriately do not receive
excision)
At prevalence
10% 90 10
126 [459]
↓333
774 [441]
↑333
At prevalence
20% 180 20
112 [408]
↓296
688 [392]
↑296
At prevalence
23% 207 23
108 [393]
↓285
662 [377]
↑285
Footnotes
RCM - reflectance confocal microscopy.
1 The denominator for the Limitations section is 20 because methodologic quality was assessed separately for each
of the 19 cohorts of lesions, and a further publication (Pellacani 2007) reporting data for two of these cohorts (Guitera 2009a
(Modena); Guitera 2009b (Sydney)) was also included and separately quality assessed, taking the total to 20. Pellacani 2007
was included only to allow analysis of additional algorithm thresholds and was not included in the main analyses.
2 The numbers observed in a hypothetical cohort of lesions have been estimated at the median and interquartile range in
prevalence across the pooled datasets for each test.
3 [ ] Dermoscopy data is denoted by square brackets throughout.
4 The arrows ↓ ↑ indicate the change in number of false positive and true negative results as a result of RCM use.
Additional tables 
1 Glossary of terms
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Term Definition
Amelanotic Without melanin
Anti-CTLA-4 therapy
system
Monoclonal antibody to CTLA-4 (cytotixc T-lymphocyte-associated protein 4) – a protein that is
involved in regulating the immune system
BRAF-inhibitors Therapeutic agents that inhibit the serine-threonine protein kinase BRAF-mutated metastatic
melanoma
Driver mutations Somatic gene mutations that are responsible for tumour progression
Elective lymph node
dissection
Surgical removal of 1 or more lymph nodes in the absence of proven involvement with
melanoma
Hybridised The process of combining 2 biological molecules
Immune checkpoint targets Signalling pathways that are inhibitory and switch off T cells in the immune system
Immunomodulation Adjustment of the immune system in an individual
Irregular nesting Unbalanced asymmetrical arrangement of groups of melanocytes in the skin
Lymphovascular invasion Tumour cells that have spread to involve the blood vessels and lymphatic vessels within the
skin
MEK inhibitors Drugs that inhibit the mitogen-activated protein kinase enzymes that are often upregulated in
melanoma
Microscopic satellites Foci of melanoma observed histologically that are distinct from the original primary tumour
Mitotic rate Microscopic evaluation of a number of cells actively dividing in a tumour
Mutated signal transduction Activation of Ras proteins such that unintended and overactive signalling occurs and causes
overgrowth of cells and higher rates of cell division
PD1 Programmed cell death protein 1: a protein involved in downregulating the immune system
PD1-L Programmed cell death protein 1 receptor – expressed on T and B cells
Phenotypic risk The various clinical/physical traits of an individual determined by genetic and environmental
factors that predispose individuals to melanoma
Prophylactic isolated limb
perfusion
A medical procedure that directly delivers a drug through the bloodstream in a limb to the site
affected by melanoma
Pseudopods Temporary projections from cells that help cellular movement
RAS-RAF signalling
pathway
Family of proteins that serve as intermediary in transmitting extracellular signals from growth
factor receptors that control cell growth, proliferation, and differentiation
RNA Ribonucleic acid involved in coding, decoding, regulation, and expression of genes
Signal transduction Occurs when extracellular signalling molecules activate a specific receptor, which then triggers
cellular pathways
Spectroscopy Study of the interaction between matter and electromagnetic radiation
Stratum corneum Uppermost layer of the epidermis composed of dead keratinocytes (corneocytes)
Xeroderma pigmentosum Autosomal recessive genetic disorder of DNA repair, resulting in an inability to repair damage
caused by ultraviolet light leading to skin malignancies
Footnotes
2 Summary characteristics for studies reporting RCM accuracy for the primary outcome
Characteristic Any suspicious
lesion
Equivocal
Number of publications 8 7
RCM datasets 9 7
Dermoscopy datasets 3; 33.3% 3; 42.9%
Study design
Prospective case series 7; 77.8% 3; 42.9%
Retrospective case series - 4; 57.1%
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Characteristic Any suspicious
lesion
Equivocal
- with prospective re-interpretation of images   3; 75.0%
Case series (unclear data collection) 2; 22.2% -
Continent
Europe 4; 44.4% 7; 100.0%
North America 2; 22.2% -
Australasia 2; 22.2% -
Multicentre 1; 11.1% -
Setting
Secondary 4; 44.4% 3; 42.9%
Specialist clinic 3; 33.3% 4; 57.1%
Mixed 2; 22.2% -
Prior testing
Clinical examination 1; 11.1% -
Clinical examination or dermoscopy 2; 22.2% 2; 28.6%
Clinical examination and dermoscopy 4; 44.4% 3; 42.9%
Follow-up of atypical lesions - 2; 28.6%
Selected for biopsy or excision 2; 22.2% -
Lesion characteristics
Any lesion (pigmented or nonpigmented) 2; 22.2% 1; 14.3%
Pigmented 3; 33.3% 1; 14.3%
Melanocytic only 4; 44.4% 5; 71.4%
Exclusion criteria    
Excludes by site (acral/awkwardly sited) 3; 33.3% -
Excludes on image quality 5; 55.6% 3; 42.9%
Participant characteristics
Number of participants (median (range)) 137 (42 to 195); 6 studies70 (62 to 264); 5 studies
Number of lesions (median (range)) 131 (50 to 323) 100 (60 to 308)
Lesion to patient ratio (median (range)) 1.07 (1 to 1.19); 7 studies1.05 (1 to 1.22); 5 studies
Disease prevalence (mean (range)) 27.6% (2.8% to 41.5%) 18.2% (1.9 to 34.8%)
Melanoma in situ as % of disease positive 25.0% (7.7% to 51.4%) 28.6% (8.3 to 61.5%)
Vivascope
Vivascope 1000 2; 22.2% -
Vivascope 1500 5; 55.6% 7; 100.0%
Vivascope 1000 followed by 1500 2; 22.2% -
RCM algorithms
No algorithm - observer diagnosis 2; 22.2% 1; 14.3%
No algorithm - selected lesion
characteristics
1; 11.1%  
No algorithm - significant lesion
characteristics
  1; 14.3%
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Characteristic Any suspicious
lesion
Equivocal
RCM score (including NR) 5; 55.6% 2; 28.6%
Segura algorithm 1; 11.1% 1; 14.3%
Pellcani two-step algorithm (including modified) 0; 0.0% 2; 28.6%
Diagnostic method
In person (real-time interpretation) 3; 33.3% 1; 14.3%
Image-based (remote interpretation) 6; 66.7% 6; 85.7%
RCM guided by dermoscopic image
Yes 6; 66.7% -
NR 3; 33.3% 7; 100.0%
Other test data available to observer
None 2; 22.2% 3; 42.9%
Lesion site, patient age or gender 3; 33.3% -
Dermoscopy image alone 1; 11.1% 2; 28.6%
Dermoscopy image plus patient age, site, or
gender
- 1; 14.3%
In person (including dermoscopy) 2; 22.2% -
Unclear 1; 11.1% 1; 14.3%
Test interpretation
Number of observers (median (range)) n = 1 (3 studies)n = 2 (4 studies)
n = 1 (4 studies)
n = 3 (3 studies)
Single 9; 100.0% 5; 71.4%
Consensus of 3 - 1; 14.3%
Not reported - 1; 14.3%
Observer qualifications
Dermatologist 4; 44.4% 5; 71.4%
Not reported 5; 55.6% 2; 28.6%
Observer experience in practice
High 3; 33.3% 4; 57.1%
Not reported 6; 66.7% 3; 42.9%
Observer experience with RCM
High 6; 66.7% 5; 71.4%
Not reported 3; 33.3% 2; 28.6%
Reference Standard
Histology alone 8; 88.9% 6; 85.7%
Histology and clinical follow-up - 1; 14.3%
Histology and expert diagnosis 1; 11.1% -
Footnotes
RCM - reflectance confocal microscopy; NR - not reported.
3 Comparison of RCM with Dermoscopy
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Test StudiesParticipants
DOR 
(95% CI)
Specificity at 
90% sensitivity
Relative DOR 
(95% CI)
P-value1
(DOR)
P-value2
(HSROC models)
'Any lesion suspicious for melanoma' studies (all studies)
RCM 9 1452
57.5
(18.5, 179.4)
82%
4.82
(2.16, 10.8)
0.0001 <0.001
Dermoscopy 3 451
14.4
(2.7, 77.6)
42%
'Any lesion suspicious for melanoma' studies (direct comparisons)
RCM 3 451
251.3
(5.7, 11050)
93%
4.96
(1.1, 21.5)
0.03 <0.001
Dermoscopy 3 451
50.6
(1.6, 1634)
41%
Equivocal lesion studies (all studies)
RCM 7 1177
97.6
(30.3, 313.8)
86%
20.1
(6.6, 61.3)
<0.001 <0.001
Dermoscopy 3 645
3.0
(1.3, 6.8)
49%
Equivocal lesion studies (direct comparisons)
RCM 3 645
154.5
(16.4, 1457)
94%
22.1
(1.7, 283.6)
0.03 <0.001
Dermoscopy 3 645
7.0
(2.1, 23.6)
44%
Footnotes
CI - confidence interval; RCM - reflectance confocal microscopy; DOR - diagnostic odds ratio; HSROC - hierarchical
summary receiver operating characteristic curve.
1 The P value assesses whether the observed difference in DOR between RCM and Dermoscopy is explicable by chance
2 The P value is a global test assessing whether the observed differences in all HSROC parameters (accuracy and
threshold) between RCM and Dermoscopy is explicable by chance.
4 Pooled sensitivity and specificity for individual algorithms
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Person /
image 
Target condition
Test
Studies
(n)
Participants
(n)
Pooled Sensitivity
(95% CI)
Pooled Specificity
(95% CI)
Detection of invasive melanoma (MM)
In person RCM ≥ 3 1 50 1.00 [0.74, 1.00] 0.92 [0.79, 0.98]
Image-based Segura >-1 1 100 0.96 [0.78, 1.00] 0.84 [0.74, 0.92]
Image-based Guitera 2-step (significant characteristics for
MM)
1 356 0.78 [0.65, 0.89] 0.86 [0.81, 0.90]
Image-based No algorithm (observer diagnosis) 1 63 0.88 [0.47, 1.00] 0.62 [0.48, 0.75]
Image-based No algorithm (significant characteristics) 1 140 1.00 [0.85, 1.00] 0.91 [0.85, 0.96]
Image-based No algorithm (any threshold) 2 203 0.98 [0.27, 1.00] 0.81 [0.52, 0.94]
Detection of invasive melanoma or atypical intraepidermal melanocytic variants (MM+MiS)
Image-based RCM ≥ 2 1 351 0.96 [0.92, 0.99] 0.52 [0.45, 0.59]
Image-based RCM ≥ 3 3 668 0.91 [0.87, 0.94]
†
0.67 [0.62, 0.71]
†
In person RCM ≥ 3 1 50 0.92 [0.64, 1.00] 0.92 [0.78, 0.98]
In person RCM unstated but likely ≥ 3 2 366 1.00 [0.88, 1.00]* 0.62 [0.40, 0.80]
Both RCM ≥ 3 or likely ≥ 3 6 1209 0.92 [0.87, 0.95] 0.72 [0.62, 0.81]
Image-based RCM ≥ 4 3 604 0.86 [0.76,0.92] 0.73 [0.60, 0.82]
Image-based Segura >-1 4 863 0.93 [0.76, 0.98] 0.88 [0.72, 0.95]
Image-based Guitera 2-step (significant characteristics) 1 356 0.78 [0.69, 0.86] 0.84 [0.79, 0.88]
Image-based Pellacani 2-step 2 130 0.96 [0.72, 1.00] 0.71 [0.61, 0.79]
Image-based No algorithm (observer diagnosis) 4 578 0.81 [0.65, 0.91] 0.88 [0.78, 0.94]
In person No algorithm (observer diagnosis) 1 317 0.67 [0.30, 0.93] 0.96 [0.93, 0.98]
Image-based No algorithm (significant characteristics) 2 331 0.93 [0.78, 0.98] 0.81 [0.63, 0.92]
In person No algorithm (selected characteristics) 1 125 0.97 [0.86, 1.00] 0.83 [0.73, 0.90]
Image-based No algorithm (excise decision) 1 323 1.00 [0.66, 1.00] 0.64 [0.58, 0.69]
In person No algorithm (excise decision) 1 317 0.89 [0.52, 1.00] 0.52 [0.46, 0.58]
Image-based RCM computer assisted 1 92 1.00 [0.86, 1.00] 0.24 [0.14, 0.35]
Detection of any skin cancer (melanoma or other skin cancer) or skin lesion with a high risk of progression to melanoma
(Any)
In person RCM ≥ or likely 3 3 541 0.98 [0.91, 0.99]‡ 0.75 [0.54, 0.89]
†
Image-based Segura >-1 1 356 0.80 [0.73, 0.86] 0.70 [0.63, 0.77]
Image-based Pellacani two-step 1 60 0.89 [0.67, 0.99] 0.80 [0.65, 0.91]
Image-based Guitera 2-step (significant characteristics) 1 356 0.92 [0.86, 0.95] 0.68 [0.61, 0.75]
In person No algorithm (observer diagnosis) 1 317 0.78 [0.67, 0.87] 0.85 [0.80, 0.89]
Image-based No algorithm (observer diagnosis) 2 423 0.85 [0.77, 0.90] 0.87 [0.83, 0.90]
In person No algorithm (excise decision) 1 317 0.85 [0.75, 0.92] 0.61 [0.55, 0.68]
Image-based No algorithm (excise decision) 1 323 0.90 [0.81, 0.95] 0.79 [0.73, 0.84]
Footnotes
CI - confidence interval; RCM - reflectance confocal microscopy; MM – malignant melanoma; MiS – melanoma in situ (or
lentigo maligna).
* computed using unstratified data as no false negatives; † computed without correlation between sensitivity and specificity;
‡zero variance assumed for sensitivity random effect
5 Investigations of heterogeneity in RCM accuracy
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Subgroup StudiesParticipants
DOR 
(95% CI)
Specificity at 
90%
sensitivity
Relative DOR
(95% CI)
P-value 
(DOR)
P-value 
(HSROC
models)
Differences in patient pathway
Any lesion suspicious for
melanoma 9 1452
44.5
(19.8, 99.9)
81%
2.88
(0.80, 10.4)
P =
0.11 P = 0.31
Equivocal lesions 7 1177
147.6
(37.2,
585.7)
94%
Differences in-person and image based
Image based 12 1963
54.1
(26.3,
111.1)
84%
4.77
(0.56, 40.8)
P =
0.15 P = 0.13
In person 4 666
257.7
(28.7, 2313)
97%
Use of a scaling system
No scale used 6 802
45.7
(16.2,
128.6)
83%
1.81
(0.41, 8.03)
P =
0.43 P = 0.06
Any scale used 10 1663
82.8
(28.9,
236.8)
90%
Footnotes
CI - confidence interval; DOR - diagnostic odds ratio; HSROC - hierarchical summary receiver operating characteristic curve
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was evaluated at the end of 15 months, as well as during the first half (8 months) and latter half (seven
months) of the study. Histopathological diagnosis was available in 95/168 lesions, including 38 melanocytic
lesions (ML: 13 melanomas and 25 nevi) and 57 non-melanocytic lesions (NML: 26 BCCs, 4 SCCs and 27
benign). The remaining 73/168 lesions (43.45%) were not biopsied (received topical treatment, monitoring). On
RCM, 22/26 (84.61%) BCCs and 11/13 (84.61%) melanomas were correctly diagnosed. BCC was missed in
3/26 (11.53%) lesions and melanoma in 2/13 (15.38%) lesions; these lesions were diagnosed mostly as
superficial BCCs and focal epidermal changes overlying deeply situated melanoma nodule on histopathology,
respectively. False positive diagnosis of BCC was obtained in 7/23 (30.4%) lesions and of melanoma in 2/22
(4.5%) lesions
AB - Reflectance confocal microscopy (RCM) is a non-invasive device that images skin lesions in vivo at a cellular resolution
to guide management of patient care. We assessed the diagnostic potential of a novice RCM reader, in clinical settings, at
the bedside. Over a period of 15 months (August 2015- November 2016), 168 lesions (from 128 cases) were imaged with
RCM to determine BCC and or melanoma in dermoscopically equivocal lesions. To evaluate the learning curve of the novice
reader, diagnostic accuracy was evaluated at the end of 15 months, as well as during the first half (8 months) and latter half
(seven months) of the study. Histopathological diagnosis was available in 95/168 lesions, including 38 melanocytic lesions
(ML: 13 melanomas and 25 nevi) and 57 non-melanocytic lesions (NML: 26 BCCs, 4 SCCs and 27 benign). The remaining
73/168 lesions (43.45%) were not biopsied (received topical treatment, monitoring). On RCM, 22/26 (84.61%) BCCs and
11/13 (84.61%) melanomas were correctly diagnosed. BCC was missed in 3/26 (11.53%) lesions and melanoma in 2/13
(15.38%) lesions; these lesions were diagnosed mostly as superficial BCCs and focal epidermal changes overlying deeply
situated melanoma nodule on histopathology, respectively. False positive diagnosis of BCC was obtained in 7/23 (30.4%)
lesions and of melanoma in 2/22 (4.5%) lesions;these were diagnosed mostly as benign inflamed keratosis and moderately
atypical dysplastic nevus on histopathology, respectively. In 7 lesions BCC or melanoma could not be ruled out. A marked
increase in the sensitivity and specificity was noticed between the two halves of the study. An overall high diagnostic
accuracy of 80.28% with high sensitivity and specificity of 80.68% and 80.8%, respectively in diagnosing skin cancers was
obtained. Based on this study, we identified some current limitations and potential pitfalls of RCM. The fact that the
diagnostic accuracy of the novice reader increased with time, indicates a learning curve reading RCM images. Additionally,
current technical limitations of RCM such as inability to differentiate various cell types, sampling error, and, shallow depth of
imaging also lead to false diagnosis. Efforts are ongoing to overcome these challenges by building US based teaching-
training program and through a multimodal imaging approach for better diagnosis and patient care..
AB 2016), 168 lesions (from 128 cases) were imaged with RCM to determine BCC and or melanoma in
dermoscopically equivocal lesions. To evaluate the learning curve of the novice reader, diagnostic accuracy
was evaluated at the end of 15 months, as well as during the first half (8 months) and latter half (seven
months) of the study. Histopathological diagnosis was available in 95/168 lesions, including 38 melanocytic
lesions (ML: 13 melanomas and 25 nevi) and 57 non-melanocytic lesions (NML: 26 BCCs, 4 SCCs and 27
benign). The remaining 73/168 lesions (43.45%) were not biopsied (received topical treatment, monitoring). On
RCM, 22/26 (84.61%) BCCs and 11/13 (84.61%) melanomas were correctly diagnosed. BCC was missed in
3/26 (11.53%) lesions and melanoma in 2/13 (15.38%) lesions; these lesions were diagnosed mostly as
superficial BCCs and focal epidermal changes overlying deeply situated melanoma nodule on histopathology,
respectively. False positive diagnosis of BCC was obtained in 7/23 (30.4%) lesions and of melanoma in 2/22
(4.5%) lesionsa
AB - Reflectance confocal microscopy (RCM) is a non-invasive device that images skin lesions in vivo at a cellular resolution
to guide management of patient care. We assessed the diagnostic potential of a novice RCM reader, in clinical settings, at
the bedside. Over a period of 15 months (August 2015- November 2016), 168 lesions (from 128 cases) were imaged with
RCM to determine BCC and or melanoma in dermoscopically equivocal lesions. To evaluate the learning curve of the novice
reader, diagnostic accuracy was evaluated at the end of 15 months, as well as during the first half (8 months) and latter half
(seven months) of the study. Histopathological diagnosis was available in 95/168 lesions, including 38 melanocytic lesions
(ML: 13 melanomas and 25 nevi) and 57 non-melanocytic lesions (NML: 26 BCCs, 4 SCCs and 27 benign). The remaining
73/168 lesions (43.45%) were not biopsied (received topical treatment, monitoring). On RCM, 22/26 (84.61%) BCCs and
11/13 (84.61%) melanomas were correctly diagnosed. BCC was missed in 3/26 (11.53%) lesions and melanoma in 2/13
(15.38%) lesions; these lesions were diagnosed mostly as superficial BCCs and focal epidermal changes overlying deeply
situated melanoma nodule on histopathology, respectively. False positive diagnosis of BCC was obtained in 7/23 (30.4%)
lesions and of melanoma in 2/22 (4.5%) lesions;these were diagnosed mostly as benign inflamed keratosis and moderately
atypical dysplastic nevus on histopathology, respectively. In 7 lesions BCC or melanoma could not be ruled out. A marked
increase in the sensitivity and specificity was noticed between the two halves of the study. An overall high diagnostic
accuracy of 80.28% with high sensitivity and specificity of 80.68% and 80.8%, respectively in diagnosing skin cancers was
obtained. Based on this study, we identified some current limitations and potential pitfalls of RCM. The fact that the
diagnostic accuracy of the novice reader increased with time, indicates a learning curve reading RCM images. Additionally,
current technical limitations of RCM such as inability to differentiate various cell types, sampling error, and, shallow depth of
imaging also lead to false diagnosis. Efforts are ongoing to overcome these challenges by building US based teaching-
training program and through a multimodal imaging approach for better diagnosis and patient care..
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Data tables by test
Test StudiesParticipants
1 RCM in any lesion suspicious for melanoma (MM) 3 506
2 RCM in studies of other lesion types (MM) 2 203
3 RCM in any lesion suspicious for melanoma (MM+MiS) 9 1452
4 RCM in equivocal lesion studies (MM+MiS) 7 1177
5 RCM in studies of other lesion types (MM+MiS) 2 159
6 Dermoscopy in any lesion suspicious for melanoma (MM+MiS) 3 451
7 Dermoscopy in equivocal lesion studies (MM+MiS) 3 645
8 Dermoscopy in studies of other lesion types (MM+MiS) 1 96
9 RCM in any lesion suspicious for melanoma (Any) 4 912
10 RCM in equivocal lesion studies (Any) 3 468
11 RCM score at ≥ 3 (MM) 1 50
12 Segura algorithm at >-1 (MM) 1 100
13 Guitera Two-step alg (significant characteristics) (MM) 1 356
14 No algorithm (observer diagnosis) (MM) 1 63
15 No algorithm (significant characteristics) (MM) 1 140
16 RCM score at ≥ 2 (MM+MiS) 1 351
17 RCM score at ≥ 3 (MM+MiS) 4 718
18 RCM score at threshold NR (likely ≥ 3) (MM+MiS) 2 491
19 RCM score at ≥ 4 (MM+MiS) 3 579
20 Segura algorithm at >-1 (MM+MiS) 4 863
21 Guitera Two-step alg (significant chars for MM) (MM+MiS) 1 356
22 Pellacani Two step algorithm (dysplastic-MM) image-based (MM+MiS) 2 130
23 RCM CAD algorithm (MM+MiS) 1 92
24 No algorithm (significant characteristics) (MM+MiS) 2 331
25 No algorithm (selected characteristics) (MM+MiS) 1 125
26 No algorithm (observer diagnosis) (MM+MiS) 4 578
27 No algorithm (observer diagnosis) paired in-person (MM+MiS) 1 317
28 No algorithm (excise decision) (MM+MiS) 1 323
29 No algorithm (excise decision) paired in-person (MM+MiS) 1 317
30 RCM score at ≥ 3 (Any) 1 50
31 RCM score at threshold NR (likely ≥ 3) (Any) 2 491
32 Segura algorithm at >-1 (Any) 1 356
33 Pellacani Two step algorithm (dysplastic-MM) (Any) 1 60
34 Guitera Two-step alg (significant characteristics) (Any) 1 356
35 No algorithm (observer diagnosis) (Any) 2 423
36 No algorithm (observer diagnosis) paired in-person (Any) 1 317
37 No algorithm (excise decision) (Any) 1 323
38 No algorithm (excise decision) paired in-person (Any) 1 317
39 Observer experience high - any lesion suspicious for melanoma (MM) 2 456
40 Observer experience low - any lesion suspicious for melanoma (MM) 1 50
41 MM1 observer experience high other 1 140
42 MM1 observer experience NR other 1 63
43 Observer experience high - any lesion suspicious for melanoma (MM+MiS)8 1402
44 Observer experience low - any lesion suspicious for melanoma (MM+MiS) 2 368
45 Observer experience high - equivocal lesion studies (MM+MiS) 6 1113
46 Observer experience low - equivocal lesion studies (MM+MiS) 1 100
47 Observer experience NR - equivocal lesion studies (MM+MiS) 1 64
48 Observer experience NR - other study populations (MM+MiS) 2 159
49 Observer experience high - equivocal lesion studies (Any) 3 468
50 Observer experience low - equivocal lesion studies (Any) 1 100
51 Observer experience high - any lesion suspicious for melanoma (Any) 3 862
52 Observer experience low - any lesion suspicious for melanoma (Any) 2 368
53 MM2 any scale 16 2465
Figures
Figure 1
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Caption
Sample photographs of superficial spreading melanoma (left) and nodular melanoma (right)
Figure 2
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Caption
RCM images of normal skin (top) and of lentigo maligna (bottom)
Figure 3
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Caption
Caliber ID Vivascope 1500 with 3000 attachment
Figure 4
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Caption
Current clinical pathway for people with skin lesions
Figure 5
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Caption
PRISMA flow diagram.
Figure 6
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Caption
Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages
across included studies
Figure 7
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Caption
Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study
Figure 8 (Analysis 3) 
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Caption
Forest plot of tests: RCM and dermoscopy data in any lesion suspicious for melanoma for detection of invasive melanoma
(MM) and atypical intraepidermal melanocytic variants (or melanoma in situ, MiS)
Figure 9 (Analysis 3) 
Caption
Summary ROC comparing RCM and Demoscopy in all lesions suspected of melanoma for detection of invasive melanoma or
atypical intraepidermal melanocytic variants (MM+MiS).
Figure 10 (Analysis 4) 
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Caption
Summary ROC of paired comparisons of RCM and Demoscopy in all lesions suspected of melanoma for detection of
invasive melanoma or atypical intraepidermal melanocytic variants (MM+MiS)
Figure 11 (Analysis 5) 
Caption
Forest plot of tests: RCM and Dermoscopy in equivocal lesion populations for detection of invasive melanoma (MM) and
atypical intraepidermal melanocytic variants (or melanoma in situ, MiS)
Figure 12 (Analysis 5) 
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Caption
Summary ROC comparing RCM and Demoscopy in equivocal lesion populations for detection of invasive melanoma (MM)
and atypical intraepidermal melanocytic variants (or melanoma in situ, MiS)
Figure 13 (Analysis 6) 
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Caption
Summary ROC for paired comparisons of RCM and Dermoscopy in equivocal lesion populations for detection of invasive
melanoma (MM) and atypical intraepidermal melanocytic variants (or melanoma in situ, MiS)
Figure 14 (Analysis 9) 
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Caption
Forest plot : RCM results by algorithm, threshold and number of observers for diagnosis of invasive melanoma (MM) and
atypical intraepidermal melanocytic variants (or melanoma in situ, MiS)
Figure 15 (Analysis 8) 
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Caption
Summary ROC Plot comparing studies which used and did not use an algorithm or scale to assist RCM diagnosis (0=none,
1=tool used) [outcome is detection of invasive melanoma (MM) and atypical intraepidermal melanocytic variants (or
melanoma in situ, MiS)]
Figure 16 (Analysis 7) 
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Caption
Summary ROC Plot - Comparison of in-person and Image based studies of RCM for detection of invasive melanoma (MM)
and atypical intraepidermal melanocytic variants (or melanoma in situ, MiS)
Figure 17 (Analysis 2) 
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Caption
Summary ROC Plot comparing RCM performance in studies of all lesions suspected of melanoma with those in patients with
equivocal lesions (for detection of invasive melanoma (MM) and atypical intraepidermal melanocytic variants (or melanoma
in situ, MiS))
Figure 18 (Analysis 13) 
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Caption
Forest plot: RCM diagnosis in studies of patients with equivocal lesions by observer experience, for the detection of invasive
melanoma (MM), of invasive melanoma and atypical intraepidermal melanocytic variants (or melanoma in situ) (MM+MiS),
and of any potential skin cancer (melanoma or other skin cancer) or skin lesion with a high risk of progression to melanoma
(Any)
Figure 19 (Analysis 12) 
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Caption
Forest plot: RCM diagnosis in studies of all lesions suspected of melanoma by observer experience, for the detection of
invasive melanoma (MM), of invasive melanoma and atypical intraepidermal melanocytic variants (or melanoma in situ)
(MM+MiS), and of any potential skin cancer (melanoma or other skin cancer) or skin lesion with a high risk of progression to
melanoma (Any)
Figure 20 (Analysis 1) 
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Caption
Forest plot of RCM performance by study group and target condition definition (invasive melanoma alone (MM), invasive
melanoma and atypical intraepidermal melanocytic variants, or melanoma in situ (MM+MiS), and for any skin cancer or or
skin lesion with a high risk of progression to melanoma (Any))
Figure 21 (Analysis 10) 
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Caption
Forest plot: RCM results by algorithm and threshold for diagnosis of invasive melanoma (MM)
Figure 22 (Analysis 11) 
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Caption
Forest plot: RCM results by algorithm and threshold for diagnosis of any skin cancer or skin lesion with a high risk of
progression to melanoma (Any)
Sources of support 
Internal sources
No sources of support provided
External sources
NIHR Systematic Review Programme, UK
The National Institute for Health Research (NIHR), UK
The NIHR, UK, is the largest single funder of the Cochrane Skin Group
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List of reviews  
Estimated number of
studies Diagnosis of melanoma 
1. Visual inspection versus visual inspection plus dermoscopy 120
2. Teledermatology 12
3. Mobile phone applications 2
4. Computer-aided diagnosis – dermoscopy-based and spectroscopy-based techniques 37
5. Reflectance confocal microscopy 19
6. High frequency ultrasound 3
7. Overview: Comparing the accuracy of tests for which sufficient evidence is identified either
alone or in combination
 
Diagnosis of keratinocyte skin cancer (BCC and cSCC)  
8. Visual inspection +/- dermoscopy 22
9. Computer-aided diagnosis – dermoscopy-based and spectroscopy-based techniques 3
10. Optical coherence tomography 6
11. Reflectance confocal microscopy 9
12. High frequency ultrasound 1
13. Exfoliative cytology 5
14. Overview: Comparing the accuracy of tests for which sufficient evidence is identified either
alone or in combination
 
Staging of melanoma  
15. Ultrasound 25 to 30
16. CT 5 to 10
17. PET or PET-CT 20 to 25
18. MRI 5
19. Sentinel lymph node biopsy +/- high frequency ultrasound 70
20. Overview: Comparing the accuracy of tests for which sufficient evidence is identified either
alone or in combination
 
Staging of cSCC  
21. Imaging tests review 10 to 15
22. Sentinel lymph node biopsy +/- high frequency ultrasound 15 to 20
2 Final search strategies
Melanoma Search strategies to August 2016
Database: Ovid MEDLINE(R) 1946 to August Week 3 2016
Search Strategy:
1 exp melanoma/
2 exp skin cancer/
3 exp basal cell carcinoma/
4 basalioma$1.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or
adenoma$1 or epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
8 nmsc.ti,ab.
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9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1
or epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or CSCC or NMSC).ti,ab.
11 keratinocy$.ti,ab.
12 Keratinocytes/
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 exp epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 exp diagnosis, computer-assisted/
38 MoleMax.ti,ab.
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 Aura.ti,ab.
44 (optical adj2 scan$).ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 (high adj3 ultraso$).ti,ab.
51 (canine adj2 detect$).ti,ab.
52 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
53 smartphone$.ti,ab.
54 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
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55 Mole Detective.ti,ab.
56 Spot Check.ti,ab.
57 (mole$1 adj2 map$).ti,ab.
58 (total adj2 body).ti,ab.
59 exfoliative cytolog$.ti,ab.
60 digital analys$.ti,ab.
61 (image$1 adj3 software).ti,ab.
62 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$ or tele-dermatoscop$).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (computer adj2 diagnos$).ti,ab.
65 exp sentinel lymph node biopsy/
66 (sentinel adj2 node).ti,ab.
67 nevisense.mp. or HFUS.ti,ab.
68 electrical impedance spectroscopy.ti,ab.
69 history taking.ti,ab.
70 patient history.ti,ab.
71 (naked eye adj (exam$ or assess$)).ti,ab.
72 (skin adj exam$).ti,ab.
73 physical examination/
74 ugly duckling.mp. or UD.ti,ab.
75 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
76 ABCDE.mp. or VOC.ti,ab.
77 clinical accuracy.ti,ab.
78 Family Practice/ or Physicians, Family/ or clinical competence/
79 (confocal adj2 microscop$).ti,ab.
80 diagnostic algorithm$1.ti,ab.
81 checklist$.ti,ab.
82 virtual imag$1.ti,ab.
83 volatile organic compound$1.ti,ab.
84 dog$1.ti,ab.
85 gene expression analy$.ti,ab.
86 reflex transmission imag$.ti,ab.
87 thermal imaging.ti,ab.
88 elastography.ti,ab.
89 or/14-88
90 (CT or PET).ti,ab.
91 PET-CT.ti,ab.
92 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
93 exp Deoxyglucose/
94 deoxy-glucose.ti,ab.
95 deoxyglucose.ti,ab.
96 CATSCAN.ti,ab.
97 exp Tomography, Emission-Computed/
98 exp Tomography, X-ray computed/
99 positron emission tomograph$.ti,ab.
100 exp magnetic resonance imaging/
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101 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
102 exp echography/
103 Doppler echography.ti,ab.
104 sonograph$.ti,ab.
105 ultraso$.ti,ab.
106 doppler.ti,ab.
107 magnetic resonance imag$.ti,ab.
108 or/90-107
109 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
110 "Sensitivity and Specificity"/
111 exp cancer staging/
112 or/109-111
113 108 and 112
114 89 or 113
115 13 and 114
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations August 29, 2016
Search Strategy:
1 basalioma$1.ti,ab.
2 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or
adenoma$1 or epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
3 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
4 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
5 nmsc.ti,ab.
6 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1
or epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
7 (BCC or CSCC or NMSC).ti,ab.
8 keratinocy$.ti,ab.
9 or/1-8
10 dermoscop$.ti,ab.
11 dermatoscop$.ti,ab.
12 photomicrograph$.ti,ab.
13 (epiluminescence adj2 microscop$).ti,ab.
14 (confocal adj2 microscop$).ti,ab.
15 (incident light adj2 microscop$).ti,ab.
16 (surface adj2 microscop$).ti,ab.
17 (visual adj (inspect$ or examin$)).ti,ab.
18 ((clinical or physical) adj examin$).ti,ab.
19 3 point.ti,ab.
20 three point.ti,ab.
21 pattern analys$.ti,ab.
22 ABCD$.ti,ab.
23 menzies.ti,ab.
24 7 point.ti,ab.
25 seven point.ti,ab.
26 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
27 artificial intelligence.ti,ab.
28 AI.ti,ab.
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29 computer assisted.ti,ab.
30 computer aided.ti,ab.
31 neural network$.ti,ab.
32 MoleMax.ti,ab.
33 image process$.ti,ab.
34 automatic classif$.ti,ab.
35 image analysis.ti,ab.
36 SIAscop$.ti,ab.
37 Aura.ti,ab.
38 (optical adj2 scan$).ti,ab.
39 MelaFind.ti,ab.
40 SIMSYS.ti,ab.
41 MoleMate.ti,ab.
42 SolarScan.ti,ab.
43 VivaScope.ti,ab.
44 (high adj3 ultraso$).ti,ab.
45 (canine adj2 detect$).ti,ab.
46 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
47 smartphone$.ti,ab.
48 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
49 Mole Detective.ti,ab.
50 Spot Check.ti,ab.
51 (mole$1 adj2 map$).ti,ab.
52 (total adj2 body).ti,ab.
53 exfoliative cytolog$.ti,ab.
54 digital analys$.ti,ab.
55 (image$1 adj3 software).ti,ab.
56 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$ or tele-dermatoscop$).ti,ab.
57 (optical coherence adj (technolog$ or tomog$)).ti,ab.
58 (computer adj2 diagnos$).ti,ab.
59 (sentinel adj2 node).ti,ab.
60 nevisense.mp. or HFUS.ti,ab.
61 electrical impedance spectroscopy.ti,ab.
62 history taking.ti,ab.
63 patient history.ti,ab.
64 (naked eye adj (exam$ or assess$)).ti,ab.
65 (skin adj exam$).ti,ab.
66 ugly duckling.mp. or UD.ti,ab.
67 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
68 ABCDE.mp. or VOC.ti,ab.
69 clinical accuracy.ti,ab.
70 (Family adj (Practice or Physicians)).ti,ab.
71 (confocal adj2 microscop$).ti,ab.
72 clinical competence.ti,ab.
73 diagnostic algorithm$1.ti,ab.
74 checklist$.ti,ab.
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75 virtual imag$1.ti,ab.
76 volatile organic compound$1.ti,ab.
77 dog$1.ti,ab.
78 gene expression analy$.ti,ab.
79 reflex transmission imag$.ti,ab.
80 thermal imaging.ti,ab.
81 elastography.ti,ab.
82 or/10-81
83 (CT or PET).ti,ab.
84 PET-CT.ti,ab.
85 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
86 deoxy-glucose.ti,ab.
87 deoxyglucose.ti,ab.
88 CATSCAN.ti,ab.
89 positron emission tomograph$.ti,ab.
90 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
91 Doppler echography.ti,ab.
92 sonograph$.ti,ab.
93 ultraso$.ti,ab.
94 doppler.ti,ab.
95 magnetic resonance imag$.ti,ab.
96 or/83-95
97 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
98 96 and 97
99 82 or 98
100 9 and 99
Database: Embase 1974 to 2016 August 29
Search Strategy:
1 *melanoma/
2 *skin cancer/
3 *basal cell carcinoma/
4 basalioma$.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$ or adenoma$
or epithelioma$ or lesion$ or malignan$ or nodule$)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or cscc).mp. or NMSC.ti,ab.
11 keratinocyte.ti,ab.
12 keratinocy$.ti,ab.
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 *epiluminescence microscopy/
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18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 MoleMax.ti,ab.
38 exp diagnosis, computer-assisted/
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 (optical adj2 scan$).ti,ab.
44 Aura.ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 confocal microscop$.ti,ab.
51 (high adj3 ultraso$).ti,ab.
52 (canine adj2 detect$).ti,ab.
53 ((mobile or cell$ or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
54 smartphone$.ti,ab.
55 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
56 Spot Check.ti,ab.
57 Mole Detective.ti,ab.
58 (mole$1 adj2 map$).ti,ab.
59 (total adj2 body).ti,ab.
60 exfoliative cytolog$.ti,ab.
61 digital analys$.ti,ab.
62 (image$1 adj3 software).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
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64 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$).mp. or tele-dermatoscop$.ti,ab.
65 (computer adj2 diagnos$).ti,ab.
66 *sentinel lymph node biopsy/
67 (sentinel adj2 node).ti,ab.
68 nevisense.ti,ab.
69 HFUS.ti,ab.
70 electrical impedance spectroscopy.ti,ab.
71 history taking.ti,ab.
72 patient history.ti,ab.
73 (naked eye adj (exam$ or assess$)).ti,ab.
74 (skin adj exam$).ti,ab.
75 *physical examination/
76 ugly duckling.ti,ab.
77 UD sign$.ti,ab.
78 ((physician$ or clinical or physical) adj (exam$ or recog$ or triage)).ti,ab.
79 ABCDE.ti,ab.
80 clinical accuracy.ti,ab.
81 *general practice/
82 (confocal adj2 microscop$).ti,ab.
83 clinical competence/
84 diagnostic algorithm$.ti,ab.
85 checklist$1.ti,ab.
86 virtual image$1.ti,ab.
87 volatile organic compound$1.ti,ab.
88 VOC.ti,ab.
89 dog$1.ti,ab.
90 gene expression analys$.ti,ab.
91 reflex transmission imaging.ti,ab.
92 thermal imaging.ti,ab.
93 elastography.ti,ab.
94 dog$1.ti,ab.
95 gene expression analys$.ti,ab.
96 reflex transmission imaging.ti,ab.
97 thermal imaging.ti,ab.
98 elastography.ti,ab.
99 or/14-93
100 PET-CT.ti,ab.
101 (CT or PET).ti,ab.
102 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
103 exp Deoxyglucose/
104 CATSCAN.ti,ab.
105 deoxyglucose.ti,ab.
106 deoxy-glucose.ti,ab.
107 *positron emission tomography/
108 *computer assisted tomography/
109 positron emission tomograph$.ti,ab.
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110 *nuclear magnetic resonance imaging/
111 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
112 *echography/
113 Doppler.ti,ab.
114 sonograph$.ti,ab.
115 ultraso$.ti,ab.
116 magnetic resonance imag$.ti,ab.
117 or/100-116
118 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
119 "Sensitivity and Specificity"/
120 *cancer staging/
121 or/118-120
122 117 and 121
123 99 or 122
124 13 and 123
Database: Cochrane Library (Wiley) 2016 searched 30 August 2016 CDSR issue 8 of 12 2016 CENTRAL Issue 7 of 12 2016
HTA Issue 3 of 4 July 2016 DARE Issue 3 of 4 2015
Search strategy:
#1 melanoma* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyte*
#2 MeSH descriptor: [Melanoma] explode all trees
#3 "skin cancer*"
#4 MeSH descriptor: [Skin Neoplasms] explode all trees
#5 skin near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
#6 nmsc
#7 "squamous cell" near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*) near/2 (skin or epiderm* or cutaneous)
#8 "basal cell" near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*)
#9 pigmented near/2 (lesion* or nevus or mole* or naevi or naevus or nevi or skin)
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 dermoscop*
#12 dermatoscop*
#13 Photomicrograph*
#14 MeSH descriptor: [Dermoscopy] explode all trees
#15 confocal near/2 microscop*
#16 epiluminescence near/2 microscop*
#17 incident next light near/2 microscop*
#18 surface near/2 microscop*
#19 "visual inspect*"
#20 "visual exam*"
#21 (clinical or physical) next (exam*)
#22 "3 point"
#23 "three point"
#24 "pattern analys*"
#25 ABDC
#26 menzies
#27 "7 point"
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#28 "seven point"
#29 digital near/2 (dermoscop* or dermatoscop*)
#30 "artificial intelligence"
#31 "AI"
#32 "computer assisted"
#33 "computer aided"
#34 AI
#35 "neural network*"
#36 MoleMax
#37 "computer diagnosis"
#38 "image process*"
#39 "automatic classif*"
#40 SIAscope
#41 "image analysis"
#42 "optical near/2 scan*"
#43 Aura
#44 MelaFind
#45 SIMSYS
#46 MoleMate
#47 SolarScan
#48 Vivascope
#49 "confocal microscopy"
#50 high near/3 ultraso*
#51 canine near/2 detect*
#52 Mole* near/2 map*
#53 total near/2 body
#54 mobile* or smart near/2 phone*
#55 cell next phone*
#56 smartphone*
#57 "mitotic index"
#58 DermoScan or SkinVision or DermLink or SpotCheck
#59 "Mole Detective"
#60 "Spot Check"
#61 mole* near/2 map*
#62 total near/2 body
#63 "exfoliative cytolog*"
#64 "digital analys*"
#65 image near/3 software
#66 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop*
or tele-dermatolog*
#67 "optical coherence" next (technolog* or tomog*)
#68 computer near/2 diagnos*
#69 sentinel near/2 node*
#70 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or
#28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45
or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or
#63 or #64 or #65 or #66 or #67 or #68 or #69
#71 ultraso*
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#72 sonograph*
#73 MeSH descriptor: [Ultrasonography] explode all trees
#74 Doppler
#75 CT or PET or PET-CT
#76 "CAT SCAN" or "CATSCAN"
#77 MeSH descriptor: [Positron-Emission Tomography] explode all trees
#78 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
#79 MRI
#80 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#81 MRI or fMRI or NMRI or scintigraph*
#82 "magnetic resonance imag*"
#83 MeSH descriptor: [Deoxyglucose] explode all trees
#84 deoxyglucose or deoxy-glucose
#85 "positron emission tomograph*"
#86 #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85
#87 stage* or staging or metasta* or recurrence or sensitivity or specificity or "false negative*" or thickness*
#88 MeSH descriptor: [Neoplasm Staging] explode all trees
#89 #87 or #88
#90 #89 and #86
#91 #70 or #90
#92 #10 and #91
#93 BCC or CSCC or NMCS
#94 keratinocy*
#95 #93 or #94
#96 #10 or #95
#97 nevisense
#98 HFUS
#99 "electrical impedance spectroscopy"
#100 "history taking"
#101 "patient history"
#102 naked next eye near/1 (exam* or assess*)
#103 skin next exam*
#104 "ugly duckling" or (UD sign*)
#105 MeSH descriptor: [Physical Examination] explode all trees
#106 (physician* or clinical or physical) near/1 (exam* or recog* or triage*)
#107 ABCDE
#108 "clinical accuracy"
#109 MeSH descriptor: [General Practice] explode all trees
#110 confocal near microscop*
#111 "diagnostic algorithm*"
#112 MeSH descriptor: [Clinical Competence] explode all trees
#113 checklist*
#114 "virtual image*"
#115 "volatile organic compound*"
#116 dog or dogs
#117 VOC
#118 "gene expression analys*"
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#119 "reflex transmission imaging"
#120 "thermal imaging"
#121 elastography
#122 #97 or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111
or #112 or #113 or #114 or #115 or #116 or #117 or #118 or #119 or #120 or #121
#123 #70 or #122
#124 #96 and #123
#125 #96 and #90
#126 #125 or #124
#127 #10 and #126
Database : CINAHL Plus (EBSCO) 1937- 30 August 2016
Search strategy:
S1 (MH "Melanoma") OR (MH "Nevi and Melanomas+")
S2 (MH "Skin Neoplasms+")
S3 (MH "Carcinoma, Basal Cell+")
S4 basalioma*
S5 (basal cell) N2 (cancer* or carcinoma* or mass or masses or tumor* or tumour* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*)
S6 (pigmented) N2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin)
S7 melanom* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt*
S8 nmsc
S9 TX BCC or cscc or NMSC
S10 (MH "Keratinocytes")
S11 keratinocyt*
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S13 dermoscop* or dermatoscop* or photomicrograph* or (3 point) or (three point) or ABCD* or menzies or (7 point) or
(seven point) or AI or Molemax or SIASCOP* or Aura or MelaFind or SIMSYS or MoleMate or SolarScan or smartphone* or
DermoScan or SkinVision or DermLink or SpotCheck
S14 (epiluminescence or confocal or incident or surface) N2 (microscop*)
S15 visual N1 (inspect* or examin*)
S16 (clinical or physical) N1 (examin*)
S17 pattern analys*
S18 (digital) N2 (dermoscop* or dermatoscop*)
S19 (artificial intelligence)
S20 (computer) N2 (assisted or aided)
S21 (neural network*)
S22 (MH "Diagnosis, Computer Assisted+")
S23 (image process*)
S24 (automatic classif*)
S25 (image analysis)
S26 SIAScop*
S27 (optical) N2 (scan*)
S28 (high) N3 (ultraso*)
S29 elastography
S30 (mobile or cell or cellular or smart) N2 (phone*) N2 (app or application*)
S31 (mole*) N2 (map*)
S32 total N2 body
S33 exfoliative cytolog*
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S34 digital analys*
S35 image N3 software
S36 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop*
or tele-dermatoscop* teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop*
S37 (optical coherence) N1 (technolog* or tomog*)
S38 computer N2 diagnos*
S39 sentinel N2 node
S40 (MH "Sentinel Lymph Node Biopsy")
S41 nevisense or HFUS or checklist* or VOC or dog*
S42 electrical impedance spectroscopy
S43 history taking
S44 "Patient history"
S45 naked eye
S46 skin exam*
S47 physical exam*
S48 ugly duckling
S49 UD sign*
S50 (physician* or clinical or physical) N1 (exam*)
S51 clinical accuracy
S52 general practice
S53 (physician* or clinical or physical) N1 (recog* or triage)
S54 confocal microscop*
S55 clinical competence
S56 diagnostic algorithm*
S57 checklist*
S58 virtual image*
S59 volatile organic compound*
S60 gene expression analys*
S61 reflex transmission imag*
S62 thermal imaging
S63 S13 or S14 or S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR
S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR
S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR
S55 OR S56 OR S57 OR S58 OR S59 OR S60 OR S61 OR S62
S64 CT or PET
S65 PET-CT
S66 FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical*
S67 (MH "Deoxyglucose+")
S68 deoxy-glucose or deoxyglucose
S69 CATSCAN
S70 CAT-SCAN
S71 (MH "Deoxyglucose+")
S72 (MH "Tomography, Emission-Computed+")
S73 (MH "Tomography, X-Ray Computed")
S74 positron emission tomograph*
S75 (MH "Magnetic Resonance Imaging+")
S76 MRI or fMRI or NMRI or scintigraph*
S77 echography
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S78 doppler
S79 sonograph*
S80 ultraso*
S81 magnetic resonance imag*
S82 S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77
OR S78 OR S79 OR S80 OR S81
S83 stage* or staging or metasta* or recurrence or sensitivity or specificity or (false negative*) or thickness
S84 (MH "Neoplasm Staging")
S85 S83 OR S84
S86 S82 AND S85
S87 S63 OR S86
S88 S12 AND S87
Database : Science Citation Index SCI Expanded (Web of Science) 1900 – 30 August 2016
Conference Proceedings Citation Index (Web of Science) 1900 – 1 September 2016
Search strategy:
#1 (melanom* or nonmelanom* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyt*)
#2 (basalioma*)
#3 ((skin) near/2 (cancer* or carcinoma or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma*
or lesion* or malignan* or nodule*))
#4 ((basal) near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*))
#5 ((pigmented) near/2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin))
#6 (nmsc or BCC or NMSC or keratinocy*)
#7 ((squamous cell (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*))
#8 (skin or epiderm* or cutaneous)
#9 #8 AND #7
#10 #9 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#11 ((dermoscop* or dermatoscop* or photomicrograph* or epiluminescence or confocal or "incident light" or "surface
microscop*" or "visual inspect*" or "physical exam*" or 3 point or three point or pattern analy* or ABCDE or menzies or 7
point or seven point or dermoscop* or dermatoscop* or AI or artificial or computer aided or computer assisted or neural
network* or Molemax or image process* or automatic classif* or image analysis or siascope or optical scan* or Aura or
melafind or simsys or molemate or solarscan or vivascope or confocal microscop* or high ultraso* or canine detect* or
cellphone* or mobile* or phone* or smartphone or dermoscan or skinvision or dermlink or spotcheck or spot check or mole
detective or mole map* or total body or exfoliative psychology or digital or image software or optical coherence or
teledermatology or telederm* or teledermoscop* or teledermatoscop* or computer diagnos* or sentinel))
#12 ((nevisense or HFUS or impedance spectroscopy or history taking or patient history or naked eye or skin exam* or
physical exam* or ugly duckling or UD sign* or physician* exam* or physical exam* or ABCDE or clinical accuracy or general
practice or confocal microscop* or clinical competence or diagnostic algorithm* or checklist* or virtual image* or volatile
organic or VOC or dog* or gene expression or reflex transmission or thermal imag* or elastography))
#13 #11 or #12
#14 ((PET or CT or FDG or deoxyglucose or deoxy-glucose or fluorodeoxy* or radiopharma* or CATSCAN or positron
emission or computer assisted or nuclear magnetic or MRI or FMRI or NMRI or scintigraph* or echograph* or Doppler or
sonograph* or ultraso* or magnetic reson*))
#15 ((stage* or staging or metast* or recurrence or sensitivity or specificity or false negative* or thickness*))
#16 #14 AND #15
#17 #16 OR #13
#18 #10 AND #17
Refined by: DOCUMENT TYPES: (MEETING ABSTRACT OR PROCEEDINGS PAPER)
3 Full text inclusion criteria
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CRITERION INCLUSION EXCLUSION
 
STUDY DESIGN
 
For diagnostic and staging reviews
Any study for which a 2x2 contingency table can be
extracted, e.g.
diagnostic case-control studies
'cross sectional' test accuracy study with
retrospective or prospective data collection
studies where estimation of test accuracy is not the
primary objective but test results for both index and
reference standard are available
randomised controlled trials of tests or testing
strategies where participants are randomised
between index tests and all undergo a reference
standard (i.e., accuracy RCTs)
 
< 5 melanoma cases (diagnosis reviews)
< 10 participants (staging reviews)
Studies developing new criteria for
diagnosis unless a separate 'test set' of
images are used to evaluate the criteria
(mainly digital dermoscopy)
Studies using 'normal' skin as controls
Letters, editorials, comment papers,
narrative reviews
Insufficient data to construct a 2x2 table
TARGET
CONDITION
 
Melanoma
Keratinocyte skin cancer (or non-melanoma skin
cancer)
basal cell carcinoma (BCC) or epithelioma
cutaneous squamous cell carcinoma (cSCC)
 
Studies exclusively conducted in children
Studies of non-cutaneous melanoma or
SCC
POPULATION For diagnostic reviews
Adults with a skin lesion suspicious for melanoma, BCC,
or cSCC (other terms include pigmented skin
lesion/nevi, melanocytic, keratinocyte, etc.)
Adults at high risk of developing melanoma skin cancer,
BCC, or cSCC
For staging reviews
Adults with a diagnosis of melanoma or cSCC
undergoing tests for staging of lymph nodes or distant
metastases or both
 
Individuals suspected of other forms of skin
cancer
Studies conducted exclusively in children
INDEX TESTS For diagnosis
Visual inspection/clinical examination
Dermoscopy/dermatoscopy
Teledermoscpoy
Smartphone/mobile phone applications
Digital dermoscopy/artificial intelligence
Confocal microscopy
Ocular coherence tomography
Exfoliative cytology
High frequency ultrasound
Canine odour detection
DNA expression analysis/Gene chip analysis
Other
For staging
CT
PET
PET-CT
MRI
Ultrasound +/fine needle aspiration cytology FNAC
Sentinel lymph node biopsy +/high frequency ultrasound
Other
Any test combination and in any order
Any test positivity threshold
Any variation in testing procedure (e.g., radioisotope used)
 
Sentinel lymph biopsy for therapeutic rather
than staging purposes
Tests to determine melanoma thickness
Tests to determine surgical margins/lesion
borders
Tests to improve histopathology diagnose
Lymph node dissection
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CRITERION INCLUSION EXCLUSION
REFERENCE
STANDARD
 
For diagnostic studies
Histopathology of the excised lesion
Clinical follow-up of non-excised/benign-appearing
lesions with later histopathology if suspicious
Expert diagnosis (studies should not be included if
expert diagnosis is the sole reference standard)
For studies of imaging tests for staging
Histopathology (via lymph node dissection or sentinel
lymph node biopsy)
Clinical/radiological follow-up
A combination of the above
For studies of SLNB accuracy for staging
Lymph node dissection (LND) of both SLN+ and
SLNparticipants to identify all diseased nodes
Lymph node dissection of SLN+ participants and follow-
up of SLNparticipants to identify a subsequent nodal
recurrence in a previously investigated nodal basin
 
For diagnostic studies
Exclude if any disease-positive participants
have diagnosis unconfirmed by histology
Exclude if more than 50% of disease-
negative participants have diagnosis
confirmed by expert opinion with no
histology or follow-up
Exclude studies of referral accuracy, i.e.,
comparing referral decision with expert
diagnosis, unless evaluations of
teledermatology or mobile phone
applications
BCC = basal cell carcinoma; cSCC = cutaneous squamous cell carcinoma; CT = computed tomography; DNA =
deoxyribonucleic acid; FNAC = fine needle aspiration cytology; LND = lymph node dissection; MRI = magnetic resonance
imaging; PET = positron emission tomography; PET-CT = positron emission tomography computed tomography; RCT =
randomised controlled trial; SLN+ = positive sentinel lymph node; SLn = negative sentinel lymph node; SLNB = sentinel
lymph node biopsy.
4 Quality assessment (based on QUADAS-2)
The QUADAS-2 checklist (Whiting 2011) was tailored to the review topic as follows below.
Patient selection domain (1)
Selective recruitment of study participants can be a key influence on test accuracy. In general terms, all participants eligible
to undergo a test should be included in a study, allowing for the intended use of that test within the context of the study. We
considered studies that separately sampled malignant and benign lesions to have used a case-control design; and those that
supplemented a series of suspicious lesions with additional malignant or benign lesions to be at unclear risk of bias
In terms of exclusions, we considered studies that excluded particular lesion types (e.g. lentigo maligna), particular lesion
sites, or that excluded lesions on the basis of image quality or lack of observer agreement (e.g. on histopathology) to be at
high risk of bias.
In judging the applicability of patient populations to the review question, we considered restriction to particular lesion
populations, such as melanocytic, nodular, high risk or restrictions by size to be of high concern for applicability.
Given that diagnosis of skin cancer is primarily lesion-based, there is the potential for study participants with multiple lesions
to contribute disproportionately to estimates of test accuracy, especially if they are at particular risk of having skin cancer. We
considered studies that include a high number of lesions in relation to the number of study to be less representative than
studies conducted in a more general population participants (i.e., if the difference between the number of included lesions
and number of included participants is greater than 5%).
Index test domain (2)
Given the potential for subjective differences in test interpretation for melanoma, the interpretation of the index test blinded to
the result of the reference standard is a key means of reducing bias. For prospective studies and retrospective studies that
used the original index test interpretation, the diagnosis will by nature be interpreted and recorded before the result of the
reference standard is known; however, studies using previously acquired images could be particularly susceptible to
information bias. For these studies to be at low risk of bias, we required a clear indication that observers were unaware of the
reference standard diagnosis at time of test interpretation. An item was also added to assess the presence of blinding
between interpretations of different algorithms, however this item was not included in the overall assessment of risk of bias.
Pre-specification of the index test threshold was considered present if the study clearly reported that the threshold used was
not data driven, i.e., was not based on study results. Studies that did not clearly describe the threshold used but that required
clinicians to record a diagnosis or management decision for a lesion were considered to be unclear on this criterion. Studies
reporting accuracy for multiple numeric thresholds, where ROC analysis was used to select the threshold, or that reported
accuracy for the presence of independently significant lesion characteristics with no separate test set of lesions were
considered at high risk of bias.
In terms of applicability of the index test to the review question, we required the test to be applied and interpreted as it would
be in a clinical practice setting, i.e., in-person or face-to-face with the patient, and by a single observer as opposed to a
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consensus decision or average across multiple observers. Image-based studies were considered to be high concern,
although RCM image interpretations where the observer was also supplied with a clinical or dermoscopic image of the lesion
along with some patient characteristics were considered ‘unclear’.
Despite the often subjective nature of test interpretation, it is also important for study authors to outline the particular lesion
characteristics that were considered to be indicative for melanoma, particularly where established algorithms or checklists
were not used. Studies were considered of low concern if the threshold used was established in a prior study or sufficient
threshold details were presented to allow replication.
The experience of the examiner will also impact on the applicability of study results. We required studies to describe the test
interpreter as ‘experienced’ or ‘expert’ in RCM to have low concern about applicability.
Reference standard domain (3)
In an ideal study, consecutively recruited participants should all undergo incisional or excisional biopsy of the skin lesion
regardless of level of clinical suspicion of melanoma. In reality, both partial and differential verification bias are likely. Partial
verification bias may occur where histology is the only reference standard used, and only those participants with a certain
degree of suspicion of malignancy based on the result of the index test undergo verification, the others either being excluded
from the study or defined as being disease-negative without further assessment or follow-up, as discussed above.
Differential verification bias will be present where other reference standards are used in addition to histological verification of
suspicious lesions. A typical example of verification bias in skin cancer occurs when investigators do not biopsy people with
benign-appearing lesions but instead follow them up for a period of time to determine whether any malignancy subsequently
develops (these would be false-negatives on the index test). We defined an 'adequate' reference standard as: all disease-
positive individuals having a histological reference standard either at the time of application of the index test or after a period
of clinical follow-up; and at least 80% of disease-negative participants have received a histological diagnosis, with up to 20%
undergoing at least three months' follow-up of benign-appearing lesions.
A further challenge is the potential for incorporation bias, i.e., where the result of the index test is used to help determine the
reference standard diagnosis. It is normal practice for the clinical diagnosis (usually by visual inspection or dermoscopy) to
be included on pathology request forms and for the histopathologist to use this diagnosis to help with the pathology
interpretation. Although inclusion of such clinical information on the histopathology request form is theoretically a form of
incorporation bias, blinded interpretation of the histopathology reference standard is not normal practice, and enforcement of
such conditions would significantly limit the generalisability of the study results. For studies evaluating RCM, this item was
divided into two questions, firstly whether the reference standard was blinded to the index test result (RCM), and secondly
whether it was blinded to the clinical diagnosis. Only the response to the first part (i.e. blinding to RCM) was included in our
overall assessment of risk of bias for the reference standard domain.
In judging the applicability of the reference standard to our review question, scored studies as high concern around
applicability if they used expert diagnosis (with no follow-up) as a reference standard in any patient, or did not report
histology interpretation by a dermatopathologist.
Flow and timing domain (4)
In the ideal study, the diagnosis based on the index test and reference standard should be made consecutively or
as near to each other in time as possible to avoid changes in lesion over time. For lesions with a histological
reference standard, we have defined a one-month period as an appropriate interval between application of the index
test and the reference standard. For studies using clinical follow-up, a minimum three-month follow-up period has
been defined as at low risk of bias for detecting false-negatives. This interval was chosen based on a study showing
that most false-negative melanomas will be diagnosed within three months of the initial negative index test although
a small number will be diagnosed up to 12 months subsequently (Altamura 2008).
In assessing whether all patients were included in the analysis, we considered studies at high risk of bias if participants were
excluded following recruitment.
Comparative domain
A comparative domain was added to the QUADAS-2 checklist for studies comparing the accuracy of RCM and dermoscopy.
Items were included to assess the presence blinding of interpretation between tests, and to specify a maximum of one month
interval between application of index tests, as intervals greater than these may be accompanied by changes in tumour
characteristics. As it would not be normal practice for RCM to be interpreted blinded to the clinical or dermoscopic diagnosis,
the scoring of this item did not contribute to our overall assessment of risk of bias. We also considered whether both tests
were applied and interpreted in a clinically applicable manner.
The following tables use text that was originally published in the QUADAS-2 tool by Whiting and colleagues ( Whiting 2011 ).
Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
1) Was a consecutive or random sample of participants or
images enrolled?
Yes – if paper states consecutive or random
No – if paper describes other method of sampling
Unclear – if participant sampling not described
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Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
2) Was a case-control design avoided? Yes – if consecutive or random or case-control design
clearly not used
No – if study described as case-control or describes
sampling specific numbers of participants with particular
diagnoses
Unclear – if not described
 
3) Did the study avoid inappropriate exclusions, e.g.,
'difficult to diagnose' lesions not excluded
lesions not excluded on basis of disagreement between
evaluators
Yes if inappropriate exclusions were avoided
No – if lesions were excluded that might affect test
accuracy, e.g., 'difficult to diagnose' lesions, or where
disagreement between evaluators was observed
Unclear – if not clearly reported but there is suspicion that
difficult to diagnose lesions may have been excluded
 
4) For between-person comparative studies only (i.e., allocating
different tests to different study participants):
A) were the same participant selection criteria used for those
allocated to each test?
B) was the potential for biased allocation between tests
avoided through adequate generation of a randomised
sequence?
C) was the potential for biased allocation between tests
avoided through concealment of allocation prior to
assignment?
For A)
Yes – if same selection criteria were used for each index
test, No – if different selection criteria were used for each
index test, Unclear – if selection criteria per test were not
described, N/A – if only 1 index test was evaluated or all
participants received all tests
For B)
Yes – if adequate randomisation procedures are
described, No – if inadequate randomisation procedures
are described, Unclear – if the method of allocation to
groups is not described (a description of 'random' or
'randomised' is insufficient), N/A – if only 1 index test
was evaluated or all participants received all tests
For C)
Yes – if appropriate methods of allocation concealment
are described, No – if appropriate methods of allocation
concealment are not described, Unclear – if the method
of allocation concealment is not described (sufficient
detail to allow a definite judgement is required), N/A – if
only 1 index test was evaluated
 
Could the selection of participants have introduced bias?
For non-comparative and within-person-comparative studies
If answers to all of questions 1), 2), and 3) 'Yes':1.
If answers to any 1 of questions 1), 2), or 3) 'No':2.
If answers to any 1 of questions 1), 2), or 3) 'Unclear':3.
For between-person comparative studies
If answers to all of questions 1), 2), 3), and 4) 'Yes':1.
If answers to any 1 of questions 1), 2), 3), or 4) 'No':2.
If answers to any 1 of questions 1), 2), 3), or 4) 'Unclear':3.
 
For non-comparative and within-person-comparative
studies
Risk is low1.
Risk is high2.
Risk unclear3.
For between-person comparative studies
Risk is low1.
Risk is high2.
Risk unclear3.
PARTICIPANT SELECTION (1) CONCERNS REGARDING APPLICABILITY
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Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
 
1) Are the included participants and chosen study setting
appropriate to answer the review question, i.e., are the study
results generalisable?
This item is not asking whether exclusion of certain
participant groups might bias the study's results (as in Risk
of Bias above), but is asking whether the chosen study
participants and setting are appropriate to answer our review
question. Because we are looking to establish test accuracy
in both primary presentation and referred participants, a
study could be appropriate for 1 setting and not for the other,
or it could be unclear as to whether the study can
appropriately answer either question
For each study assessed, please consider whether it is more
relevant for A) participants with a primary presentation of a
skin lesion or B) referred participants, and respond to the
questions in either A) or B) accordingly. If the study gives
insufficient details, please respond Unclear to both parts of
the question
 
A) For studies that will contribute to the analysis of
participants with a primary presentation of a skin lesion
(i.e., test naive)
Yes – if participants included in the study appear to be
generally representative of those who might present in a
usual practice setting
No – if study participants appear to be unrepresentative of
usual practice, e.g., in terms of severity of disease,
demographic features, presence of differential diagnosis or
comorbidity, setting of the study, and previous testing
protocols
Unclear – if insufficient details are provided to determine
the generalisability of study participants
B) For studies that will contribute to the analysis of referred
participants (i.e., who have already undergone some form
of testing)
Yes – if study participants appear to be representative of
those who might be referred for further investigation. If the
study focuses only on those with equivocal lesions, for
example, we would suggest that this is not representative of
the wider referred population
No – if study participants appear to be unrepresentative of
usual practice, e.g., if a particularly high proportion of
participants have been self-referred or referred for cosmetic
reasons. Other factors to consider include severity of
disease, demographic features, presence of differential
diagnosis or comorbidity, setting of the study, and previous
testing protocols
Unclear – if insufficient details are provided to determine
the generalisability of study participants
2) Did the study avoid including participants with multiple
lesions?
Yes – if the difference between the number of included
lesions and number of included participants is less than 5%
No – if the difference between the number of included
lesions and number of included participants is greater than
5%
Unclear – if it is not possible to assess
 
Is there concern that the included participants do not match the
review question?
If the answer to question 1) or 2) 'Yes':1.
If the answer to question 1) or 2) 'No':2.
If the answer to question 1) or 2) 'Unclear':3.
 
Concern is low1.
Concern is high2.
Concern is unclear3.
INDEX TEST (2) RISK OF BIAS (to be completed per test evaluated)
1) Was the index test or testing strategy result interpreted
without knowledge of the results of the reference standard?
Yes – if index test described as interpreted without
knowledge of reference standard result or, for prospective
studies, if index test is always conducted and interpreted
prior to the reference standard
No – if index test described as interpreted in knowledge of
reference standard result
Unclear – if index test blinding is not described
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Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
2) Was the diagnostic threshold at which the test was
considered positive (i.e., melanoma present) prespecified?
Yes – if threshold was prespecified (i.e., prior to analysing
study results)
No – if threshold was not prespecified
Unclear – if not possible to tell whether or not diagnostic
threshold was prespecified
3) For within-person comparisons of index tests or testing
strategies (i.e., > 1 index test applied per participant): was each
index test result interpreted without knowledge of the results of
other index tests or testing strategies?
Yes – if all index tests were described as interpreted
without knowledge of the results of the others
No – if the index tests were described as interpreted in the
knowledge of the results of the others
Unclear – if it is not possible to tell whether knowledge of
other index tests could have influenced test interpretation
N/A – if only 1 index test was evaluated
 
Could the conduct or interpretation of the index test have
introduced bias?
For non-comparative and between-person comparison studies
If answers to questions 1) and 2) 'Yes':1.
If answers to either questions 1) or 2) 'No':2.
If answers to either questions 1) or 2) 'Unclear':3.
For within-person comparative studies
If answers to all questions 1), 2), for any index test and 3)1.
'Yes':
If answers to any 1 of questions 1) or 2) for any index test or2.
3) 'No':
If answers to any 1 of questions 1) or 2) for any index test or3.
3) 'Unclear':
 
For non-comparative and between-person comparison
studies
Risk is low1.
Risk is high2.
Risk is unclear3.
For within-person comparative studies
Risk is low1.
Risk is high2.
Risk is unclear3.
INDEX TEST (2) CONCERN ABOUT APPLICABILITY
 
1) Was the diagnostic threshold to determine presence or
absence of disease established in a previously published
study?
E.g., previously evaluated/established
algorithm/checklist used
lesion characteristics indicative of melanoma used
objective (usually numerical) threshold used
Yes – if a previously evaluated/established tool to aid
diagnosis of melanoma was used or if the diagnostic
threshold used was established in a previously published
study
No – if an unfamiliar/new tool to aid diagnosis of melanoma
was used, if no particular algorithm was used, or if the
objective threshold reported was chosen based on results
in the current study
Unclear – if insufficient information was reported
 
2) Were thresholds or criteria for diagnosis reported in sufficient
detail to allow replication?
Study results can only be reproduced if the diagnostic threshold
is described in sufficient detail. This item applies equally to
studies using pattern recognition and those using checklists or
algorithms to aid test interpretation
Yes – If the criteria for diagnosis of melanoma were
reported in sufficient detail to allow replication
No – if the criteria for diagnosis of melanoma were not
reported in sufficient detail to allow replication
Unclear – If some but not sufficient information on criteria
for diagnosis to allow replication were provided
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Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
3) Was the test interpretation carried out by an experienced
examiner?
Yes – if the test was interpreted by 1 or more speciality-
accredited dermatologists, or by examiners of any clinical
background with special interest in dermatology and with
any formal training in the use of the test
No – if the test was not interpreted by an experienced
examiner (see above)
Unclear – if the experience of the examiner(s) was not
reported in sufficient detail to judge or if examiners were
described as 'Expert' with no further detail given
N/A – if system-based diagnosis, i.e., no observer
interpretation
 
Is there concern that the index test, its conduct, or interpretation
differ from the review question?
If answers to questions 1), 2), and 3) 'Yes':1.
If answers to questions 1), 2), or 3) 'No':2.
If answers to questions 1), 2), or 3) 'Unclear':3.
 
Concern is low1.
Concern is high2.
Concern is unclear3.
REFERENCE STANDARD (3) RISK OF BIAS
 
1) Is the reference standard likely to correctly classify the target
condition?
A) Disease-positive – 1 or more of the following:
histological confirmation of melanoma following biopsy or
lesion excision
clinical follow-up of benign-appearing lesions for at least 3
months following the application of the index test, leading to
a histological diagnosis of melanoma
B) Disease-negative – 1 or more of the following:
histological confirmation of absence of melanoma following
biopsy or lesion excision in at least 80% of disease-negative
participants
clinical follow-up of benign-appearing lesions for a minimum
of 3 months following the index test in up to 20% of disease-
negative participants
 
A) Disease-positive
Yes – if all participants with a final diagnosis of melanoma
underwent 1 of the listed reference standards
No – If a final diagnosis of melanoma for any participant
was reached without histopathology
Unclear – if the method of final diagnosis was not reported
for any participant with a final diagnosis of melanoma or if
the length of clinical follow-up used was not clear or if a
clinical follow-up reference standard was reported in
combination with a participant-based analysis and it was
not possible to determine whether the detection of a
malignant lesion during follow-up is the same lesion that
originally tested negative on the index test
B) Disease-negative
Yes – If at least 80% of benign diagnoses were reached by
histology and up to 20% were reached by clinical follow-up
for a minimum of 3 months following the index test
No – if more than 20% of benign diagnoses were reached
by clinical follow-up for a minimum of 3 months following
the index test or if clinical follow-up period was less than 3
months
Unclear – if the method of final diagnosis was not reported
for any participant with benign or non-melanoma diagnosis
 
2) Were the reference standard results interpreted without
knowledge of the results of the index test?
Please score this item for all studies even though
histopathology interpretation is usually conducted with
knowledge of the clinical diagnosis (from visual inspection or
dermoscopy or both). We will deal with this by not including the
response to this item in the 'Risk of bias' assessment for these
tests. For reviews of all other tests, this item will be retained
Yes – if the reference standard diagnosis was reached
blinded to the index test result
No – if the reference standard diagnosis was reached with
knowledge of the index test result
Unclear – if blinded reference test interpretation was not
clearly reported
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Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
 
Could the reference standard, its conduct, or its interpretation
have introduced bias?
For visual inspection/dermoscopy evaluations
If answer to question 1) 'Yes':1.
If answer to question 1) 'No':2.
If answer to question 1) 'Unclear':3.
For all other tests
If answers to questions 1) and 2) 'Yes':1.
If answers to questions 1) or 2) 'No':2.
If answers to questions 1) or 2) 'Unclear':3.
 
For visual inspection/dermoscopy evaluations
Risk is low1.
Risk is high2.
Risk is unclear3.
For all other tests
Risk is low1.
Risk is high2.
Risk is unclear3.
REFERENCE STANDARD (3) CONCERN ABOUT APPLICABILITY
1) Are index test results presented separately for each
component of the target condition (i.e., separate results
presented for those with invasive melanoma, melanoma in situ,
lentigo maligna, severe dysplasia, BCC, and cSCC)?
Yes – if index test results for each component of the target
condition can be disaggregated
No – if index test results for the different components of the
target condition cannot be disaggregated
Unclear – if not clearly reported
 
2) Expert opinion (with no histological confirmation) was not
used as a reference standard
'Expert opinion' means diagnosis based on the standard clinical
examination, with no histology or lesion follow-up
***do not complete this item for teledermatology studies
Yes – if expert opinion was not used as a reference
standard for any participant
No – if expert opinion was used as a reference standard for
any participant
Unclear – if not clearly reported
3) Was histology interpretation carried out by an experienced
histopathologist or by a dermatopathologist?
Yes – if histology interpretation was reported to be carried
out by an experienced histopathologist or
dermatopathologist
No – if histology interpretation was reported to be carried
out by a less experienced histopathologist
Unclear – if the experience/qualifications of the pathologist
were not reported
 
Is there concern that the target condition as defined by the
reference standard does not match the review question?
If answers to all questions 1), 2), and 3) 'Yes':1.
If answers to any 1 of questions 1), 2), or 3) 'No':2.
If answers to any 1 of questions 1), 2), or 3) 'Unclear':3.
***For teledermatology studies only
If answers to all questions 1) and 3) 'Yes':1.
If answers to questions 1) or 3) 'No':2.
If answers to questions 1) or 3) 'Unclear':3.
Concern is low1.
Concern is high2.
Concern is unclear3.
***For teledermatology studies only
Concern is low1.
Concern is high2.
Concern is unclear3.
FLOW AND TIMING (4): RISK OF BIAS
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Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
 
1) Was there an appropriate interval between index test and
reference standard?
A) For histopathological reference standard, was the interval
between index test and reference standard ≤ 1 month?
B) If the reference standard includes clinical follow-up of
borderline/benign-appearing lesions, was there at least 3
months' follow-up following application of index test(s)?
 
A)
Yes – if study reports ≤ 1 month between index and
reference standard
No – if study reports > 1 month between index and
reference standard
Unclear – if study does not report interval between index
and reference standard
B)
Yes – if study reports ≥ 3 months' follow-up
No – if study reports < 3 months' follow-up
Unclear – if study does not report the length of clinical
follow-up
2) Did all participants receive the same reference standard? Yes – if all participants underwent the same reference
standard
No – if more than 1 reference standard was used
Unclear – if not clearly reported
3) Were all participants included in the analysis? Yes – if all participants were included in the analysis
No – if some participants were excluded from the analysis
Unclear– if not clearly reported
 
4) For within-person comparisons of index tests
Was the interval between application of index tests ≤ 1 month?
Yes – if study reports ≤ 1 month between index tests
No – if study reports > 1 month between index tests
Unclear – if study does not report the interval between
index tests
 
Could the participant flow have introduced bias?
For non-comparative and between-person comparison studies
If answers to questions 1), 2), and 3) 'Yes':1.
If answers to any 1 of questions 1), 2), or 3) 'No':2.
If answers to any 1 of questions 1), 2), or 3) 'Unclear':3.
For within-person comparative studies
If answers to all questions 1), 2), 3), and 4) 'Yes':1.
If answers to any 1 of questions 1), 2), 3), or 4) 'No':2.
If answers to any 1 of questions 1), 2), 3), or 4) 'Unclear':3.
For non-comparative and between-person comparison
studies
Risk is low1.
Risk is high2.
Risk is unclear3.
For within-person comparative studies
Risk is low1.
Risk is high2.
Risk is unclear3.
BCC = basal cell carcinoma; cSCC = cutaneous squamous cell carcinoma.
5 Details of RCM algorithms and diagnostic thresholds for diagnosis
RCM algorithms (based on analysis of training set)
RCM score
(Pellacani 2005; 
Pellacani 2007)
 
Segura score -
two step to id
melanocytic
first and then
melanomas (Segura
2009)
 
Guitera two-step method for
BCC and MM (Guitera 2012)
 
Pellacani two-step method
for dysplastic lesions and
then MM (Pellacani 2012)
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RCM algorithms (based on analysis of training set)
Used in:
Curchin 2011 (w LM
score)
Guitera 2009
Guitera 2012
Lovatto 2015
Pellacani 2007
Pellacani 2014
 
Used in:
Alarcon 2014
Guitera 2012
Lovatto 2015
Segura 2009
   
Used in:
Pellacani 2012
Stanganelli 2015
 
RCM score ≥ 2, ≥ 3,
≥ 4
Presence of two
major features (each
scoring 2):
- non-edged papillae
- cellular atypia at
dermal–epidermal
junction
Presence of four
minor features (each
scored 1)
- roundish pagetoid
cells,
- widespread
pagetoid infiltration,
- cerebriform nests,
- nucleated cells
within the papilla
 
Cutoff of >-1 = 'most
probable melanoma'
Within melanocytic
lesions
2 protective features
associated with
benign lesions (score
-1 each)
- typical basal cells
and
- edged papillae
2 risk features
associated with
melanoma (score +1
each)
- roundish pagetoid
cells and
- atypical dermal
nucleated cells.
Lesions were
assigned a value from
-2 to 2 according to
the presence or
absence of these
factors
 
Correct id as MM or BCC (based on
independently significant features as id
from training set)
Melanoma:
- cerebriform nests,
- atypical cobblestone pattern with small
nucleated cells in the epidermis,
- marked cytological atypia, and
- pagetoid cells, and
- disarranged epidermal layer with no
honey comb
- Large inter-papillae spaces filled with
honeycomb
- Dense nest
 
Two step algorithm (≥ 3
characteristics present, two at step 1
and one at step 2)
Step 1: id dysplastic nevus
Presence of cytologic atypia (≥ 1
present)
- round pagetoid cells
- atypical cells at DEJ
and
Presence of architectural atypia (≥ 1
present)
- irregular junctional nests
- short interconnections between
junctional nests
- nonhomogenous cellularity within
junctional nests
Step 2: id melanoma from dysplastic
nevus (≥ 1 characteristic present)
- widespread (≥ 50% of lesional area)
round pagetoid cells,
- widespread (≥ 50% of lesional area)
atypical cells at the DEJ, and
- nonedged papillae (≥ 10% of the
lesional area)
RCM ‘no algorithm’ (selected lesion characteristics, independently significant characteristics identified, or ‘observer
diagnosis’)
Langley 2007 (based on
Langley 2001)
 
Ferrari 2015
Koller 2011 (MM)
Rao 2013 (MM/BCC/SCC)
Farnetani 2015 (MM and BCC)
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RCM algorithms (based on analysis of training set)
 
≥ 1 characteristic present
(selected from prior study)
Any one of:
- epidermal disarray with loss of
the normal honeycomb pattern;
- a grainy image;
- pagetoid cells in the epidermis;
- complex branching dendrites or
dendritic cells;
- atypical and pleomorphic
refractile cells, and the
- presence of bright, highly
refractile particles
 
Independently significant features
(These four features are referenced to
Pellacani 2012 as ‘melanoma clues’)
For featureless lesions (score 0-2 on
dermoscopy 7PCL), presence of at
least one of:
- ≥5 round pagetoid cells
- architectural disorder
For equivocal lesions (score 3-4 on
dermoscopy 7PCL), presence of at
least one of:
- any number of round pagetoid cells
- five or more atypical cells at the
junction
≥ 1 characteristic present for each
 
Observer diagnosis
Koller 2011
'diagnoses based on 'expert experience'
Rao 2013 (MM/BCC/SCC)
Observers gave diagnosis and excise decision (no
further details)
Farnetani 2015 (MM and BCC)
Evaluators completed a ‘pattern description’
(presence/absence of a number of RCM features)
and gave an overall diagnosis of malignant
(melanoma or BCC) or benign
RCM ‘no algorithm’ (developed for specific study populations)
 
Longo 2013
Nodular lesions
 
Pupelli 2013
<=5 mm melanocytic lesions
 
Figueroa Silva 2016
‘Thin’ MM with dermoscopic island
 
Independently significant
features
- widespread pagetoid
distribution (graded as focal,
localized, widespread);
- many atypical cells;
- cerebriform nests.
 
Independently significant features
- presence of at least five pagetoid
cells per mm2,
- tangled lines within the epidermis,
and
- atypical roundish cells at the
dermoepidermal junction
 
Overall diagnosis reported; features assessed
included:
- cobblestone pattern,
- pagetoid cells,
- architecture type (ringed, meshwork or clod
prevalent pattern at DEJ, regular/irregular)
- and atypical cells at the DEJ
RCM - reflectance confocal microscopy; DEJ - dermo-epidermal junction; 7PCL - seven point checklist; MM -melanoma;
BCC - basal cell carcinoma; SCC; squamous cell carcinoma.
Graphs
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